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1.1  Background 
 In men prostate cancer is the most common cancer and one of the leading causes of 
cancer death in western countries. In 2008, the estimated incidence of prostate cancer and 
resulting deaths in Europe was 3.2 million cases and 1.7 million cases, respectively. 
Compared to other solid tumors, prostate cancer is a disease with slow progression. 
The 5-year survival of patients with localized prostate cancer approximates 100%, but 
almost half of the patients will be assessed for metastases and five-year survival of these 
patients drops to 31%. The most common site of prostate cancer metastasis is bone, 
particularly the axial skeleton. Bone metastases of prostate cancer may be painful and 
represents a functionally limiting stage of the disease.  
Nowadays, the screening of prostate cancer is mainly based on serum prostate-specific 
antigen (PSA) testing and digital rectal examination (DRE) (1). Random transrectal 
ultrasound (TRUS) guided biopsy is the gold standard method for histological diagnosis of 
prostate cancer. PSA is a 34 kD androgen-regulated exocrine serine protease. It cleaves the 
prostate-derived protein “seminogelin” in the seminal fluid for the liquefaction of the 
semen. Normal cells as well as diseased prostate cells produce PSA. A PSA level of 4.0 
ng/mL or higher is used as cut-off to refer for further evaluation or biopsy. However, it has 
been estimated that 23% - 42% of patients are over-diagnosed using a PSA test (2).  Also 
DRE has its drawback with regard to sensitivity and specificity.  
Abnormal results from screening using PSA or DRE will be confirmed by random 
TRUS-guided biopsy. However, sampling of biopsies remains a significant problem, 
especially when small tumors are present in a large gland. The entire TRUS-guided biopsy 
procedure has a false negative rate as high as 30 % and is affected by the number of cores 
obtained. The adverse effects from treatment of prostate cancer due to over-diagnosis are 
serious. On the other hand, imaging methods allowing accurate localization of tumors in the 
prostate are still lacking. Hence, new non-invasive imaging techniques of prostate cancer to 
improve cancer detection and guide proper therapy are warranted. 
Positron Emission Tomography (PET) and Single Photon Emission Computed 
Tomography (SPECT) are non-invasive nuclear imaging technologies that may provide true 
3D information of the areas of interest. When applying suitable radiotracers to patients, it is 
possible to measure and quantify important body functions such as blood flow, oxygen use, 
and glucose metabolism that are involved in several diseases, including cancer. In prostate 
cancer diagnosis, PET/SPECT could offer regional information of the primary cancer and 
metastasis. PET/SPECT could also serve as a tool to measure the effect of therapy.     
The quality of PET and SPECT images is mainly depending on the distribution of 
radiotracers. The critical issue in prostate cancer imaging using PET and SPECT is the 
development of suitable radiotracers, which selectively accumulate in cancer, but not in 
other normal organs, and of which uptake correlates with tumor growth. In this regard 
several promising radiotracers such as 18F-FDG, 18F or 11C-labelled acetate, and 18F 
of11C-labelled choline are being investigated. The most common PET tracer used for 
imaging of cancer, 2-deoxy-2-18F-fluoro-D-glucose (18F-FDG), is a glucose analogue taken 
up by highly-glucose-consuming cells, such as brain, kidney, and cancer cells. The 
overexpression of cellular membrane glucose transporters and enhanced hexokinase 
enzymatic activity in tumor cells leads to the malignancy-induced hypermetabolism 
of 18F-FDG. Unfortunately, accumulation of 18F-FDG in prostate cancer may overlap with 
normal prostate activity and uptake in benign prostatic hyperplasia. Radioactivity excreted 
in the urinary bladder may also affect detection of lesions in the prostate gland. 
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Therefore, 18F-FDG is not suitable for diagnosis or staging of primary prostate cancer and 
of local recurrence in general (3-4). On the other hand, 18F-FDG may be useful in the 
detection of poorly differentiated primary tumors (Gleason scores 8-10) with high serum 
PSA values (5), and it may be also useful in evaluating treatment response of patients with 
metastatic disease and in prognostication of castrate-resistance. 
Acetate participates in cytoplasmic lipid synthesis, which is increased in tumors. 
Although 11C-acetate uptake in primary prostate cancer, in benign prostatic hyperplasia and 
in normal prostate tissue may overlap, uptake in prostate cancer generally is higher. In 
comparison with 18F-FDG, 11C-acetate is more sensitive in the detection of primary prostate 
cancer (6). The limited urinary excretion of 11C-acetate is another advantage over 18F-FDG 
for imaging prostate cancer.   
The upregulation of choline kinase in malignancy leads to the accumulation of 
phosphatidylcholine (lecithin) in membranes of tumor cells. 11C-choline and11C-acetate 
appear to be equally useful in imaging prostate cancer in individual patients. Similar 
to 11C-acetate and 18F-FDG, 11C-choline cannot differentiate between tumor and benign 
prostate disease. 
Radiolabelled antibodies and peptides were developed as probes for nuclear imaging 
of cancer because of their specific binding affinity to receptors overexpressing in primary 
tumor and/or metastasis, but not so in healthy tissues. Gastrin-releasing peptide receptor 
(GRPR) is a well-studied target for prostate cancer imaging. As imaging probes 
radiolabelled peptides have several advantages over antibodies: lack of immunogenicity, 
quick diffusion and well-established conjugation and labeling strategies. On the other hand, 
the drawback of peptides may be metabolic stability which needs to be improved. Although 
research focusing on developing radiolabelled bombesins for GRPR imaging was blooming 
the last two decades, only a few bombesins were translated into clinical trials. Improvement 
of the binding affinity to the GRPR, in vivo stability, and pharmaceutical kinetics of 
radiolabelled bombesins are still needed for imaging prostate cancer. Therefore we 
developed a variety of new radiolabelled bombesin peptides for imaging of prostate cancer 
using PET or SPECT.  
 
1.2  Aim and Outline 
The aim of this thesis was to develop radiotracers, based on bombesin peptides, for 
SPECT or PET imaging of GRPR receptor expressing cancers, especially prostate cancer.   
Chapter 2 reviews the trends in the development of new bombesin radiotracers over 
the last years. This chapter is conceived as an update of a previous review from our group.    
In Chapter 3, we describe the synthesis and evaluation of a 99mTc labelled truncated 
bombesin peptide for imaging GRPR.  In this study, we used bombesin(7-14) as the 
biomolecule as it is the peptide sequence responsible for specific binding to the GRPR. 
HYNIC was employed as the bifunctional chelator to constitute the ternary ligand system 
with TPPTS and tricine for the labeling of 99mTc, which is the most common radionuclide 
used in clinical SPECT imaging. The optimal labeling efficiency, stability, and in vivo 
kinetics of the 99mTc-HYNIC core (combined with TPPTS and tricine) have been 
demonstrated in a previous study on Arginine-Glycine-Aspartic acid (RGD) peptides. An 
alpha -alanine linker was applied as a spacer to reduce the steric effect of the 99mTc-HYNIC 
core. Overexpression of GRPR has been reported in colon cancer. Therefore, a human 
colon cancer (HT-29 cell line) bearing mouse model was chosen as animal model.  
As the GRPR is also overexpressed in prostate cancer cells, an attempt to image 
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prostate cancer using 99mTc-HYNIC-Tricine/TPPTS-bombesin was carried out. Compared 
to alpha-Ala-BN(7-14) (24.0±2.0 nM), alpha-aminocaproic acid (Aca) conjugated BN(7-14) 
showed lower IC50 value (20.8±0.3 nM) in competitive binding assay (7). By changing 
alpha-alanine to alpha-aminocaproic acid (Aca) we sought to improve GRPR targeting 
properties and pharmacokinetics of 99mTc-HYNIC-Tricine/TPPTS-Aca-bombesin(7-14) 
(99mTc-HABN, both in vitro and in vivo in a human prostate cancer bearing mouse model. 
The results of the in vivo and in vitro evaluation were reported in Chapter 4. 
The potential prostate cancer imaging candidate 99mTc-HABN therefore was tested to 
meet radiopharmaceutical requirements under GMP conditions. The clinical translation and 
primary clinical study results of the 99mTc-HABN were summarized in Chapter 5. 
The results from a clinical imaging trial on biopsy proven prostate cancer of eight 
patients (four patients scheduled for laparoscopic radical prostatectomy (RP), four planned 
for external beam radiotherapy (EBRT)) using 99mTc-HABN SPECT/CT yielded concerns 
on the low radioactivity retention in tumor, rapid degradation and affinity of the radiotracer.  
Three projects which aim to increase the half-life and retention of radioactivity in 
tumor, to improve the in vivo stability, and to increase the binding affinity to GRPR are 
reported in Chapter 6, 7, and 8. 
In an attempt to obtain a bombesin tracer with relatively long physical half-life 
allowing extended retention in tumor cells and SPECT imaging, 123I-cubane-TFP ester was 
coupled with Aca-bombesin(7-14). The 123I-cubane introduced was proven to be stable in 
vivo. The reaction condition for the conjugation between 123I-cubane-TFP ester and peptide 
was mild and easy to be translated for the radio-labeling of peptides or proteins. As a 
candidate for SPECT imaging of prostate cancer, the newly developed 123I-bombesin was 
systematically evaluated in vitro and in vivo (Chapter 6). 
To overcome the stability issues of the bombesin tracers, a lanthionine internal bridge 
was introduced between two cystine residues which placed in bombesin peptide sequence. 
A series of lanthionine-stablized bombesins were synthesized with variety locations of 
lanthionine crosslink. The binding affinity of the stabilized bombesins to GRPR was 
compared in in vitro comparative binding assay. Two of the stabilized bombesins (C5 and 
C6) with best binding affinity to GRPR were selected and labelled with 18F by coupling 
with the established labeling agent N-succinimidyl-4-18F-fluorobenzoate (18F-SFB). The 
potential of using 18F-labelled C5 and C6 for imaging prostate cancer with PET was 
evaluated in vitro and in vivo with human prostate cancer bearing athymic mice (Chapter 
7). 
Multimerization strategy has been shown to improve the binding kinetics of small 
peptides (such as RGD peptides) to their targets. In Chapter 8, we reported a new 
bombesin homo-dimer with two identical Aca-BN(7-14) moieties (chapter 4, 5, 6) linked 
with Glutamine acid. Comparison of the bombesin dimer and monomer on their potential 
for imaging prostate cancer was feasible by applying same 99mTc-labeling strategy (as 
described in Chapter 4) on the dimeric bombesin. The in vitro stability, cellular uptake 
kinetic, internalization and efflux kinetics, biodistribution and SPECT/CT imaging prostate 
of 99mTc-homo-dimer were demonstrated in Chapter 8. Compared to 99mTc-HABN, the 
effect of the additional Aca-bombesin(7-14) moiety  in 99mTc-dimer was discussed as well. 
Chapter 9 summarizes the studies performed in this thesis and gives a general future 
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Prostate cancer is a critical public health problem in USA and Europe. New 
non-invasive imaging methods are urgently needed, due to the low accuracy and specificity 
of current screen methods and the desire of localizing primary prostate cancer and bone 
metastasis. Positron Emission Tomography (PET) and Single Photon Emission Computed 
Tomography (SPECT) are the non-invasive and sensitive imaging methods which have 
been widely used for diagnosing diseases in the clinic. Lack of suitable radiotracers is the 
major issue for nuclear imaging of prostate cancer, although radiolabelled bombesin 
peptides targeting the Gastrin-Releasing Peptide Receptor (GRPR) on tumor cells are 
widely investigated. In this review we discuss the recent trends in the development of 
GRPR-targeted radiopharmaceuticals based on BN analogues with regard to their potential 
for imaging and therapy of GRPR-expressing malignancies. Following a brief introduction 
of GRPR and bombesin peptides, we summarize the properties of prostate cancer specific 
radiolabelled bombesins. New bombesin tracers published in the last five years are 
reviewed and compared according to their novelties in biomolecules, radionuclides, 
labeling methods, bifunctional chelators and linkers. Hot topics such as multimerization, 
application of agonists and antagonists are highlighted in the review. Lastly, a few clinical 
trials of cancer nuclear imaging with radiolabelled bombesin are being discussed.       
 


























2.1  Introduction 
Cancer is a major public health problem worldwide. In the United States, one in four 
deaths is due to cancer. There were an estimated 3.2 million new cases of cancer and 1.7 
million deaths from cancer in Europe in 2008 (1). 
Molecular imaging techniques such as magnetic resonance spectroscopy, 
single-photon emission computed tomography (SPECT) and positron emission tomography 
(PET) have been well developed in the last three decades. Suitable imaging probes have 
been developed for a broad array of molecular targets, allowing in vivo detection and 
functional characterization of tumors. Current molecular imaging techniques can provide 
relevant biological information needed for a better understanding of tumor biology, thereby 
enabling more accurate diagnosis and enhanced therapeutic monitoring (2-5). 
In many cases the exact cause and development of cancer remains largely unknown. 
However, a variety of receptors (somatostatin receptors (6), integrin αvβ3 (7), gastrin 
releasing peptide receptors (GRPRs) (8), sigma receptors (9), neurokinin receptors (10), etc.) 
have been identified as over-expressed in cancer cells and appear to play key roles in cancer 
development. Importantly, many of these receptors are absent or sparsely expressed in 
normal cells and tissues. Therefore, these receptors could be potential targets for cancer 
detection if suitable probes and imaging facilities are available. 
Radiolabelled peptides for receptor-targeted molecular imaging and radionuclide 
therapy have been extensively investigated since 1990s. The most successful sample, 
[111In-DTPA0]-octreotide (Octreoscan) was introduced since late 1980s and became the gold 
standard for diagnosis and staging of somatostatin receptor-positive neuroendocrine tumors 
(11). Octreoscan and Neotect are still the only two radiopeptides on the market approved by 
the Food and Drug Administration. Compared to monoclonal antibody (MAbs), peptides 
show superiority in clearance kinetics, immunogenicity, ease of manufacturing and 
radiolabelling. Due to their low molecular weight, peptides easily diffuse into target tissues 
and clear rapidly from the blood pool, resulting in high tumor-to-non-tumor ratios. In 
general, peptides are non-immunogenic and can readily be labelled with a variety of 
radionuclides to serve in SPECT and PET imaging of cancer. Ligands, such as octreotide, 
Arginine-Glycine-Aspartic (RGD), bombesin, substance P, all have nano-molar binding 
affinity to specific receptors and as such are promising candidates for cancer imaging (12, 
13).  
Over the past few years, several reviews have been published regarding the 
development of GRPRs targeting radiopharmaceuticals for nuclear imaging of prostate 
cancer (2, 14-16). In this review, we discuss the latest trends in this rapidly expanding field.  
2.2  Peptide-Based Radiopharmaceuticals 
A radiolabelled peptide (Figure 1) for SPECT or PET imaging of receptors should 
fulfill several requirements including:  
1) An isotope with optimal nuclear properties, availability and physical half-life 
matching the biological half-life of the tracer in vivo;  
2) A multidentate bifunctional chelator (BFC) which enables efficient labeling, stable 
radionuclide chelating, and optimal in vivo behavior is used to attach the metallic 
radionuclide to the BN peptide, whereas an organic precursor or synthon is often 
needed for the 18F and 11C-labeling;  
3) A pharmacokinetic modifying (PKM) linker, which could improve the excretion 
16 






Receptor of  interest
 
Figure 1.  Schematic presentation of the components for membrane receptor-targeting 
radiotracer design. 
 
The development of novel radiolabelled peptides is aiming to improve the 
radioactivity accumulation and retention in tumor while reducing the whole body 
background. However, a simple combination of the elements mentioned above is not a 
guarantee for a successful receptor-targeting tracer. For predicting the cancer imaging 
potential of the radiolabelled peptides, chemical, biological and pharmacokinetic characters 
of the tracer are frequently investigated and discussed, such as the binding affinity to 
receptors, stability, lipophilicity, internalization and efflux kinetics in tumor cells, tumor 
uptake and tumor-to-non-tumor (T/NT) ratio, tumor retention time, charge, and in vivo 
clearance. In this article, we addressed the development of bombesin tracers according to 
the requirements on biomolecule, chelators, linkers and radionuclides mentioned above, and 
focusing on topics such as the stability issue of peptide, multimerization, bombesin agonist 
and antagonist. 
 
2.3  Bombesin and GRPRs  
BN is a 14 amino-acid peptide (pyroglutamic acid-glutamine-arginine-leucine- 
glycine-asparagine-glutamine-tryptophan-alanine-valine-glycine-histidine-leucine- 
methionine -NH2) first isolated from the skin of frog (17). BN and its mammalian 
counterpart Gastrin-Releasing Peptide (GRP) share an identical C-terminal region of seven 
amino acid residues. This stretch of 7 residues is essential for binding of GRP and BN to 
the receptor.  
Four subtypes of BN receptors have been reported: neuromedin B receptor, GRPR, 
and the BB3 and BB4 receptor subtypes (18-21). GRPR seems most attractive as it is 
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over-expressed in many human malignancies, such as prostate, breast, lung, pancreatic, 
ovarian, renal and gastrointestinal cancer (8, 22-25). GRPR expression in breast cancer 
tissues showed 33 positive cases in 100 carcinomas (26).Schally et al. reported the 
presence of the bombesin receptor subtypes in human ovarian epithelial cancers using 
RT-PCR (27).About 64% of the specimens expressed mRNA for both GRPR and 
NMBR. In a recently study we found that GRPR is expressed in the vast majority (18 
of 21 cases) of lymph node metastases and in 52.9% of bone metastases 
of prostate cancer (8, 22-25). A study investigating the GRPR expression profile in 
large cohorts of different prostate specimens (benign prostate tissue, primary prostate 
cancer following radical prostatectomy, castration-resistant prostate cancer (CRPC)) by 
immunohistochemistry was reported by Beer et al.(28). They found GRPR expression 
to be significant (p<0.001) higher in prostate carcinomas than in benign prostate tissues, 
which was significantly inverse correlated to the PSA level (p=0.026), tumor size 
(p=0.014) and Gleason scores (p=0.026), but not correlated to tumor stage (p=0.439) 
and margin status (p=0.100). The expression of GRPR also shows a highly significant 
correlation with androgen receptor (AR) expression (p<0.001), as well as with cyclin 
D1 expression (p<0.001). Cyclin D1 protein over-expression might be related to the 
evolution of androgen-independent disease in prostate cancer (29, 30). These data 
indicate that GRPR might have influence on the course and therapy of prostate cancer, 
but also constitute a caveat for the use of GRPR as a target in diagnostic or therapeutic 
approaches of prostate cancer since high grade prostate cancer can be low in GRPR. 
 
2.4  Targeting Biomolecules 
2.4.1  Improving Stability with Non-natural Amino Acids 
BN-like peptides have potent biological effects such as stimulating gastric acid and 
pancreatic enzyme secretion or gall bladder contraction (31), so it is common that the 
peptides could be rapidly and selectively degraded by proteolytic enzymes to regulate 
expression levels (32).  
Therefore many attempts to stabilize peptides have been published. Linder et al. 
studied the metabolism of 177Lu-DO3A-CH2CO-G-(4-aminobenzoyl)-Gln-Trp-Ala-Val- 
Gly-His-Leu-Met-NH2 (177Lu-AMBA) in vitro and in vivo in a mouse and a rat model (33). 
Three major and two minor metabolites (figure 2) of 177Lu-AMBA were reported. Rapid 
metabolism in blood of mice and rats was observed. Two minutes after i.v. administration to 
normal mice, only ∼45% of the radioactivity in the plasma was present as 177Lu-AMBA. 
None of the metabolites of 177Lu-AMBA showed any significant binding to GRPR. The 
biodistribution results of animal experiments in human prostate cancer bearing mice 
indicated that only intact 177Lu-AMBA has GRPR targeting ability.  
For prolonging the exposure of GRPR to radiolabelled BN , it’s important to improve 
the stability of radiolabelled BN. Replacement of the original amino acids of BN(7-14) by 
non-natural amino acids or modified amino acids to increase the metabolic stability of BN 





















































Figure 2. Chemical structure of 177Lu-AMBA and five in vivo cleavage sites 
 
Recently, Honelet al. reported the synthesis and evaluation of four 18F labelled BN 
tracers (34). Met14 was replaced by Leu for stabilization against aminopeptidase 3.4.11.1, 
and Leu13 was replaced by a non-natural amino acid (FA01010 or Sta) to prevent cleavage 
by neutral endopeptidase 3.4.24.11, while methylated versions of His12 and/or Gly11 were 
introduced for the preparation of four truncated BN analogues (Figure 3). 
Arg-Ava-Gln-Trp-Ala-Val-NMeGly-His-Sta-Leu-NH2 (4b) was selected according to its 
higher in vitro binding affinity to GRPR than the other three analogues and 
2-(4-(di-tert-butyl[18F]fluorosilyl)phenyl)acetyl-Arg-Ava-Gln-Trp-Ala-Val-NMeGly-His-St
a-Leu-NH2 ([18F]-4b) was further evaluated in vitro and in vivo. No significant degradation 
of [18F]-4b was detected in PBS, neither in mouse nor in human plasma within 2 h. This 
compound also showed high in vivo stability against degradation by endogenous enzymes 
which are present in the blood of mouse. Although the in vitro binding affinity of 
Arg-Ava-Gln-Trp-Ala-Val-NMeGly-His-Sta-Leu-NH2 was in the low nanomolar range 
(22.9 nm), the tumor uptake of 18F-4b was low and unspecific in human prostate tumor 
(PC-3)-bearing nude mice. In contrast, mouse pancreas revealed a high and specific 
accumulation of [18F]-4b that may be due to the higher GRPR density in pancreas than in 
PC-3 tumors and the better accessibility of 18F-4b to the pancreatic acinar cells than to PC-3 
tumor cells. Due to the lipophilic character of [18F]-4b, it exhibited a mainly hepatobiliary 
route clearance. 
As an improvement of Demobesin 1 (42), Waelet al. reported an 111In labelled 
antagonist-BN with the formula DOTA-aminohexanoyl-[D-Phe6, Leu-NHCH2CH2CH313, 
des Met14]BN(6-14)(Bomproamide) (36). Rapid (0.25 h), specific and significant high 
tumor uptake (6.90 ± 1.06 %ID/g), fast clearance from the other tissues were observed in 
biodistribution experiments using 111In-Bomproamide. The PC-3 tumor-xenografts were 
visualized clearly in microSPECT/CT images with low abdominal background. The 
stability of 111In-Bomproamide was not reported in the article.  
Although, non-natural amino acids may enhance the stability of radiolabelled BN, 
improvement of imaging quality is not guaranteed. The enhanced stability of radiolabelled 
BN will also lead to the higher accumulation and longer retention of radiolabelled 
bombesins in normal organs and tissues, which will initially result in increase of 
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2.4.2  Improving the Binding Affinity with Multimerization 
The approach of maximizing binding affinity of radiolabelled peptides for receptors by 
multimerization started in the 1990s. Usually, a rationally-designed multimer consists of a 
framework and two or more motifs that target the desired binding site (Figure 4). The 
multimerization aims at increasing the receptor binding affinity and improving the binding 
kinetics of the biomolecule (40). A prominent example thereof is the use of radiolabelled 
cyclic RGD multimers(41). The monovalent-interactions between one multimer and 
neighboring receptors are key for a higher integrin αvβ3 receptors targeting capability and 








Figure 4. Schematic view of receptor targeted radiolabelled multimer. 
 
Several properties should be taken into account for the design of multimeric tracers, 
including the choice of frameworks and receptor specific motifs, the distance between 
motifs (flexibility of the spacer) and receptor density on targeted tumor cells. 
The framework of the multimer usually consists of a peptide, protein (antibodies or 
albumin), liposome, nanoparticle or small chemical compound. The framework mainly 
functions as a linker for several motifs that target the receptors of interest. Furthermore, the 
framework supplies active positions for radiolabelling or conjugation of chelators and/or 
radiolabelling group. For example, polyethylene glycolic acid (PEG) linkers have been 
successfully used as the framework for a variety of cyclic RGD multimers and are 
responsible for the enhanced integrin αvβ3-mediated avidity and improved in vivo kinetics 
(42-44).        
Accardoet al. (45) developed two liposomes obtained by co-assembling two different 
amphiphilic molecules for selective targeting of BN receptors (Figure 5). Compared to the 
corresponding aggregate containing the negative control peptide scrBN, 
only 111In-(C18)2DOTA/(C18)2L5-BN(7-14) has higher specific uptake on PC-3 cells. The 
presence of the PEG3000 unit on the external liposomal surface may have masked the 
peptide, thereby preventing receptor binding. Long circulation time (4-5 h half-life) in blood 
was observed. Only slightly increased on tumor uptake of 111In-(C18)2DOTA/(C18)2 
L5-BN(7-14) (2.4%ID/g) was observed when compared to the scrambled peptide as 


















































Figure 5. Schematic representation of amphiphilic monomers and liposomal aggregates. 
 
A 64Cu labelled dimeric BN was reported by Ma et al. (46). The dimeric BN peptide 
(L2-BBN2) was synthesized by conjugation of two Lys3-BN motifs to a single cage amine 
ligand (Figure 6). The 64Cu labeling was performed in high radiochemical yield at room 













Figure 6. Structure of dimeric Lys3-BN (compound name L2-BBN2). 
 
For BN multimers, as described above, a variety of GRPR specific BN motifs with 
high binding affinity have been developed.  
To further improve the tumor accumulation and imaging contrast of BN tracers, a 
heterodimer of RGD-BN, which can target two types of receptors (integrin αvβ3 and GRPR) 
simultaneously, was developed (47-54). The newly developed RGD-BN heterodimers 
shared two different bioactive ligands: Aca-BN(7-14) and c(RGDyK). A variety of linkers 
has been used to improve the in vivo pharmacokinetics and tumor accumulation of the 
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heterodimers. RGD-BN heterodimers have been labelled with 64Cu, 68Ga, 18F, and 99mTc for 
PET and SPECT imaging of prostate cancer, breast cancer and lung cancer (Table 1). 
The first RGD-BN heterodimer which has comparable binding affinity to the GRPR 
and integrin αvβ3, compared to corresponding BN and RGD monomers, was reported by Li 
et al. (47). 18F-RGD-BN had significantly higher tumor uptake and higher T/N ratios 
compared with 18F-FB-[Lys3]BN(1-14), resulting in significantly higher imaging quality. 
The results of blocking experiments in PC-3 tumor bearing mice indicate that both ligands 
(RGD and BN) are responsible for specific accumulation of the 18F-BN-RGD in tumor. 
RGD-BN is synthesized with glutamate as the framework. Actually RGD-BN is a mixture 
of Glu-BN-RGDGlu-RGD-BN (Figure 7). These isomers cannot be separated by HPLC. 
Also for improving the radiochemical yield, a -Glu-OAll was introduced as orthogonally 
protecting building block in a follow up study (48). A PEG3 spacer has also been inserted 
into the glutamate α–amino group to increase the hydrophilicity and to alleviate the steric 
hindrance without affecting the biological activity of RGD and BN motif (Figure 7). 
Both 18F RGD-BN heterodimers have comparable tumor uptake and non-specific tissue 
uptake, while the kidney uptake of 18F- PEG3-RGD-BN was lower.  
The glutamate linker was replaced by a symmetric linker 3, 3’- (2-amino- 
ethylazanediyl) dipropanoic acid (AEADP) to obtain a mixture of isomers of RGD-BN 
heterodimer (52). The 18F- AEADP-BN-RGD showed comparable tumor imaging ability 
as 18F- PEG3-RGD-BN. The 64Cu, 68Ca and 99mTc labelled bombesin heterodimers have 
been developed based on the identical RGD-BN (Figure 7, Table 1, table 2) (49-51, 
53-54). 68Ga-NOTA-RGD-BN showed higher tumor uptake and blood retention as 
compared to 18F and 64Cu-labelled RGD-BN. The T/NT ratios of 18F-FB-RGD-BN were all 
significantly higher than those of 68Ga-NOTA-RGD-BN and 64Cu-NOTA-RGD-BN due to 
the more rapid washout of 18F-FB-RGD-BN in blood and normal organs. 
The 99mTc-labelled HYNIC-RGD-BN dimer was compared with the gold standard 
tracer 18F-2-ﬂuoro-2-deoxyglucose (18F-FDG) in a lung carcinoma animal model (54). 
Compared to 18F-FDG, the tumor-to-muscle and tumor-to-inflammation ratio were 
significant higher although the absolute uptake of 99mTc- HYNIC-RGD-BN was lower. 
They also found that 99mTc- HYNIC-RGD-BN was able to detect the pulmonary metastases 
in mice. 
So far, 18F-PEG3-RGD-BN hetero-dimer is the most promising BN hetero dimer for 
nuclear imaging of GRPR positive prostate cancer. Compared to the corresponding RGD 
and BN tracers, 18F-PEG3-RGD-BN showed superiority in tumor uptake and in vivo 
kinetics.    
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Figure 7. Chemical structures of Glu-BN-RGD, 
Glu-RGD-BN, 18F-RGD-BN, 18F-PEG3-RGD-BN, Cu-NO2A-RGD-BN, 
Cu-NOTA-RGD-BN, c(RGDyK), and Aca-BN(7-14). 
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2.4.3  Agonist versus Antagonist BN Analogues 
An agonist is considered to be a ligand that activates receptors to produce second 
messengerst hat cause a cascade of biochemical transformations. An antagonist produces no 
effect on its own but blocks the effect of agonist by occupying the same active site of the 
receptor. Most BN radiotracers developed for cancer imaging are agonists, which can 
internalize into the tumor cells via membrane receptors. It has been suggested that this 
could result in higher accumulation than antagonists. The antagonists can be divided in to 
permissive and non-permissive antagonists according to their binding site on the G-protein 
coupled receptor (GCPR).  1) Permissive antagonist: if the antagonist binds to its own site 
on the receptor, it can (changes the shape of the receptor) modify the receptor reactivity 
toward agonist in different ways from increasing affinity to decreasing it 
(allostericmodulator), in other words, they impart probe-dependent effects on receptor.  2) 
Non-permissive antagonist: when antagonists bind to the agonist-binding site, it does not 
allow any agonist to impart information to the receptor (55). The probe could also be 
radiolabelled antagonist.   
Nowadays, newly developed BN antagonists with improved in vivo profiles such as 
high tumor accumulation, rapid clearance from normal organs, etc., may yield qualified 
candidates for cancer nuclear imaging as well.  
      A systematic comparison of one BN antagonist and four agonists was reported by 
Schroeder et al. (56). The five radiolabelled BN analogues were selected on the basis of 
their prostate cancer targeting efficacy reported previously and evaluated in PC-3 
tumor-bearing mice. The tumor uptake of Demobesin-1(antagonist) (Figure 8) reached peak 
levels (3.0±0.4 %/ID/g) at 1h p.i., although higher than other four analogues it was not 
significant different from that of AMBA (Figure 8) (2.7±0.5 %/ID/g) and PESIN (Figure 8) 
(2.3±0.5 %/ID/g). Comparing the decrease of Demobesin-1 uptake in tumor from 1h to 24h, 
the tumor uptake of AMBA and PESIN remain fairly stable which indicate better suitability 
for imaging at later time points or therapeutic applications. 
A comparison between an 18F-labelled BN antagonist and agonist was reported by 
Yang. et al. (57). The tumor uptake of 18F labelled agonist (MAGBBN 
(Gly-Gly-Gly-Arg-Asp- Asn-Gln-Trp-Ala-Val-Gly-His-Leu-MetNH2)) was almost doubled 
compared to the 18F labelled antagonist (MATBBN(Gly-Gly-Gly-Arg-Asp-Asn- 
D-Phe-Gln-Trp-Ala-Val-Gly-His-Leu-NHCH2CH3)) counterpart at 1h p.i.. They concluded 
that 18F-labelled BBN peptide agonists may be better tracers for prostate cancer imaging 
due to their relatively higher tumor uptake and retention as compared with the antagonist 
counterparts. 
Abirajet al. synthesized a 99mTc labelled BN antagonist N4-X-D-Phe-Gln-Trp-Ala- 
Val-Gly-His-Sta-Leu-NH2 (N4-BB-ANT) with high labeling yield (>97%) and specific 
activity (37 GBq/μmol) using 6-carboxy-1,4,8,11-tetraazaundecane as chelator (58). The 
tumor uptake was 22.5±2.6 %ID/g at 1 h after administration of the tracer and reached the 
highest uptake of 29.9±4%ID/g at 4 h p.i.. The SPECT images of PC-3 bearing mice 
showed a clear delineation of the tumor, low abdominal uptake (except the high uptake in 
pancreas) with the kidneys being the main excretion organ at 12 h p.i.. Due to the excellent 
accumulation, long retention in tumor, and high tumor-to-non-tumor 
ratios, 99mTc-N4-BB-ANT is a potential candidate as imaging probe for GRPR-positive 










































































































































Figure 8.  Chemical structures of 99mTc-Demobesin-1, 111In-AMBA and 111In-PESIN. 
 
An 18F-labelled BN antagonist (18F-BAY86-4367) (Figure 9) with favorable 
pharmacokinetics and rapid tumor targeting and retention has been reported by Honeret 
al.(59). The IC50 value of BAY86-4367 was 0.94±0.19 nM. The tumor uptake 
of 18F-BAY86-4367 in prostate cancer-bearing mice was 4.66±0.20%ID/g at 10 min p.i. and 
steady increased to 6.19±2.49 %ID/g while that of 18F-FDG and 18F-FCH was 1.02 
±0.08 %ID/g and 2.44±0.21 %ID/g at 1h p.i.. GRPR expressing murine pancreas also 
showed high uptake (>35%ID/g) of the 18F-BAY86-4367 at all examined time points. 
Consequently, 18F-BAY86-4367 may have higher diagnostic accuracy than the 18F-FDG 





























Figure 9.  Chemical structure of 18F-BAY86-4367 
 
A few comparative studies suggested that the in vivo behavior of receptor antagonists 
is superior to receptor agonists (35-36, 56, 60). However, Yang. et al. (57) observed 
different results from their studies based on a 18F labelled agonist and antagonist. Although 
radiolabelled BN antagonists with desirable tumor accumulation and in vivo behavior have 
been reported, it’s still not clear which would be better candidate for GRPR-positive cancer 
imaging.  
 
2.5  Chelator and Linker 
2.5.1  Bifunctional helator 
The choice of the bifunctionalchelator depends on the radionuclide and plays an 
important role in the performance of radiopharmaceuticals containing radiometals.  
The bifunctionalchelators of 99mTc have quite often been discussed regarding the 
binding affinity, hydrophilicity, stability of the BN tracers and the retention of these 
compounds in tumor cells. Ternary ligand systems has been introduced to the synthesis 
of 99mTc-HYNIC-Biomecule synthesis since 1990s. 6-hydazinonicotinic acid (HYNIC) is of 
great interest due to its high 99mTc-labeling efficiency, the high solution stability of its 99mTc 
complexes, and the easy use of different co-ligands (61). HYNIC has been employed 
for 99mTc labeling of a variety of bioactive peptides, such as RGD, Octreotide, IL-2, BN, 
and et al.(43, 54, 62-66). The preparation and preclinical evaluation of 99mTc-HYNIC 
(Tricine/TPPTS)-ε-aminocaproic acid-BN(7-14) (99mTc-HABN) in prostate cancer bearing 
mice was reported by Ananias et al.(65). ε-aminocaproic acid-BN(7-14) has also been 
labelled with 18F (18F-Aca-BN)and compared with 4-18F-Fluorobenzoyl-Lys3-bombesin 
(18F-Lys3-BN) (67) . Compared to 18F-Aca-BN (0.71 %ID/g at 30 min p.i.), 99mTc-HABN 
exhibited improved GRPR-mediate specific tumor uptake (2.24±0.64 %ID/g at 30 min p.i.) 
and retention. In contrast with 18F-Lys3-BN, although the absolute tumor uptake was lower, 
the T/NT ratios of 99mTc-HABN were comparable due to the rapid clearance. Due to the 
hydrophilicity of 99mTc-HYNIC/Tricine/TPPTS complex, the radioactivity accumulation in 
liver was 3-fold lower than that of 18F-Aca-BN and 18F-Lys3-BN at 1h p.i.. Santos-Cuevas 
et al. have reported a clinical study of 99mTc-EDDA/HYNIC-Lys3-BN of four breast cancer 
patients and seven healthy volunteers (68). The images of the GRPR expression in breast 
cancer patients show a distinct accumulation of radioactivity in malignant tissue. Although 
the uptake of 99mTc-EDDA/HYNIC-Lys3-BN in breast of cancer patients was higher than 
healthy volunteers, no statically significant difference was revealed. DTPA, DOTA, NOTA 
and their derivatives are the most commonly available chelators for the labeling 
of 177Lu, 111In, 68Ga, and 64Cu (11, 49-52, 69-72). Giacchetti et al. reported on the superior 
microPET imaging quality of 64Cu labelled NOTA-BN over that of DOTA-BN in a GRPR 
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expressing prostate cancer animal model (73). NO2A is a derivative of NOTA, which lacks 
a p-NCS-Bz arm and forms an amide linkage via the third carboxylic acid unit, resulting in 
a neutral conjugate upon binding to copper. The neutral conjugation may reduce the 
retention of 64Cu-BN in renal tissues. Compare to data of corresponding DOTA conjugated 
BNs, the NO2A conjugated BNs exhibited better in vivo profile (53, 73).  
Two Aoc linker modified BN analogues labelled with 64Cu using 
(1-N-(4-aminobenzyl)-3,6,10,13,16,19-hexaazabicyclo[6.6.6]- eicosane-1,8-diamine)(SarAr) 
as chelator was reported by Learset al.(74). Efficient radiolabelling of SarAr-BNs with 64Cu 
were achieved at room temperature. The PC-3 tumor uptake of 8.5%ID/g and 13.0%ID/g 
for 64Cu-SarAr-SA-Aoc-GSG-BN(7-14) and 64Cu-SarAr-SA-Aoc-BN(7-14) respectively at 
1h p.i were much higher than other 64Cu labelled BN analogues using DOTA or NOTA as 
chelators. The liver uptake of 64Cu-SarAr-SA-Aoc-GSG-BN(7-14) and 64Cu-SarAr 
-SA-Aoc-BN(7-14) were 5.1 and 9.5%ID/g at 1h p.i. which are at same level of most 
DOTA-BN analogues.  
Several new chelators such as Oxo-DO3A, PCAT, TRAP and bis(thiosemicarbanzone) 
chelators have been applied on BN radiopharmaceuticals (75-76), but the in vivo behavior 
of those novel BN tracers has not been evaluated yet. 
2.5.2.1  Full Length BN (Instead of Linker) 
The amino acids 7 to14 of BN are responsible for binding to the GRPR receptor. For 
full length BN analogues, first 6 amino acids in N terminal of BN could be considered as a 
linker. The Arg3, Leu4 are often replaced by Lys3 and Tyr4 for the attachment of chelators or 
labeling prosthetic groups for full length BN. Lys3-BN, one of the most well studied BN 
analogues, has been labelled with 99mTc, 64Cu, and 18F (67, 71, 77-78). Recently, Ho et al. 
synthesized a full length BN: [DTPA1, Lys3, Tyr4]BN and labelled with 111In (72). The Tyr4 
may allow further studies with radioiodine. Lower IC50 (1.05±0.46 nM) of [DTPA1, Lys3, 
Tyr4]BN was observed compared to the IC50 (2.2±0.5 nM )value of DOTA-Lys3-BN 
reported previously (71). The tumor uptake of 111In-[DTPA1, Lys3, Tyr4]BN was 
2.48±0.48% %ID/g at 8h p.i. High accumulation (32.0±9.78 %ID/g) of radioactivity was 
also observed in pancreas at 8h p.i.. Compared to the 99mTc-Lys3-BN (78), 111In-[DTPA1, 
Lys3, Tyr4]BN exhibited much higher accumulation in tumor and murine pancreas. The 
uptake values of 111In-[DTPA1, Lys3, Tyr4]BN in non-targeted organs such as blood, kidney, 
liver were also much higher than that of 99mTc-Lys3-BN.    
111In-[DTPA1, Lys3, Tyr4]BN was mainly excreted via urine, and high uptake was 
observed in kidney(>14%ID/g) until 48 hours post injection. When compared to 64Cu 
and 18F labelled Lys3-BN analogues, the 111In-[DTPA1, Lys3, Tyr4]BN exhibited lower PC-3 








































































































Figure 10. Chemical structures of PKM linkers 
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2.5.2.2  Other Linkers 
In general, linkers have been employed to improve the in vivo kinetics of the 
radiolabelled biomolecules. Garrison et al. concluded that the linker not only effects the in 
vivo clearance but also the in vivo uptake and retention of the radiopharmaceutical in 
targeted tissues (79). When comparing different linkers in similar bombesin peptides, 
the natIn-labelled conjugates had IC50 values of 0.51 ± 0.05, 0.7 ± 0.1, 1.13 ± 0.07, 1.88 ± 
0.06, 3.2 ± 0.3 and 6.2 ± 0.3 nM for the 8-AOC, Gly-AM2BA, AMBA, Gly-AMBA, 
8-ADS and 5-AOS (Figure 10), respectively. In general, the natIn-conjugates containing 
aromatic linking groups possessed higher binding affinities for the GRPR 
than natIn-conjugates with ether linking groups. The in vivo pancreatic uptake of the 
radiotracers did not correlate strongly with the tumor uptake. The differences of the 
radioactivity accumulation between pancreas and PC-3 tumor could be due to differences in 
the tumor vascular system and/or difference between murine and human GRPR homology.  
Since the high lipophilicity of the tracer leads to hepatobiliary excretion, and positive 
charge cause long retention in kidney, negatively charged or neutral and/or hydrophilic 
linkers such as amino acids and PEG were introduced to reduce the abdominal background 
of the radiolabelled BN analogues (48, 79-83).  
To optimize the GRPR-expressing tumor uptake and retention of the 64Cu labelled BN 
while retaining good pharmacokinetic properties, Lane et al. synthesized a series 
of 64Cu-NO2A-(X)-BN(7-14)NH2 (X=β-Ala, 5-Ava, 6-Ahx, 8-Aoc, 9-Anc or 
AMBA)(Figure 10). The spacer modification by substituting an aliphatic or aromatic 
linking substituent with varied length for X did not change the binding affinity of BN to 
GRPR. But the effect of hydrophilicity/hydrophobicity caused by linkers did change the in 
vivo kinetics of the radiotracer. The shorter, more hydrophilic pharmacokinetic modifier, 
AMBA was found to be the best candidate with highest tumor accumulation and most 
efficient clearance via renal excretion pathway, of the linkers which have been evaluated in 
their study (82).  
Series of hydrophilic carbohydrated groups (βAla-βAla, Lys(Sha)- βAla-βAla, 
Lys(Amd)- βAla-βAla, Ala(NTG)-βAlaβAla)(Figure 10) have been reported as linkers for 
the 99mTc-labelled truncated BN (80). Although the introduction of βAla-βAla led to 
improvedin vivo tumor uptake, poor tumor-to-liver and tumor-to-kidney ratios were 
reported due to the high radioactivity accumulation in liver and kidney. The introduction of 
shikimic acid and glucose results in increased polarity of the new 99mTc-labelled analogues. 
The results of in vivo studies indicate that the introduced polar carbohydrates had no effect 
on internalization, efflux, or metabolic stability in vitro but led to a significant positive 
impact of the in vivo kinetics which include higher tumor uptake, reduction of abdominal 
accumulation and improved tumor-to-background ratios. The inference of molecular charge 
of polar linkers on the biodistribution of the 99mTc-labelled BN analogues was also 
evaluated (83). The introduction of a positive charge (β3hLys) resulted in unfavorable 
increased kidney uptake. The introduction of an uncharged hydroxyl group (β3hSer), one or 
two negative charges compounds (β3hGlu, β3hGlu-β3hGlu) significant improved the 
tumor-to-tissue ratios. Better SPECT imaging with an enhanced delineation of the 
xenografts and decreased radioactivity in the abdominal area was provided by single charge 
linker (β3hGlu-βAla-βAla) containing BN tracer than by other analogues with uncharged 
(βAla-βAla) or two negative charges (β3hGlu-βAla-βAla) linker. The superior 
biodistribution characteristics of the negative charge linker than of the positive charge 
linker for the 18F-labelled non-natural amino acids modified BN has also been reported by 
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Mu et al.(81). 18F-7b with negative charged linker Ala(SO3H)-Ava exhibited more than 
doubled tumor accumulation (4.67±0.04 %ID/g at 1h p.i.) than the 18F-6b 
(2.36±0.47 %ID/g at 1h p.i.) with the positive charged linker Arg-Ava. Although bearing 
the same BN peptide sequence and having the same lipophilicity, the charge of the linker 
plays a major role in in vivo pharmacokinetics. Liu et al. also found that the introduction of 
the PEG linker can improve the tumor uptake and excretion kinetics of RGD-BN hetero 
dimer (48). 
Linkers/spacers which can improve the in vivo kinetics and clearance are very 
useful for the development of radiopharmaceuticals. The hydrophilic linkers/spacers with 
an aromatic group, or/and negative charge may be the best option of the linkers that 
reviewed in this article.  
 
2.6  Clinical Imaging Studies with GRPR Targeted Radiotracers 
The safety, radiopharmaceutical biokinetics, dosimetry of 99mTc-HYNIC-BN and the 
feasibility of imaging GRPR in breast cancer were determined in seven healthy women and 
in four women with breast cancer (68). No adverse reaction was found after administration 
of 99mTc-HYNIC-BN (555-740 MBq). No significant differences of blood clearance and 
absorbed doses for the main organs were observed between health women and patients with 
breast cancer. Tumor-to-normal-breast tissue ratio was 1.58±0.19 at 90 min. Although a 
significant difference (p<0.05) was found in the accumulation of 99mTc-HYNIC-BN 
between normal mammary gland and mammary gland of patients, the relationship between 
radioactivity accumulation and GRPR expression has not been confirmed. 
     Two clinical studies of 68Ga-labelled BN analogues (68Ga-BZH3) were reported by 
Dimitrakopoulou-Strauss et al.. and Strauss et al.(84-85). Fifteen patients with 
histologically confirmed recurrent gliomas were studied to investigate the relation between 
the pharmacokinetics of68Ga-BZH3 data and the (WHO) grading of recurrent gliomas (85). 
Furthermore, the pharmacokinetic 68Ga-BZH3 was compared with the 18F-FDG kinetics. Of 
fifteen patients, ten patients revealed an increased uptake of as 68Ga-BZH3 compared with 
surrounding brain parenchyma while three patients also demonstrated an increase uptake 
of18F-FDG as well. Another three patients revealed an enhanced FDG metabolism without 
increased 68Ga-BZH3 uptake. They found that, the identification of high-grade gliomas was 
better with 68Ga-BZH3 than with18F-FDG, since 68Ga-BZH3 revealed an enhanced uptake 
in more patients with high WHO grade than 18F-FDG (4 vs 3 of 6 with WHOII, and 3 vs 0 
of 3 patients with WHO IV). From the results with 68Ga-BZH3, they found high fractional 
blood volume VB (>0.07) and k1 (>0.2) values gave evidence of a high-grade glioma.  
The kinetics of 68Ga-BZH3 was compared to molecular data obtained from gene arrays 
in seven recurrent glioma patients in their second clinical article on 68Ga-BZH3 (84). Their 
results demonstrated a preferential enhancement of the BB2 and BB3 receptor. The 
compartment parameter k1 was correlated with the expression of BB2 (r=0.89), while k3, 
reflecting the internalization, revealed no significant correlation. They concluded that the 
expression of BB2 may be predicted by kinetics of 68Ga-BZH3. 
 
2.7  Conclusion 
     In the last decade, the development of BN tracers for receptor targeting nuclear 
imaging has increasingly gained attention. New biomolecules (multimers) and concepts 
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(agonist, antagonist) have been successfully introduced for improving the targeting ability 
and nuclear imaging quality of GRPR expressing cancer.      
Novel tracers which were based on BN such as [111In] DOTA-PESIN, [111In]AMBA, 
99mTc-Demobesin 1 (56) , [111In/68Ga]-RM1 (60), 99mTc-N4-BB-ANT (58), 18F-BAY86-4367 
(59) have better imaging characteristics than previously reported BN analogues. These 
tracers are promising probes for GRPR nuclear imaging.  
 
Table 2 Radionuclides reviewed in this article. 
Radionuclide T1/2 Emax (kev) 
99mTc 6.0 h 141 
111In 67.2 h 245 
18F 109.7 min 635 
64Cu 12.7 h 655 
68Ga 68.1 min 1900 
177Lu 6.7 d 497 
90Y 2.7 d 2270 
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In this report, we present the synthesis and evaluation of the 99mTc-labelled 
β-Ala-BN(7-14)NH2 (ABN = β-Ala-Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH2) as a new 
radiotracer for tumor imaging in the BALB/c nude mice bearing HT-29 human colon cancer 
xenografts.  The gastrin releasing peptide receptor binding affinity of ABN and 
HYNIC-ABN (6-hydrazinonicotinamide) were assessed via a competitive displacement 
of 125I-[Tyr4]BBN bound to the PC-3 human prostate carcinoma cells.  The IC50 values 
were calculated to be 24 ± 2 nM and 38 ± 1 nM for ABN and HYNIC-ABN, respectively.  
HYNIC is the bifunctional coupling agent for 99mTc-labeling while tricine and TPPTS 
(trisodium triphenylphosphine-3,3',3''-trisulfonate) are used as coligands to prepare the 
ternary ligand complex [99mTc(HYNIC-ABN)(tricine)(TPPTS)] in very high yield and high 
specific activity.  Because of its high hydrophilicity (log P = -2.39 ± 0.06), 
[99mTc(HYNIC-ABN)(tricine)(TPPS)] was excreted mainly through the renal route with 
little radioactivity accumulation in the liver, lungs, stomach, and gastrointestinal tract.  
The tumor uptake at 30 min postinjection (p.i.) was 1.59 ± 0.23 %ID/g with a steady tumor 
washout over the 4 h study period.  As a result, it had the best T/B ratios in the blood (2.37 
± 0.68), liver (1.69 ± 0.41) and muscle (11.17 ± 3.32) at 1 h p.i.  Most of the injected 
radioactivity was found in the urine sample at 1 h p.i., and there was no intact 
[99mTc(HYNIC-ABN](tricine)(TPPTS)] detectable in the urine, kidney and liver samples.  
Its metabolic instability may contribute to its rapid clearance from the liver, lungs and 
stomach.  Despite the steady radioactivity washout, the tumors could be clearly visualized 
in planar images of the BALB/c nude mice bearing the HT-29 human colon xenografts at 1 
and 4 h p.i.  The favorable excretion kinetics from the liver, lungs, stomach, and 
gastrointestinal tract makes [99mTc(HYNIC-ABN)(tricine)(TPPTS)] a promising SPECT 
radiotracer for imaging colon cancer. 
 














3.1  Introduction 
Colon cancer is the second leading cause of cancer-related death.  It is estimated 
that about 130,000 men and women will develop colon cancer and more than 50,000 will 
die from it each year in the United States (American Cancer 
Society: http://www.cancer.org).  The life-time risk for individuals to develop colon cancer 
is ~6%, but it may increase to 18% among the individuals who have a relative (parent, 
sibling or child) with colon cancer.  Therefore, accurate early detection is highly desirable 
so that various therapeutic regimens can be given before the primary tumors become widely 
spread.   
Bombesin (BN) is a small peptide containing 14 amino acids(Glu-Gln-Arg-Leu- 
Gly-Asn-Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH2). It was originally isolated from the skin 
of amphibian Bombina Orientalis (1, 2).  The BN-like peptides have very high binding 
affinity for the gastrin releasing peptide (GRP) receptor (3-5), and produce a wide range of 
biological responses in peripheral tissues as well as in the central nervous system, including 
stimulation of gastrointestinal hormone release, exocrine secretion and maintenance of 
circadian rhythms.  In addition, it has been established that the GRP/BN peptides 
promotes proliferation in cancer cells.  The overexpression of GRP receptor (GRPR) has 
been demonstrated in a large number of tumors, including prostate, breast, colon and small 
cell lung cancer (6-13).  The distribution of BN-like peptides and the expression of their 
receptors have been reviewed (3, 4).  Because of its highly restricted overexpression on 
tumor cells, the GRPR is emerging as an attractive target for both cancer therapy and early 
detection (3, 4, 14-17).   
BN(7-14)NH2 is the peptide sequence responsible for specific binding of the 
GRPRs overexpressed on tumor cells.  Most of the radiolabelled BN-like peptides are 
based on or contain the BN(7-14)NH2 peptide sequence.  These radiolabelled BN-like 
peptides were designed as tumor-specific radiotracers for early diagnosis or systemic 
radiotherapy of the GRPR-positive tumors, and have been reviewed extensively (14-17).  
The radionuclides include 111In (18-20), 177Lu (21-23), 68Ga (24), 64Cu (25-32), 188Re (33), 
and 99mTc (34-47).  While 68Ga and 64Cu are particularly useful for imaging tumors by 
positron emission tomography (PET), 99mTc is the radionuclide of choice for tumor imaging 
by single photon computed tomography (SPECT) due to its excellent nuclear properties (t1/2 
= 6 h and single photon emission at 140 keV), rich and diverse coordination chemistry, 
easy availability at low cost, and high specific activity (48-50).   
In this study, we used β-Ala-BN(7-14)NH2 (Figure 1: ABN in short) as the 
biomolecule for tumor targeting and 6-hydrazinonicotinic acid (HYNIC) as the bifunctional 
coupling agent (BFC) for the 99mTc-labeling.  Since HYNIC is monodentate in 
the 99mTc-HYNIC core, tricine and TPPTS (trisodium 
triphenylphosphine-3,3',3''-trisulfonate) are used as coligands to prepare the complex 
[99mTc(HYNIC-ABN)(tricine)(TPPTS)] (Figure 1).  This ternary ligand system (HYNIC, 
tricine and TPPTS) has been successfully used for the 99mTc-labeling of small biomolecules, 
including chemotactic peptides (51) and LTB4 receptor antagonists (52, 53) for imaging 
infection and inflammation, integrin αvβ3 antagonists for imaging tumor angiogenesis 
(54-58), and GPIIb/IIIa receptor antagonists for imaging deep vein thrombosis (59).  The 
BALB/c nude mice bearing HT-29 human colon cancer xenografts were used for both 
biodistribution and imaging studies.  Normal BALB/c nude mice were used for 
metabolism study.  The main objective is to evaluate 
[99mTc(HYNIC-ABN)(tricine)(TPPTS)] as a potential new radiotracer for SPECT imaging 
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Figure 1. Structure of the ternary ligand complex [99mTc(HYNIC-ABN)(tricine)(TPPTS)]. 
 
3.2  Experimental 
3.2.1  Materials 
Tricine and TPPTS were purchased from Sigma/Aldrich (St. Louis, MO), and were 
used without further purification.  The peptide conjugate, HYNIC-β-Ala-BN(7-14)NH2 
(HYNIC-ABN), was obtained from CS Bio Co. (Menlo Park, CA).  Na99mTcO4 was 
obtained from a commercial 99Mo/99mTc generator (Beijing Atom High Tech Co. Ltd., 
Beijing, China).  125I-[Tyr4]BBN was obtained from Perkin-Elmer Life and Analytical 
Sciences (North Billarica, MA). 
 
3.2.2  Methods 
The radio-HPLC method used a HP Hewlett® Packard Series 1100 HPLC system 
equipped with a Radioflow Detector LB509 and a reversed-phase Zorbax SB-C18 column 
(4.6 mm x 250 mm, 5 μm).  The flow rate was 1.0 mL/min.  The mobile phase was 
isocratic with 90% solvent A (0.01 M phosphate buffer, pH = 6.0) and 10% solvent B 
(acetonitrile) at 0-5 min, followed by a gradient mobile phase going from 10% solvent B at 
5 min to 50% solvent B at 20 min, then to 80% solvent B at 22 min, and back to baseline 10% 
solvent B at 25 min.  The ITLC method used Gelman Sciences silica-gel paper strips and a 
1:1 mixture of acetone and saline as eluant.  The 99mTc complexes migrated to solvent 
front while 99mTcO4- and [99mTc]colloid remained at origin.   
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3.2.3  Synthesis of [99mTc(HYNIC-ABN](tricine)(TPPTS)] 
To a clean 5 cc vial were added 100 μL of the HYNIC-ABN solution (100 μg/mL in 
H2O), 100 μL of tricine solution (100 mg/mL in 25 mM succinate buffer, pH 5.0), 20 μL of 
SnCl2 solution (3.0 mg/mL in 0.1 N HCl) and 100 μL of Na99mTcO4 (370 MBq) in saline.  
The reaction mixture was kept at room temperature for 10 min.  To the reaction mixture 
above was added 120 μL of the TPPTS solution (50 mg/mL in 25 mM succinate buffer, pH 
5.0).  The vial containing the reaction mixture was sealed, cramped, and heated at 100 oC 
for 30 min.  After cooling to room temperature, a sample of the resulting solution was 
analyzed by ITLC and radio-HPLC. 
 
3.2.4  Dose Preparation for Animal Studies 
[99mTc(HYNIC-ABN](tricine)(TPPTS)] was purified using a Sep-Pak C-18 cartridge 
(Waters, MA) before being used for animal studies.  The Sep-Pak C-18 cartridge was 
activated with ethanol (10 mL) and was washed with water (10 mL).  After the radiotracer 
was loaded, the Sep-Pak C-18 cartridge was washed with saline (10 mL) to remove the 
unlabelled 99mTc and excess coligands.  The radiotracer was eluted with 80% ethanol (0.4 
mL).  Doses for animal studies were prepared by dissolving the Sep-Pak purified 
radiotracer in saline to give a concentration of 150 μCi/mL for biodistribution study, 4.0 
mCi/mL for the metabolism study, and 2.0 mCi/mL for the planar imaging study.  
 
3.2.5  Partition Coefficient 
The partition coefficient was determined using the following procedure: 
[99mTc(HYNIC-ABN](tricine)(TPPTS)] was prepared and purified using the Sep-Pak C-18 
cartridge.  Volatiles in the mobile phase were completely removed under vacuum.  The 
residue was dissolved in a mixture of equal volume (0.5 mL:0.5 mL) n-octanol and 25 mM 
phosphate buffer (pH = 7.4).  After vortexing for 2 min, samples in triplicate were 
obtained from n-octanol and aqueous layers, and were counted in a γ-counter (Wallac 
1470-002, Perkin Elmer, Finland).  The log P value is reported as an average of three 
different measurements. 
 
3.2.6  In Vitro Cell-Binding Assay  
In vitro GRPR binding affinity and specificity of ABN and HYNIC-ABN were 
assessed via a competitive displacement assay with 125I-[Tyr4]BBN as the radioligand.  
Experiments were performed using the GRPR-positive PC-3 prostate carcinoma cells 
according to the literature method (32).  The 50% inhibitory concentration (IC50) values 
were calculated by fitting the data with nonlinear regression using Graph-Pad Prism 4.0 
(GraphPad Software, San Diego, CA).  Experiments were performed twice with triplicate 




3.2.7  Internalization Kinetics   
The internalization assay was performed according to the literature method (37, 47) 
with slight modification.  Briefly, the HT-29 cells were incubated in the 24-well plates in 
quadruplicate with [99mTc(HYNIC-ABN](tricine)(TPPTS)] (~0.1 μCi/well) for 2 h at 4 ºC, 
and then were washed with ice-cold PBS to remove the unbound radioactivity.  After 
washing, the cells were incubated in the pre-warmed culture medium at 37 ºC for 0, 5, 15, 
30, 60 and 120 min for internalization.  The cell-surface bound radiotracer was removed 
by acid wash (50 mM glycine-HCl/100 mM NaCl, pH 2.8).  Subsequently, the cells were 
solubilized by incubation with 2 M NaOH at 37 °C, and the resulting solution in each well 
was harvested to determine the internalized radioactivity in a γ-counter (Wallac 1470-002, 
Perkin Elmer, Finland).  The results were expressed as a percentage of the total 
radioactivity (surface-bound plus internalized).  The same experiment was performed 
twice with quadruplicate samples. 
 
3.2.8  Efflux Kinetics  
The HT-29 cells cultured in 24-well plates were incubated at 37 ºC with 
[99mTc(HYNIC-ABN](tricine)(TPPTS)] (~0.1 μCi/well) for 1 h to allow maximal 
internalization.  The cells were washed three times with ice-cold PBS to remove the 
unbound radioactivity, then were incubated in the pre-warmed culture medium at 37 ºC for 
a specific period of time (0, 15, 30, 60, 120 and 240 min).  At the specified time point, the 
cell-surface bound radioactivity was removed by acid wash (50 mM glycine-HCl/100 mM 
NaCl, pH 2.8).  Subsequently, the cells were solubilized by incubation with 2 M NaOH at 
37 °C, and the resulting solution in each well was harvested to determine the internalized 
radioactivity in a γ-counter (Wallac 1470-002, Perkin Elmer, Finland).  Data is expressed 
as percentage of maximal intracellular radioactivity.  The same experiment was performed 
twice with quadruplicate samples. 
 
3.2.9  Animal Model 
All animal experiments were performed in accordance with guidelines of Peking 
University Health Science Center Animal Care and Use Committee. The HT-29 human 
colon cancer cells were obtained from Professor Xiaoyan Qiu, Peking University Health 
Science Center, and were maintained at 37 oC and 5% CO2 in Dulbecco’s modified Eagle’s 
medium (DMEM) containing 10% fetal bovine serum (FBS).  Female BALB/c nude mice 
(4 – 5 weeks of age) were purchased from the Department of Experimental Animal, Peking 
University Health Science Center.  The HT-29 cells (5 × 106) were implanted 
subcutaneously into the right upper flanks of nude mice.  When tumors reached ~0.8 cm in 
mean diameter, the tumor-bearing mice were used for biodistribution and imaging studies.  
Sixteen tumor-bearing mice were randomly divided into four groups, each of which had 
four animals.  Each tumor-bearing mouse was administered intravenously with 
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[99mTc(HYNIC-ABN](tricine)(TPPTS)] (~15 μCi) dissolved in 0.1 mL of saline via the tail 
vein.  Animals were anesthetized with intraperitoneal injection of sodium pentobarbital at 
a dose of 45.0 mg/kg, and were sacrificed by cervical dislocation at 0.5, 1, 2 and 4 h 
postinjection (p.i.).  Blood was withdrawn from the eye through a capillary tube.  Organs 
of interest (tumor, heart, liver, spleen, kidney, lung, stomach, intestine, and muscle) were 
harvested, washed with saline, dried with absorbent tissues, weighed, and measured for 
radioactivity in a γ-counter (Wallac 1470-002, Perkin Elmer, Finland).  The organ uptake 
was calculated as a percentage of the injected dose per gram of tissue mass (%ID/g).  The 
biodistribution data and T/B ratios were reported as an average plus the standard deviation 
based on the results from four animals at each time point.   
 
3.2.10  Metabolism   
The metabolic stability of [99mTc(HYNIC-ABN](tricine)(TPPTS)] was evaluated 
using two normal BALB/c nude mice. Each mouse was administered via tail vein with the 
radiotracer (~800 μCi) dissolved in 0.2 mL saline. The urine samples were collected at 1 h 
p.i. by manual void, and were mixed with an equal volume of saline. The mixture was 
centrifuged at 8000 rpm for 5 min. The supernatant was collected and filtered through a 
0.22 μm Millex-LG syringe driven filter unit to remove the precipitate and large proteins. 
The filtrate was analyzed by radio-HPLC. Both the liver and kidney simples were also 
harvested at 1 h p.i., and were pulped. The homogenates were mixed with an equal volume 
of saline, separately. The resulting mixture was vortexed for 5 – 10 min.  After 
centrifuging at 8000 rpm for 5 min, the supernatant was collected and passed through a 0.22 
μm Millex-LG syringe driven filter unit to remove any precipitate and particles. The filtrate 
was then analyzed by radio-HPLC. 
 
3.2.11  Scintigraphic Imaging  
The imaging study was performed using the female BALB/c nude mice bearing the 
HT-29 human colon cancer xenografts.  Animals were anesthetized with intraperitoneal 
injection of sodium pentobarbital at a dose of 45.0 mg/kg.  Each tumor-bearing mouse was 
administered intravenously with [99mTc(HYNIC-ABN](tricine)(TPPTS)] (~400 µCi) in 0.2 
mL saline via tail vein.  Animals were placed prone on a two-head γ-camera (SIEMENS, 
E. CAM) equipped with a parallel-hole, low-energy, and high-resolution collimator.  
Posterior images were acquired 1 h and 4 h p.i.  The imaging data were stored digitally in 
a 128 x 128 matrix.  The acquisition count limits were set at 200 K.  In the blocking 
experiment, each tumor-bearing mouse was administered intravenously with excess 
HYNIC-ABN (300 µg dissolved in 0.1 mL of saline) 30 min prior to administration of 
[99mTc(HYNIC-ABN](tricine)(TPPTS)].  The posterior images were acquired 1 h p.i. 
using the same procedure above.  After completion of imaging, animals were sacrificed by 
cervical dislocation.  
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3.3  Results 
3.3.1  GRP Receptor Binding Affinity of ABN and HYNIC-ABN   
The in vitro GRPR binding affinities and specificities of ABN and HYNIC-ABN 
were assessed via a competitive displacement assay using 125I-[Tyr4]BBN as the 
radioligand. It was found that ABN and HYNIC-ABN were able to compete 
with 125I-[Tyr4]BBN bound to PC-3 prostate carcinoma cells (Figure 2).  The IC50 values 
were 24 ± 2 nM and 38 ± 1 nM for ABN and HYNIC-ABN, respectively.  The attachment 
of HYNIC group seems to slightly reduce the GRPR binding affinity of ABN; but this 
difference may not be significant within the error of this assay.  
























Figure 2.  Displacement curves of 125I-[Tyr4]BBN bound to the GRPR-positive PC-3 
human prostate carcinoma cells by ABN and HYNIC-ABN. The IC50 values were 
calculated to be 24 ± 2 nM and 38 ± 1 nM for ABN and HYNIC-ABN, respectively. 
 
3.3.2  Radiochemistry 
[99mTc(HYNIC-ABN](tricine)(TPPTS)] was prepared in two steps.  First, 
HYNIC-ABN reacted with Na99mTcO4 in the presence of excess tricine and SnCl2 to form 
the intermediate [99mTc(HYNIC-ABN)(tricine)2], which was then allowed to react with 
TPPTS to form the ternary ligand complex [99mTc(HYNIC-ABN](tricine)(TPPTS)].  The 
specific activity was ~120 mCi/µmol.  The radiochemical purity was >95% after Sep-Pak 
purification. [99mTc(HYNIC-ABN](tricine)(TPPTS)] was analyzed using a reversed-phase 
HPLC method. A radio-HPLC chromatogram is shown in the top panel of Figure 3. The 
HPLC retention time was 12.2 min for [99mTc(HYNIC-ABN](tricine)(TPPTS)]. The 
47 
partition coefficient was determined in an equal volume mixture of n-octanol and 25 mM 
phosphate buffer (pH = 7.4). The log P value was -2.39 ± 0.06. The solution stability of 
[99mTc(HYNIC-ABN](tricine)(TPPTS)] was monitored by radio-HPLC in saline and in the 
presence of excess cysteine (1.0 mg/mL, pH = 7.4).  The solution stability data of 
[99mTc(HYNIC-ABN](tricine)(TPPTS)] is shown in the bottom panel of Figure 3. It is quite 
clear that [99mTc(HYNIC-ABN](tricine)(TPPTS)] is able to maintain its stability over 12 h 
in saline and in the presence of excess cysteine. 
 
    














Figure 3.A typical radio-HPLC chromatogram (92) and solution stability data (bottom) 
for [99mTc(HYNIC-ABN)(tricine)(TPPTS)] in saline and in the presence of excess 
cysteine (1 mg/mL, pH = 7.4). 
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3.3.3  Internalization and Efflux Kinetics  
The internalization and efflux kinetics of [99mTc(HYNIC-ABN](tricine)(TPPTS)] is 
shown in Figure 4.  The rate of internalization was time and temperature dependent.  At 
4°C, the receptor binding took place; but there was no internalization (< 1%).  At 37°C, 
there was a rapid internalization with 35 ± 2% of the cell-associated radioactivity being 
internalized at 5 min post-incubation (Figure 4, Left).  The maximum was reached with 68 
± 5% of the internalized radioactivity at 30 min post-incubation.  In spite of the fast 
internalization, there was no significant retention of radioactivity inside tumor cells since 
the internalized radioactivity was quickly released.  After 15 min incubation at 37 °C, 49 ± 
3% of the internalized radioactivity remained.  Only ~20% of the internalized radioactivity 
remained after 1 h (Figure 4, Right). 
























































Figure 4. Internalization (left) and efflux (right) kinetics of [99mTc(HYNIC-ABN)(tricine) 
(TPPTS)]. 
 
3.3.4  Biodistribution Characteristics  
The biodistribution study was performed using the BALB/c nude mice bearing HT-29 
human colon cancer xenografts.  The selected biodistribution data and T/B ratios for 
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[99mTc(HYNIC-ABN)(tricine)(TPPTS)] are summarized in Figure 5.  In general, 
[99mTc(HYNIC-ABN)(tricine)(TPPTS)] had a rapid clearance, predominantly through the 
renal route.  Most of the injected dose was in the urinary system by 1 h p.i. with little 
radioactivity accumulation in the blood (0.50 ± 0.15 %ID/g), liver (0.68 ± 0.16 %ID/g), 
muscle (0.14±0.04 %ID/g), and gastrointestinal tract (0.63 ± 0.21 %ID/g) at 1 h p.i.  The 
tumor uptake was the highest (1.59 ± 0.23 %ID/g) at 30 min p.i., with a steady decrease 
over the 4 h study period.  [99mTc(HYNIC-ABN](tricine)(TPPTS)] had the best T/B ratios 
for blood (2.37 ± 0.68), liver (1.69 ± 0.41), and muscle (11.17 ± 3.32) at 1 h p.i.    





























Figure 5.  Organ uptake (92) and T/B ratios (bottom) for [99mTc(HYNIC-ABN) 
(tricine)(TPPTS)] in BALB/c nude mice bearing the HT-29 human colon cancer 




3.3.5  Imaging Studies 
 
Figure 6.  Static planar images of the tumor-bearing mice administered with ~400 
µCi of [99mTc(HYNIC-ABN)(tricine)(TPPTS)] at 1 h (left) and 4 h p.i. (middle), as 
well as in the presence of excess HYNIC-ABN (right).  Arrows indicate the presence 
of the tumor (T) and kidneys (K). 
 
Figure 6 illustrates representative planar images of the tumor-bearing mice 
administered with ~400 µCi of [99mTc(HYNIC-ABN)(tricine)(TPPTS)] at 1 h (left) and 4 h 
p.i. (middle), as well as in the presence of excess HYNIC-ABN (right) at 1 h p.i.  Arrows 
indicate the presence of the tumor (T) and kidneys (K).  The HT-29 tumor is clearly 
visualized at 1 h p.i. with excellent tumor-to-background contrast.  At 1 h p.i., the “hottest” 
spots are tumor, kidneys and bladder.  By 4 h p.i., the radioactivity in the chest region 
almost completely disappears while the tumor is still clearly seen.  These data are 
consistent with those obtained from the ex vivo biodistribution study (Figure 5). 
The blocking experiment by pre-injecting or co-injecting a known receptor ligand 
is often used to demonstrate the tumor-specificity of the target-specific radiotracers.  In 
this study, we used HYNIC-ABN as the blocking agent.  Pre-injection of excess 
HYNIC-ABN result in a significant reduction in the tumor uptake of 
[99mTc(HYNIC-ABN)(tricine)(TPPTS)] (Figure 6: right), indicating that its tumor 
localization is at least partially GRPR-mediated. There is also a significant reduction in 
radiotracer accumulation in several non-cancerous organs, such as liver, stomach, intestine 
and kidneys, due to the blockage of GRPRs in these organs (1, 3, 4). 
 
3.3.6  Metabolic Properties 
Metabolism study was performed using normal BALB/c mice by analyzing the 
samples from urine, kidney and liver. Figure 7 shows typical radio-HPLC chromatograms 
51 
of [99mTc(HYNIC-ABN](tricine)(TPPTS)] in the kit matrix before injection (A), in the urine 
(B), in the kidney (C), and in the liver (D).  [99mTc(HYNIC-ABN](tricine)(TPPTS)] was 
completely metabolized in urine, kidney and liver samples at 1 h p.i.  The majority of the 
injected radioactivity was found in the urine sample at 1 h p.i.  The radioactivity level was 
almost undetectable in the liver and kidney samples.   
    
     
Figure 7.  Radio-HPLC chromatograms of [99mTc(HYNIC-ABN)(tricine)(TPPTS)] in 
the kit matrix before injection (A), in the urine (B), in the liver (C), and in the kidney 
(D) at 1 h p.i. 
 
3.4  Discussion 
Since colon cancer occurs in the torso area, it is necessary for the radiotracer to 
have a minimal radioactivity accumulation in the liver, lungs, stomach and gastrointestinal 
tract.  There are several factors influencing the radiotracer excretion kinetics.  These 
include the molecular charge, solution stability, lipophilicity and metabolic stability of the 
radiotracer.  For the last several years, intensive efforts have been made to optimize the 
radiotracer pharmacokinetics by using different 99mTc cores (34, 36, 37, 41, 44, 46), BFCs 
(34, 39, 44) and linker groups (36, 39).  It was reported that the linker groups, such as 
β-Ala–β-Ala or 3,6-dioxa-8-aminooctanoic acid, had a significant impact on tumor uptake, 
excretion kinetics and metabolic stability of the 99mTc-labelled BN(7-14)NH2 (36).  A 
major disadvantage of using the 99mTc(CO)3+ core for the 99mTc-labeling of BN(7-14)NH2 
derivatives is that the radiotracer often has high uptake in the liver and intestine (36).  
Recently, NOTA and DOTA were used as BFCs for preparation of the 64Cu-labelled 
BN-like peptides (25-29).  Results from biodistribution and microPET imaging studies 




lungs, stomach and intestine (29).  The BFCs and radiometal chelates can be used to 
improve the radiotracer clearance from the non-cancerous organs.     
In this study, we used HYNIC as the BFC and tricine/TPPTS as coligands to 
prepare [99mTc(HYNIC-ABN](tricine)(TPPTS)].  We found that [99mTc(HYNIC-ABN] 
(tricine)(TPPTS)] was excreted rapidly via the renal route with very little radioactivity 
accumulation in the blood, liver, muscle and gastrointestinal tract at >1 h p.i. (Figure 5).  
The tumor uptake was the highest (1.59 ± 0.23 %ID/g) at 30 min p.i. with a steady decrease 
over the 4 h study period.  This radiotracer had the best T/B ratios in the blood (2.37 ± 
0.68), liver (1.69 ± 0.41) and muscle (11.17 ± 3.32) at 1 h p.i.  The rapid tumor washout is 
also seen in images of the tumor-bearing mice (Figure 6), which is consistent with the rapid 
efflux kinetics of [99mTc(HYNIC-ABN](tricine)(TPPTS)] (Figure 4). Similar tumor 
washout was also reported for the 99mTc(CO)3-labelled BN(7-14)NH2 derivatives (36, 37).  
Results from the blocking experiment show that the tumor uptake of 
[99mTc(HYNIC-ABN](tricine)(TPPTS)] is at least partially GRPR-mediated.  The 
radiotracer uptake decreased in the liver, stomach and intestine in the presence of excess 
HYNIC-ABN, which strongly suggests that the GRPRs are also expressed in these organs.  
Compared with the 99mTc(CO)3-labelled His-linker-BN(7-14)NH2 (linker = β-Ala–β-Ala or 
3,6-dioxa-8-aminooctanoic acid) (36),  [99mTc(HYNIC-ABN](tricine)(TPPTS)] has the 
advantage with respect to its rapid clearance from blood, liver, muscle and gastrointestinal 
tract. 
The solution stability data shows that [99mTc(HYNIC-ABN](tricine)(TPPTS)] is 
stable for > 12 h in the presence of excess cysteine (Figure 3).  However, results from the 
metabolism study indicate that [99mTc(HYNIC-ABN](tricine)(TPPTS)] is completely 
metabolized at 1 h p.i. in the urine, kidney and liver samples, probably due to rapid 
enzymatic degradation.  Earlier studies showed that BN-like peptides could be easily 
metabolized by the neutral endopeptidase E.C.3.4.24.11 and the angiotensin-converting 
enzyme (60-62).  This metabolic instability may contribute, in part, to the rapid washout 
of [99mTc(HYNIC-ABN](tricine)(TPPTS)] from tumor and non-cancerous organs, such as 
the liver, lungs, muscle, stomach and gastrointestinal tract. 
 The GRPR binding affinities of ABN and HYNIC-ABN are very similar to those 
reported for DOTA-Linker-Bombesin(7-14) (Linker = triglycine, glycine-serine-glycine or 
glycine-serine-serine) (27) and those reported for the Re(CO)3 complexes of 
His-linker-BN(7-14)NH2 (linker = β-Ala–β-Ala or 3,6-dioxa-8-aminooctanoic acid) (36).  
However, the tumor uptake of [99mTc(HYNIC-ABN](tricine)(TPPTS)] in HT-29 colon 
cancer is not as high as those reported for the 64Cu-labelled DOTA-Linker-Bombesin(7-14) 
conjugates (Linker = triglycine, glycine-serine-glycine or glycine-serine-serine) in the PC-3 
prostate cancer (27).  There are two main reasons for the low tumor uptake of 
[99mTc(HYNIC-ABN](tricine)(TPPTS)] reported in this study.  The expression level of 
GRPRs on HT-29 cells may not be as high as that PC-3 prostate cancer cells.  The 
attachment of the 99mTc chelate (99mTc, HYNIC, tricine and TPPTS) may significantly 
reduce the GRPR binding affinity of [99mTc(HYNIC-ABN](tricine)(TPPTS)], which seems 
to be supported by the fact that the IC50 value of ABN (24 ± 2 nM) is slightly lower than 
that of HYNIC-ABN (38 ± 1 nM).  It must be emphasized that the difference in the 
tumor-bearing mice (BALB/c versus SCID) may also contribute to the variation of the 
tumor uptake and excretion kinetics of the radiotracer.  Therefore, caution must be taken 
when comparing the biodistribution data obtained by two different research laboratories 
using two different tumor-bearing animal models.  
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3.5  Conclusion 
The ternary ligand system (HYNIC, tricine and TPPTS) has been successfully used 
for 99mTc-labeling of β-Ala-BN(7-14)NH2. [99mTc(HYNIC-ABN)(tricine)(TPPTS)] can be 
prepared in high yield and high specific activity.  Because of its hydrophilicity (log P = 
-2.39 ± 0.06), [99mTc(HYNIC-ABN)(tricine)(TPPS)] is excreted mainly via the renal route 
with little radioactivity accumulation in the liver, lungs, stomach, and gastrointestinal tract. 
Its metabolic instability may contribute, in part, to its rapid clearance from the tumor and 
non-tumor organs, such as the blood, liver, lungs and stomach.  As a result, it has the best 
T/B ratios in the blood, liver and muscle at 1 h p.i.  The tumor can be clearly visualized as 
early as 30 – 60 min p.i. by planar imaging of the BALB/c nude mice bearing the HT-29 
human colon xenografts.  The combination of relatively high tumor uptake with its 
extremely favorable pharmacokinetics makes [99mTc(HYNIC-ABN)(tricine)(TPPTS)] a 
promising SPECT radiotracer for imaging colon cancer. 
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Introduction: The peptide bombesin (BN) and derivates thereof show high binding 
affinity for the gastrin-releasing peptide receptor (GRPR), which is highly expressed in 
primary and metastasized prostate cancer. We have synthesized a new BN-based 
radiopharmaceutical 99mTechnetium-HYNIC(tricine/TPPTS)-Aca-BN(7-14) (99mTc-HABN) 
and evaluated its GRPR targeting properties in vitro and in a xenograft tumor model for 
human prostate cancer in athymic mice. 
Methods: 99mTc-HABN was synthesized and its lipophilicity and stability were 
investigated. The IC50, internalization and efflux properties were determined in vitro using 
the GRPR expressing human prostate cancer cell line PC-3. 99mTc-HABN biodistribution 
and microSPECT imaging were performed in PC-3 tumor-bearing athymic mice. 
Results: 99mTc-HABN was prepared with high labeling yield (>90%), high 
radiochemical purity (>95%) and a specific activity of ~19.8 MBq/nmol. The partition 
coefficient log D value was -1.60±0.06.99mTc-HABN proved to be stable in human serum 
for 6 hours. The IC50 of HYNIC-Aca-BN(7-14) was 12.81±0.14 nM. Incubation of PC-3 
cells with 99mTc-HABN demonstrated rapid cellular internalization and a long intracellular 
retention time. When mice were injected with 99mTc-HABN the activity was predominantly 
cleared via the kidneys. Uptake in the tumor was 2.24±0.64 %ID/g after 30 minutes, with a 
steady decrease during the 4 hours study period. In vivo experiments with a blocking agent 
showed GRPR mediated uptake. 99mTc-HABN microSPECT imaging resulted in clear 
delineation of the tumor. 
Conclusion: 99mTc-HABN is a novel BN-based radiopharmaceutical that proved to be 
suitable for targeted imaging of prostate cancer with microSPECTusing the human prostate 
cancer cell line PC-3 in a xenograft mouse model. 
 




















4.1  Introduction 
Worldwide, prostate cancer is one of the most common causes of cancer in men 
and a common cause of morbidity and death (1-2). As current conventional diagnostic 
techniques are not sensitive enough to accurately detect early, advanced or recurrent 
prostate cancer, new diagnostic modalities have to be developed (3-5). Radionuclide 
imaging with SPECT or PET (single photon emission computed tomography and positron 
emission tomography, respectively) may provide a sensitive technique for reliable diagnosis 
and/or staging of prostate cancer. However, current radiopharmaceuticals appear to have 
drawbacks with regard to sensitivity or specificity in prostate cancer assessment (6-8). 
Crucial for accurate new radionuclide imaging techniques is the development of 
radiopharmaceuticals that can be targeted to tumor-associated specific antigens, which are 
overexpressed in prostate cancer and sparse in normal tissue. 
In this respect the gastrin-releasing peptide receptor (GRPR) appears to be 
particularly appealing since it is overexpressed in a variety of human malignancies 
including primary and metastatic prostate cancer (9-12). Importantly, GRPR expression in 
normal tissue is relatively low (13-16). The natural ligand for GRPR in mammals is the 
gastrin-releasing peptide (GRP). GRP is not suitable for modification into a 
radiopharmaceutical since it has poor in vivo stability. The amphibian counterpart of GRP, 
the 14 amino acid peptide bombesin (BN), appeared to be more suitable. GRP and BN 
share an identical 7-amino acid long C-terminal region that is needed for binding to GRPR. 
A series of BN analogues have been constructed that were labelled with a variety of 
radionuclides (i.e. 99mTc, 111In, 64Cu, 18F) (17).  Several groups have used either the full 
length BN molecule, BN(1-14), or the truncated peptide BN(7-14), with or without amino 
acid substitutions, spacer insertion and different radionuclide-chelator complexes in order 
to achieve increased affinity for GRPR, higher metabolic stability, improved biodistribution 
properties or manipulation of the mode of excretion.  
Although radiolabelled BN derivatives have been extensively investigated for 
diagnosis and treatment of GRPR positive prostate tumors in preclinical studies (17-19), 
clinical research in prostate cancer patients is limited to only a few compounds (20-24). For 
that reason, in this study we investigated the efficacy of a novel BN-based 
radiopharmaceutical in a human prostate cancer xenograft mouse model as a prelude to 
clinical evaluation.  
Therefore, we synthesized a novel radiopharmaceutical composed of the truncated 
BN peptide BN(7-14) which was conjugated to the bifunctional coupling agent 
6-hydrazinonicotinic acid (HYNIC) linked by ε-Aminocaproic acid (Aca) that was used as 
a spacer. With the co-ligands tricine and trisodium triphenylphosphine-3,3’,3’’-trisulfonate 
(TPPTS), the HYNIC/tricine/TPPTS complex was used for 99mTc labeling and to 
form 99mTc-HYNIC(tricine/TPPTS)-Aca-BN(7-14) (99mTc-HABN, figure 1). The ternary 
ligand system was chosen because of its high labeling efficiency (rapid and high yield 
radiolabelling), high stability, relatively easy use and hydrophilicity(25). The 
HYNIC(tricine/TPPTS) complex has been successfully used for radiolabelling peptides and 
receptor antagonists(26-31). 
The main objective of the current study is to preclinically evaluate the suitability 
of the novel radiopharmaceutical 99mTc-HABN as a targeted imaging agent of prostate 


























































Figure 1: 99mTc-HYNIC(tricine/TPPTS)-Aca-BN(7-14) 
Note: coordination of the ternary ligand complex to 99mTc according to Surfraz et al.53 
 
4.2  Experimental Section 
4.2.1  Chemicals  
Tricine (N-(Tri(hydroxymethyl)methyl)glycine) and Aca-BN(1-14) were 
purchased from Sigma/Aldrich (St. Louis, Missouri, USA), TPPTS was purchased from 
Alfa Aesar (Karlsruhe,Germany). Both were used without further purification. The peptide 
conjugate Aca-BN(7-14) was acquired as described previously(32). HYNIC-Aca-BN(7-14) 
was synthesized as described below. Na99mTcO4 was produced according to standard 
procedures using the 99Mo/99mTc generator in our department. 125I-Tyr4-BN was obtained 
from Perkin-Elmer Life and Analytical Sciences (Waltham, Massachusetts, USA). 
 
4.2.2  Equipment   
Analytical as well as semi-preparative reversed-phase high-performance liquid 
chromatography (RP-HPLC) was performed on a HITACHI L-2130 HPLC system (Hitachi 
High Technologies America Inc., Pleasanton, California, USA) equipped with a Bicron 
Frisk-Tech area monitor. Isolation of radiolabelled peptides was performed using a 
Phenomenex reversed-phase Luna C18 column (10 mm × 250 mm, 5μm) (Torrance, 
California, USA). The flow was set at 2.5 ml/min using a gradient system starting from 90% 
solvent A (0.01 M phosphate buffer, pH=6.0) and 10% solvent B (acetonitrile) (5 
minutes)and ramped to 45% solvent A and 55% solvent B at 35 minutes. The analytic 
HPLC was performed using the same gradient system but with a reversed-phase Grace 




4.2.3  Synthesis of HYNIC-Aca-Bombesin(7-14) 
HYNIC-Boc 16.7 mg (47.5 µmol) (Boc = tert-butyloxycarbonyl) and BN(7-14) 50 
mg (47.5 µmol) were dissolved in 0.3 ml of N,N-dimethylformamide. 30 µL of 
N,N-diisopropylethylamine was then added and the mixture was vortexed for 1 minute. The 
reaction was complete after 2 hours and no degradation products of HYNIC-Aca-BN(7-14) 
were found in the final product. 40 µL of acetic acid was added to quench the reaction. The 
crude product was subjected to HPLC purification. The desired fraction was collected and 
lyophilized. Anhydrous trifluoroacetic acid (2 ml) was then added to remove the protecting 
Boc group. After 20 minutes, the trifluoroacetic acid solution was blown dry. The crude 
HYNIC-Aca-BN(7-14) was purified by HPLC and lyophilized. Product identity was 
confirmed by MALDI-TOF MS (matrix-assisted laser desorption/ionization time-of-flight 
mass spectrometry): m/z 1188.29 for [MH]+ (C55H81N17O11S) calculated molecular 
weight: 1187.60. Pure product was stored in a -20 °C freezer.  
 
4.2.4  Radiochemistry 
      Twenty μL of the HYNIC-Aca-BN(7-14) solution (1mg/ml in H2O), 100 μL of 
tricine solution (100 mg/ml in 25 mM succinate buffer, pH 5.0), 10 μL of SnCl2 solution 
(3.0 mg/ml in 0.1 N HCl) and 100 μL of Na99mTcO4 (370 MBq) in saline were added to a 
1.5 ml Eppendorf vial. The reaction mixture was kept at 95 °C for 5 minutes. 100 μL of the 
TPPTS solution (50 mg/ml in 25 mM succinate buffer, pH 5.0) was added to the reaction 
mixture. The Eppendorf vial containing the reaction mixture was sealed and heated at 95 °C 
for 20 minutes. After cooling to room temperature, the mixture was purified by 
semi-preparative HPLC. The product was then passed through a Sep-Pak C-18cartridge.  
The Sep-Pak C-18 cartridge was activated with ethanol (10 ml) and was washed with water 
(10 ml) before use. After the product was loaded, the Sep-Pak C-18 cartridge was washed 
with saline (10 ml). The radiotracer was eluted with 70% ethanol (0.4 ml) for in vitro and in 
vivo experiments. A sample of the resulting solution was analyzed by radio-HPLC. 
 
4.2.5  Partition Coefficient 
The partition coefficient was determined using the method described previously29. 
The tracer was dissolved in a mixture of 0.5 ml n-octanol and 0.5 ml 25 mM phosphate 
buffer (pH7.4) and well mixed. Then the mixture was centrifuged at 3000 rpm for 5 
minutes. 100 μL samples were obtained from n-octanol and aqueous layers and were 
counted in a γ-counter (Compugamma CS1282, LKB-Wallac, Turku, Finland). The logD 
value is reported as an average of three different measurements. 
 
4.2.6  In Vitro Stability 
99mTc-HABN was dissolved in 1 ml saline or cysteine solution (1 mg/ml), incubated at 
room temperature and analyzed by RP-HPLC at 1, 2, 4, 6, and 24 hours post incubation. 
The study of metabolic stability was performed in human serum. Human serum from 
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healthy donors was incubated at 37 °C with 99mTc-HABN for different time periods (1, 2, 4, 
6, 24 hours). After incubation, a sample of 250 μL was precipitated with 750 μL 
acetonitrile/ethanol (Vacetonitrile/Vethanol =1:1) and then centrifuged (3 minutes at 3000 rpm), 
the supernatants were passed through a filter and afterwards analyzed by RP-HPLC. Results 
were plotted as the radiochemical purity (RCP) at different time-points. 
 
4.2.7  Dose Preparation for Animal Studies 
Doses for animal studies were prepared by dissolving the Sep-Pak C18 cartridge 
purified radiotracer in saline to give a concentration of 5.6MBq/ml (~0.56 MBq/mouse, 
ethanol concentration ~0.1%) for the biodistribution study and 300 MBq/ml 
(~60MBq/mouse, ethanol concentration ~10%) for the imaging study.  
 
4.2.8  Cell Culture 
The GRPR positive PC-3 human prostate cancer cell line (ATCC, Manassas, Virginia, 
USA) was cultured in RPMI 1640 (Lonza, Verviers, France) supplemented with 10% fetal 
calf serum (Thermo Fisher Scientific Inc., Logan, Utah, USA) at 37 °C in a humidified 5% 
CO2 atmosphere.  
 
4.2.9  In Vitro Competitive Receptor Binding Assay 
The in vitro GRPR binding affinities of Aca-BN(7-14) and HYNIC-Aca-BN(7-14) 
were compared to BN(1-14) and assessed via a competitive displacement assay 
with 125I-Tyr4-BN(1-14) as the GRPR specific radioligand. Experiments were performed at 
37 °C with PC-3 human prostate cancer cells according to a method previously 
described(33). The 50% inhibitory concentration (IC50) values were calculated by fitting 
the data with nonlinear regression using GraphPad Prism 5.0 (GraphPad Software, San 
Diego, California, USA). Experiments were performed with triplicate samples. IC50 values 
are reported as an average of these samples plus the standard deviation (SD). 
 
4.2.10  Internalization Studies 
One day prior to the assay, PC-3 cells were seeded in 6-well plates. The 6-well 
plates were then incubated with 99mTc-HABN (0.0037 MBq/well) for 2 hours at 4 °C. To 
remove unbound radioactivity, the cells were washed twice afterwards with ice-cold PBS 
and were then incubated in the pre-warmed culture medium at 37 °C for 0, 5, 15, 30, 45, 60, 
90 and 120 minutes in triplicate to allow for internalization.  
To remove cell-surface bound 99mTc-HABN, the cells were washed twice for 3 
minutes with acid (50 mM glycine−HCl/100 mMNaCl, pH 2.8). Next, the cells were lysed 
by incubation with 1 M NaOH at 37 °C and the resulting lysate in each well was aspirated 
to determine the internalized radioactivity in a γ-counter (Compugamma CS1282, 
LKB-Wallac, Turku, Finland). Results are expressed as the percentage of total radioactivity 
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(internalized activity / (surface-bound activity + internalized activity)), (mean±SD). 
 
4.2.11  Efflux Studies 
One day prior to the assay, PC-3 cells were seeded in 6-well plates. The 6-well 
plates were then incubated with 99mTc-HABN (0.0037 MBq/well) for 1 hour at 37 °C to 
allow for internalization. To remove unbound radioactivity, the cells were washed twice 
afterwards with cold (0 °C) PBS and were then incubated using pre-warmed culture 
medium (37 °C) for 0, 15, 30, 45, 60, 90, 120, and 240 minutes in triplicate to allow for 
externalization. To remove cell-surface bound 99mTc-HABN, the cells were washed twice 
for 3 minutes with acid (50 mM glycine−HCl/100 mMNaCl, pH 2.8). Next, the cells were 
lysed by incubation with 1 M NaOH at 37 °C, and the resulting lysate in each well was 
aspirated to determine the remaining radioactivity in a γ-counter (Compugamma CS1282, 
LKB-Wallac, Turku, Finland). Results are expressed as the percentage of maximum 
intracellular radioactivity (remaining activity at specific time-point / activity at time-point 
0), (mean±SD). 
 
4.2.12  Animal Model 
The xenograft tumor model for human prostate cancer in athymic mice was 
generated by subcutaneous injection of 2 × 106 PC-3 cells (suspended in 0.1 ml sterile 
saline) in the right front flank of male athymic mice (Harlan, Zeist, The Netherlands). 
During the injection, animals were anesthetized with a gas composed of ~3.5% isoflurane 
in an air/oxygen mixture. The mice were used for biodistribution experiments and 
microSPECT imaging when the tumor volume reached a mean diameter of ~0.8-1.0 cm 
(3-4 weeks after inoculation). 
All animal experiments were performed in accordance with the regulations of 
Dutch law on animal welfare and the institutional ethics committee for animal procedures 
approved the protocol. 
 
4.2.13  Biodistribution Experiments 
Twelve PC-3 tumor-bearing mice were randomly divided into three groups of four 
animals. Isoflurane inhalation was used as method of anesthesia. 99mTc-HABN 
(~0.56 MBq/mouse) dissolved in 0.1 ml saline was injected intravenously via the penis vein. 
At time points 0.5, 1, and 4 hours post-injection (p.i.), the mice were anesthetized again and 
sacrificed by cervical dislocation. Immediately after sacrifice, blood samples were 
withdrawn from the retro orbital sinus using capillary tubes and organs of interest (heart, 
liver, spleen, lung, kidney, pancreas, small intestine, large intestine, stomach, bone, muscle 
and tumor) were collected and wet weighed. Radioactivity was determined in a γ-counter 
(Compugamma CS1282, LKB-Wallac, Turku, Finland).  
To determine specificity of the in vivo uptake of 99mTc-HABN, a fourth group of 4 
mice received an intravenous injection of 300 μg of unlabelled HYNIC-Aca-BN(7-14) (in 
0.2 ml saline) as blocking agent 30 minutes prior to injection of 99mTc-HABN (~0.56 
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MBq/mouse in 0.1 ml). The mice were sacrificed 1 hour after injection of the radiotracer. 
Blood and organs were collected, weighed and counted as described above. 
Organ and tissue uptake was calculated as a percentage of the injected dose per 
gram of tissue mass (%ID/g). Biodistribution data is reported as an average plus the SD 
based on the results from four animals at each time point. Significant blocking was 
calculated with the student’s t-test. P-values are considered significant when 
p≤0.05.Tumor-to-normal-tissue (T/NT) ratios are reported as an average at each time point 
(without the blocking group). 
 
4.2.14  MicroSPECT Imaging 
The imaging study was performed in seven PC-3 tumor-bearing mice, of which 
four were used for 99mTc-HABN imaging and three were used for the blocking experiment. 
Each PC-3 tumor-bearing mouse was penis vein injected with 99mTc-HABN (~60 
MBq/mouse) in 0.2 ml saline using isoflurane anesthesia. Animals were placed prone on a 
three-head γ-camera (MILabs, U-SPECT-II, Utrecht, the Netherlands) equipped with a 
multi-pinhole high-resolution collimator (diameter 0.6 mm, resolution about 0.4 mm). 
Immediately after injection of the radiotracer, dynamic data was acquired for 1 hour (6 
frames, 10 minutes per frame). The mice were sacrificed 4 hours after injection of the 
radiotracer, placed prone in the U-SPECT-II and a static scan was performed for 1 hour. 
The imaging data was stored digitally in list mode.  
For the blocking experiment, excess cold HYNIC-Aca-BN(7-14) (300 µg 
dissolved in 0.2 ml saline) was administered intravenously via the penis vein in three mice 
30 minutes prior to administration of 99mTc-HABN(~60 MBq/mouse). Data was acquired 
using the same procedure as described above.  
Images were reconstructed by using U-SPECT-Rec v 1.34i3 (MILabs, Utrecht, the 
Netherlands) with a pixel-based ordered-subsets expectation maximum (POSEM) algorithm. 
Final images were 1 mm slices, made with Amide 0.9.1 (open source software). 
Radioactivity accumulation in tumor was quantified with the use of Amide 0.9.1 
by drawing regions of interest (ROI) around the tumor on U-SPECT images of PC-3 tumor 
bearing mice at 10, 20, 30, 40, 50, 60, and 240 minutes post injection of 99mTc-HABN, 
pre-injected with or without excess blocking agent. ROI values were corrected for the 
injected dose (final ROI = ROI calculated with Amide software divided by the injected dose) 
and expressed as mean±SD. Significant blocking was calculated with the student’s t-test. 
 
4.3  Results 
4.3.1  Synthesis, Radiolabelling, Partition Coefficient and In Vitro 
Stability 
Within 30 minutes 99mTc-HABN (figure 1) was prepared at 95 °C with high 
labeling yield (>90%) and radiochemical purity after purification (>95%). The specific 
activity was ~19.8 MBq/nmol. 99mTc-HABNwas analyzed using a reversed phase HPLC 
method. The HPLC retention time was 21.5 minutes for 99mTc-HABN and 19.5 minutes for 
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HYNIC-Aca-BN(7-14).  
The partition coefficient was determined in a mixture of n-octanol and phosphate 
buffer (pH=7.4). The log D value was -1.60±0.06. The in vitro stability of 99mTc-HABNwas 
tested both in saline, human serum and in the presence of excess cysteine (1.0 mg/ml, 
pH=7.4) (figure 2). 99mTc-HABN was stable in the presence of excess cysteine and human 
serum for at least 6 hours. The RCP of 99mTc-HABN in serum slowly decreased to 77% 
after 24 hours. 

















Figure 2: In vitro stability of 99mTc-HYNIC(tricine/TPPTS)-Aca-BN(7-14). Results are 
plotted as the RCP at different time points. 
 
 
4.3.2  In vitro Competitive Receptor Binding Assay 
Using 125I-Tyr4-BN(1-14) as the GRPR specific radioligand, the binding affinities 
of Aca-BN(7-14) and HYNIC-Aca-BN(7-14) for GRPR were compared to BN(1-14), set as 
the standard, via a competitive displacement assay. Results are plotted in sigmoid curves for 
the displacement of 125I-Tyr4-BN(1-14) as a function of increasing concentrations of 
Aca-BN(7-14), BN(1-14) and HYNIC-Aca-BN(7-14) (figure 3). The IC50 values were 





Figure 3: Displacement curve of 125I-Tyr4-BN(1-14) binding to GRPR on PC-3 cells. 
Log[M] = Log of increasing concentration (Mol/l) of Aca-BN(7-14), BN(1-14) and 
HYNIC-Aca-BN(7-14).  
 
4.3.3  Internalization and Efflux Studies 
The internalization study depicted in figure 4A showed rapid internalization 
of 99mTc-HABN into PC-3 cells within 5-15 minutes. Internalization reached a plateau of 
~84% after 30 minutes, which remained steady for the duration of the experiment (120 
minutes).  
Figure 4B shows the efflux kinetics of 99mTc-HABN. Moderate efflux in the first 
60 minutes was demonstrated with only one third of the activity externalized by the PC-3 
cells. After 90 minutes a relatively stable situation was created with just over 50% of the 
internalized radioactivity remaining in the cells for the remainder of the experiment. The 
t1/2-efllux of 99mTc-HABN PC-3 cells was 38±5 minutes. 
























































Figure 4: (A) 99mTc-HYNIC(tricine/TPPTS)-Aca-BN(7-14) internalization experiment. 
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Results are expressed as the percentage of total radioactivity (internalized 
activity/(surface-bound activity plus internalized activity)) (mean±SD). 
(B) 99mTc-HYNIC(tricine/TPPTS)-Aca-BN(7-14) efflux experiment. Results are expressed 
as the percentage of maximum intracellular radioactivity (remaining activity at specific 
time-point divided by activity at time-point 0) (mean±SD). 
 
4.3.4  Biodistribution Experiments 
Biodistribution of 99mTc-HABN was evaluated in athymic mice bearing PC-3 
tumors. Results of the biodistribution, the blocking experiment and T/NT ratios are shown 
in table 1.  
Uptake in PC-3 tumor and the GRPR rich mouse pancreas(34) was highest 
(2.24±0.64 and 17.3±1.69 %ID/g, respectively) at 30 minutes p.i., with a steady decrease 
over the 4 hours study period. Uptake in the tumor and pancreas was reduced significantly 
after injection of the blocking agent, indicating specific GRPR targeting of 99mTc-HABN. 
Uptake in other GRPR expressing organs (stomach and intestine) was also significantly 
reduced in the study of GRPR blockade.  
While hepatic uptake was modest, uptake in the kidneys was high and radioactivity 
was rapidly cleared from the blood via the preferred renal-urinary route. When an excess of 
cold HYNIC-Aca-BN(7-14) was injected prior to 99mTc-HABN injection non-specific 
uptake in the kidneys was increased further, probably as a result of an increased level of 
circulating unbound 99mTc-HABN. 
Low uptake of radioactivity in bone and muscle, combined with the rapid 
clearance from the blood pool, resulted in high T/NT ratios, increasing over time.  
 
4.3.5  MicroSPECT Imaging 
 Figure 5 shows the coronal microSPECT images (sections) acquired with the high 
resolution U-SPECT-II after injection of ~60 MBq99mTc-HABN with and without the 
blocking agent in PC-3 tumor bearing mice. The tumor could already be seen 10 minutes 
after injection of 99mTc-HABN and tumor-to-background contrast increased over the first 
hour (figure 5A) resulting in excellent tumor delineation after 4 hours (figure 5B). 
Noteworthy, the outer rim of the tumor displayed high uptake of activity while the central 
part of the tumor shows reduced binding.  
Prominent uptake was also seen in the pancreas (not shown) and both kidneys in 
all time frames. In addition, clearance via the urinary bladder was evident. Pre-injection of 
an excess of the blocking agent reduced uptake in the tumor and other GRPR positive 









Table 1: Biodistribution of and tumor-to-normal-tissue ratios of 99mTc-HABN after 
intravenous injection in PC-3 prostate tumor bearing athymic mice 
Organ 30 minutes 1 hour 4 hours 1 hour + 
blocking 














































































































 0.47 ± 
0.14* 
Values are expressed as %ID/g, mean±standard error of the mean/standard deviation 
(n=4 at each time point) or as T/NT ratios. Blocking was achieved by pre-injection 







Figure 5: Coronal microSPECT images (sections) at a ten minute interval during the first 
hour after injection of 99mTc-HABN without blocking agent (figure 5A) and with blocking 
agent (figure 5C). Static coronal, sagittal and axial images (sections) 4 hours after injection 
of 99mTc-HABN without blocking agent (figure 5B) and with blocking agent (figure 5D). 
Arrows indicate the tumor.  
 
Figure 6 shows the radioactivity accumulation quantification in thetumor from 
the 99mTc-HABN U-SPECT images with and without blocking agent. Tumor uptake 
diminished over time as was determined before in the biodistribution study. Uptake was 
significantly higher without the pre-administration of the blocking agent at all time-points, 
except at 20 and 40 minutes p.i. 




































Figure 6: The radioactivity accumulation quantification in tumor from the microSPECT 
images of PC-3 tumor bearing mice at 10, 20, 30, 40, 50, 60, and 240 min post injection 
of 99mTc-HABN, pre-injected with or without excess blocking agent. The ROI values were 
corrected for the injected dose and expressed as mean±SD. * = statistical significant 
difference (p<0.05), ** = statistical significant difference (p<0.01). 
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4.4  Discussion 
Current conventional diagnostic techniques are not sensitive enough to accurately 
detect early advanced or recurrent prostate cancer. Therefore, better diagnostic modalities 
are urgently needed. We developed a novel BN-based radiopharmaceutical, 
designated 99mTc-HABN, and investigated its potency for the in vitro and in vivo binding to 
prostate cancer expressed GRPR. 
For widespread use of a tracer in clinical practice, a radio-isotope with a relatively 
long half-life, high labeling efficiency and good availability is mandatory. We therefore 
utilized the popular γ-emitting isotope 99mTc(17). The HYNIC/tricine/TPPTS complex was 
used because of its high labeling efficiency (rapid and high yield radiolabelling), high 
solution stability and relatively easy use(25). It was also chosen because of its hydrophilic 
character leading to the preferred excretion route via the renal-urinary system(26, 29, 35, 
36). Shi et al. demonstrated excellent results with HYNIC coupled β-Alanine-BN(7-14) 
(29)in vitro in PC-3 prostate cancer cells and in vivo in a colon cancer mouse model. By 
changing β-Alanine to Aca we sought to improve GRPR targeting properties and 
pharmacokinetics both in vitro and in vivo in a prostate cancer model.  
99mTc-HABN was synthesized with high radiochemical yield and purity. In 
addition, 99mTc-HABN proved highly stable in saline, cysteine solution and human serum. 
In vitro experiments revealed that although the addition of HYNIC to Aca-BN(7-14) 
reduces the binding affinity for GRPR, the IC50-value of HYNIC-Aca-BN(7-14) is still in 
the nanomolar range (12.8±0.14 nM) and therefore very similar to IC50-values reported for 
other BN derivatives with HYNIC, DOTA or (NaHis)Ac as chelator(29, 37-43). 
Internalization into PC-3 cells occurred rapidly, while long retention was seen in the efflux 
experiments with more than 50% of the internalized radioactivity remaining after 4 hours. 
Because primary prostate cancer is located in the pelvis and lymph node 
metastases are situated mainly in the pelvis and abdomen, rapid renal-urinary clearance is 
generally preferred over hepato-enteric clearance in order to limit pelvico-abdominal 
background activity as much as possible and thus to achieve good imaging contrast.  
In clinical practice, urinary activity in the bladder can be evacuated by micturition 
prior to the scan or if needed, by bladder drainage. Determination of the partition 
coefficient of 99mTc-HABN demonstrated a hydrophilic compound, which should govern 
excretion through the kidneys rather than via the liver. This was confirmed by the in vivo 
determination of the biodistribution of 99mTc-HABN in athymic mice bearing human 
prostate cancer tumors as uptake in liver was only 1.33±0.20 %ID/g after 30 minutes, while 
uptake in the kidneys was high after 30 minutes (7.09±4.40 %ID/g) and remained high for 4 
hours p.i. Pre-injection with the blocking agent did not reduce kidney uptake or excretion 
of 99mTc-HABN.  
 Furthermore, in vivobiodistribution experiments also showed rapid tumor uptake, 
being the highest at 30 minutes p.i. (2.24±0.64 %ID/g) and decreasing slowly over the 
evaluated period of 4 hour. Uptake in tumor is even higher before 30 minutes p.i. as could 
be seen in the experimental part where radioactivity accumulation in thetumor was 
quantified from the U-SPECT images of 99mTc-HABN. High tumor-to-background ratios 
were obtained due to low uptake of radioactivity in bone and muscle on one hand and the 
rapid clearance from the blood pool on the other hand. Generally, T/NT ratios increased 
over time because of the long retention time of the radiotracer in tumor, confirming the in 
vitro results of the efflux experiment. As was expected, high uptake was detected in the 
GRPR rich mouse pancreas (34), but was reduced significantly (p<0.0001) when the 
73 
blocking agent HYNIC-Aca-BN(7-14) was injected prior to injection of 99mTc-HABN. 
Uptake in tumor, stomach, and intestine was also significantly reduced in the study of 
GRPR blockade, indicating that uptake was also GRPR mediated. 
At first glance the tumor uptake appears rather low when compared to the best 
performing BN analogues reported in literature. However, when the best performing BN 
analogues Demobesin-1 (reported %ID/g ranging from 13.45 to 24.61)(40, 44, 45), 
DOTA-PESIN (14.8%ID/g )(41) and AMBA (6.35%ID/g)(39) were compared under the 
same circumstances in a study by Schroeder et al., uptake by PC-3 xenografts 1 hour p.i. 
was considerably lower and not statistically significant different from each other (3.0, 2.3 
and 2.7%ID/g, respectively)(46). Furthermore, the results of Schroeder et al. are not so 
different from the results reported by other authors or our results (17). Schroeder stated that 
the variation in radionuclides, amounts of peptide, mouse strain (species, sex, weight), PC-3 
cells used (passage number, culture conditions), tumor size and vascularisation of the tumor 
may all be factors that determine uptake of radioactivity in tumor resulting in variable 
outcomes (46).  
As can be appreciated from our microSPECT images there is high uptake of activity 
in the outer tumor regions resulting in a “hot rim” around a central area with lower uptake. 
As several authors have shown before, the central part of a xenografttumor is often necrotic 
or pre-necrotic with reduced viable cell density, especially in larger tumors, which can 
result in lower central uptake of a radiotracer (46-48). When measuring total tumor uptake 
of a radiotracer, the central necrosis, reduced central cell viability and reduced 
vascularisation or diffusion will result in an underestimation of the actual tumor cell uptake. 
Even with standardization of the different variables mentioned by Schroeder et al., because 
of these many variables influencing the outcome of the experiments, a comparison between 
individual radiopharmaceuticals tested in separate studies is in fact rather difficult. 
Absolute tumor uptake is an important factor, but for good image contrast high 
T/NT ratios are also imperative. Rapid internalization observed in vitro (70-80% within 
5-15 minutes) is reflected in rapid tumor uptake in mice, which can be appreciated from the 
microSPECT images as activity is already appearing in the first timeframe after 10 minutes. 
However, because uptake in other organs is also rapid in combination with high circulating 
levels of activity in the blood, the tumor-to-background contrast after 10 minutes is rather 
low. Still, the tumor is clearly visualized after 10 minutes and even better after 20 minutes 
or more. While internalization was quick, PC-3 cell efflux was slow both in vitro and in 
vivo, with persistent retention of activity in the tumor resulting in increasing T/NT ratios 
and clear delineation of the tumor over time up to 4 hours p.i.  
Multiple BN-like radiopharmaceuticals with many different designs have shown to 
be highly specific for GRPR and sensitive for prostate cancer. So far, studies on antagonists 
that have been recently published have mostly shown higher or at least similar tumor 
uptake and T/NT ratios when compared to agonist compounds (42, 49-52). However, in the 
previously mentioned study by Schroeder et al. multiple BN-agonists were compared to an 
antagonist and although the latter showed the highest uptake in tumor, this was not 
significant (46). Despite these contrasting results, it will be interesting to see how these 
preclinical studies will translate into clinical studies as there may be large interspecies 
differences between mice and men with respect to GRPR imaging. For example, in humans, 
differences in metabolism, excretion, non-target GRPR expression, prostate tumor 
characteristics, vascularization or anatomy may account for uptake differences. Also, 
background interference from bladder or intestinal tissues may or may not hinder detection 
of (extra)prostatic cancer foci or lymph node metastases. 
For clinical imaging purposes, small tumors pose a diagnostic dilemma as they 
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cannot be detected by conventional imaging techniques like CT or MRI, because these 
techniques have a limited resolution and depend on morphology (size and shape criteria) for 
making a diagnosis. SPECT and PET can be superior techniques as they may be able to 
differentiate between benign or malignant tissue based on differences in metabolism and 
contrast (e.g. T/NT ratios), rather than on morphology. 
In conclusion 99mTc-HABN is a novel BN-based radiopharmaceutical that proved 
to be suitable for targeted imaging of prostate cancer using microSPECT in a human 
derived PC-3 xenograft model.  
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Rationale: The peptide bombesin (8) and derivates thereof show high binding affinity 
for the gastrin-releasing peptide receptor (GRPR), which is highly expressed in prostate 
cancer (PCa). We used the BN-based 
radiopharmaceutical 99mTechnetium-HYNIC(tricine/TPPTS)-Aca-Bombesin(7-14) 
(99mTc-HABN) to perform a first-in-man clinical pilot study in order to evaluate the 
feasibility of 99mTc-HABN SPECT/CT for detection and localization of PCa in patients.  
Methods: Eight patients with biopsy proven PCa and scheduled for either a radical 
prostatectomy or external beam radiotherapy underwent 99mTc-HABN scintigraphy and 
SPECT/CT prior to treatment. Serial blood samples were taken to assess blood radioactivity 
and to determine in vivo metabolic stability. Clinical parameters were measured and 
reported side-effects were recorded. PCa specimens of all patients were 
immunohistochemically stained for GRPR. 
Results: 99mTc-HABN was synthesized with high yield, specific activity and purity. 
There were no significant changes in clinical parameters and there were no adverse or 
subjective side-effects. Low metabolic stability was observed, with less than 20% 
of 99mTc-HABN intact after 30 min. Immunohistochemical staining for GRPR was observed 
in the PCa specimens in all patients. 99mTc-HABN scintigraphy and SPECT/CT did not 
detect or localize PCa in patients with proven disease.  
Conclusions: 99mTechnetium-HYNIC(tricine/TPPTS)-Aca-Bombesin(7-14) SPECT/ 
CT for visualization of PCa is safe but hampered by unexpected low in vivo metabolic 
stability in men. The difference between the excellent in vitro stability in human serum 
determined in our previous study on 99mTc-HABN and the low in vivo metabolic stability 
determined in this study, is striking. This issue warrants further study of peptide-based 
radiopharmaceuticals. 
 





















5.1  Introduction  
Prostate cancer is one of the most common causes of cancer in males and a 
common cause of morbidity and death worldwide (1). Early detection of prostate cancer 
may lead to an improved cure rate. An increased level of prostate-specific antigen (PSA) in 
serum or a palpable prostatic nodule found with digital rectal examination raises the 
suspicion of prostate cancer and necessitates transrectal ultrasound-guided biopsies of the 
prostate for histological diagnosis. Although performing transrectal ultrasound-guided 
biopsies is the gold standard procedure, it has certain drawbacks, such as the chance of 
under- or over-staging due to sampling error in multifocal diseases (2). Furthermore, 
transrectal ultrasound-guided biopsies have a suboptimal sensitivity with missing up to 35% 
of cancers (3-5). A negative (repeat) biopsy, despite a persistently elevated PSA, poses a 
diagnostic dilemma (6,7).  
An imaging technique that is sufficiently sensitive to detect prostate cancer and/or 
sufficiently specific to exclude cancer is necessary. In addition to detection and local 
staging of prostate cancer, other possible uses of such an imaging technique could be 
guidance of prostate biopsies, application of intensity-modulated radiotherapy on hot-spots, 
detection of distant metastases or local recurrence and therapy response monitoring.  
Nuclear imaging techniques such as single photon emission computed tomography 
(SPECT) and positron emission tomography (PET) have emerged as promising diagnostic 
tools in oncology(8-10). Of the available radiopharmaceuticals for prostate cancer 
detection, 18F PET/CT and 11C-choline PET/CT are mostly used in centers all worldwide, 
as they are currently the best–performing nuclear imaging techniques. However, the limited 
sensitivity for small-size metastases, relatively low uptake of choline at low PSA levels and 
uptake of choline in normal or inflamed prostate limit the accuracy of choline PET/CT in 
staging prostate cancer(10,11). Therefore, crucial for accurate new nuclear imaging 
techniques is the development of radiopharmaceuticals that can be targeted to specific 
tumor-associated antigens, which are over-expressed in prostate cancer but are sparse in 
normal tissues.  
A tumor-associated antigen that is of particular interest is the gastrin-releasing peptide 
receptor (GRPR). GRPR is over-expressed in various human malignancies, including 
primary and metastatic prostate cancer (12,13). Importantly, GRPR expression in normal 
tissue ranges from absent to low(14-17), making GRPR an excellent target for high-contrast 
imaging. The mammalian ligand for GRPR and its amphibian counterpart bombesin (BN) 
share an identical seven-amino-acid carboxyl-terminal region, and both possess the same 
affinity for GRPR. However, BBN has been shown to be significantly more stable, and a 
series of BBN analogs has been constructed and labelled with various radionuclides 
(i.e., 99mTc, 111In, 64Cu, 18F)(18,19). 
Recently we reported on the synthesis of 99mTc-HYNIC(tricine/TPPTS)-Aca- 
BN(7-14) (from here on: 99mTc-HABN; HYNIC = 6-hydrazinonicotinic acid; TPPTS = 
trisodium triphenylphosphine-3,3’,3’’- trisulfonate; Aca = ε-Amino-caproic acid) and its 
promising results as an imaging agent in a xenografted tumor model for human prostate 
cancer in athymic mice(20). 
The aim of the study presented here was to perform a first-in-man clinical pilot 
study to evaluate the feasibility of 99mTc-HABN SPECT/CT for detection of prostatic 
cancer in patients.  
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5.2  Material and Methods  
 
5.2.1  Chemicals, Materials and Equipment 
Na99mTcO4 was eluted from the 99Mo/99mTc generator (Ultra-Technekow, Covidien, 
Petten, the Netherlands). Succinic acid and tricine (N-(Tri(hydroxymethyl)methyl)glycine) 
were purchased from Sigma/Aldrich (St. Louis, MO, USA). TPPTS was purchased from 
Alfa Aesar (Karlsruhe, Germany). The peptide Aca-BN(7-14) was provided by Peptides 
International (Louisville, KY, USA). HYNIC-Aca-BN(7-14) was synthesized as reported 
previously(20). For sterilization, a 0.22-μm Millex GV-filter (Merck Millipore, Billerica, 
MA, USA) was used. High-performance liquid chromatography (HPLC) was performed 
using a HITACHI L-2130 HPLC system (Hitachi High Technologies America Inc., 
Pleasanton, CA, USA). Isolation of radiolabelled peptides was performed using a 
Phenomenex reversed phase Luna C18 column (Phenomenex, Torrance, CA, USA). The 
Sep-Pak C18 light cartridge was from Waters Corporation (Milford, MA, USA). 
Radioactivity of samples was measured in a γ-counter (Compugamma CS1282; 
LKB-Wallac, Turku, Finland). For immunohistochemistry experiments, PC-3 human 
prostate cancer xenograft tumors (ATCC, Manassas, VA, USA), normal goat serum, 0.05% 
3,3’-diaminobenzidine, Eukitt mounting medium, 1% AB serum (Sigma-Aldrich, St. Louis, 
MO, USA), hematoxylin (Merck,Whitehouse Station, NJ, USA), anti-human-GRPR rabbit 
polyclonal antibody ab39963 (Abcam, Cambridge, UK) and goat anti-rabbit antibody 
P0448 (Dako, Glostrup, Denmark) were used. 
 
5.2.2  Preparation of 99mTc-HABN   
Synthesis of 99mTc-HABN was performed as described previously (20), under GMP 
conditions with modifications. All solutions (except the HYNIC-Aca-BN(7-14) and the 
SnCl2 solution) were sterilized before use by passing through a 0.22 μm Millex GV-filter 
under aseptic conditions (class A) in the cleanroom. Briefly, 99mTc-pertechnetate solution 
(~2.8 GBq, ~2 ml saline) was collected in a sterile vial (5 ml). 50 μl of 
HYNIC-Aca-BN(7-14)  (1 mg/ml in sterile water), 100 μl of tricine solution (100 mg/ml 
in 25 mM succinate buffer, pH 5.0), 100 μl of TPPTS solution (50 mg/ml in 25 mM 
succinate buffer, pH 5.0) and 15 μl of SnCl2 (1.0 mg/ml in water) were added to the vial 
and well mixed. The pH value (pH 5.0) of the mixture was checked with pH paper, and then 
the mixture was incubated at 95° C for 20 min. A needle connected to a 0.22 μm Millex 
GV-filter was placed in the cap of the vial to avoid overpressure and contamination.  
After cooling to room temperature, the reaction mixture was purified with 
semi-preparative reversed-phase HPLC equipped with a UV detector (wave length =218 nm) 
and a radioactivity detector. Isolation of radiolabelled peptides was performed using a 
Phenomenex reversed-phase Luna C18 column (10 mm × 250 mm, 5 μm) with a flow rate 
at 2.5 mL/min. A gradient system was applied for isolation of 99mTc-HABN, starting from 
90% solvent A (0.01 M phosphate buffer with 0.1 mg/ml ascorbic acid (AA), pH=6.0) and 
10% solvent B (acetonitrile (ACN) with 0.1 mg/ml AA) (5 min) and ramped to 45% solvent 
A and 55% solvent B at 35 min.  
The 99mTc-HABN eluate from the HPLC system was diluted with saline with 1 % AA 
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(10 mL) before loading on a Sep-Pak C18 light cartridge. The C18 cartridge was washed 
with saline with 1 % AA (50 mL) and eluted with absolute ethanol (400 μL) afterwards. 
The ethanol solution was diluted with saline solution (with 1 % AA; limit: ~10 ml) and was 
sterilized by passing through a 0.22 μm GV-filter. A quantity of 550-700 MBq was 
dispensed in a syringe under aseptic conditions (class A).   
 
5.2.3  Quality Control of 99mTc-HABN 
Before release of the final product, the integrity of the 0.22 μm Millex GV filter (used 
for sterilization of the final product) was determined using the bubble point test, and the 
radiochemical purity of the final product was determined by analyzing a 5-MBq portion 
using HPLC. After release, the sterility test was performed by keeping two samples (100 
μL) of the final product in two bottles of Clausen medium at 25 °C and 37 °C for 1 week. 
The remaining product was used for the pyrogenicity test, the residual solvents test and the 
EtOH concentration test performed at the Pharmacy Department of the University Medical 
Center Groningen after decay. 
5.2.4  Patient Recruitment 
The present study was approved by the Medical Ethics Committee of the University 
Medical Center Groningen and was performed according to Good Clinical Practice 
guidelines. 
Eight patients with biopsy proven prostate cancer (four patients scheduled for 
laparoscopic radical prostatectomy (RP), and four planned for external beam radiotherapy 
(EBRT)) were recruited on the outpatient clinic of the department of Urology at the 
University Medical Center Groningen, after providng written informed consent. The 
pre-therapy PSA level, prostate volume as determined by transrectal ultrasound, tumor 
stage (according to 1997 TNM staging criteria), results of prostate histology (either via 
whole prostatectomy specimens or prostate biopsies; Gleason sum score, % tumor volume) 
and results of the pelvic lymph node dissection (1/4 in the RP group, 4/4 in the EBRT group) 
were recorded.   
 
5.2.5  Scintigraphy, SPECT/CT and image analysis 
SPECT/CT scanning was performed before the EBRT or 1 day before surgery. 
Subjects were positioned supine with their arms outstretched in holders, and a venous 
canula was placed in both forearms-left for injection of the radiopharmaceutical and right 
for blood sampling. For low-dose computed tomography, the arms were positioned above 
the head. Images of the pelvis were performed using a Siemens Symbia T2 double headed 
gamma camera, equipped with low-energy, high-resolution collimators, combined with an 
integrated 2-slice computed tomography. To acquire quantitative results, a sample of 99mTc 
of known activity (20-28 MBq) was scanned along with the patient. 
Different data acquisition protocols were used in order to acquire an optimal 
time-point for scanning. Patients 1-4 were subjected to a dynamic scanning protocol with 
the gamma camera heads in the anterior-posterior (AP) position, 1 min per frame during 20 
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min, starting immediately after 99mTc-HABN injection (549-688 MBq). Thereafter, a 2x180° 
SPECT of the pelvic region was performed with a matrix size of 128x128 in 64 positions 
and an acquisition time of 40 s per position. Next, a low-dose CT of the pelvis was 
performed (110 kV, 30 mAs). At 2, 4, 6 and 20 hours post-injection(p.i.), SPECT was 
performed again at the 20 h-time-point combined with a low-dose CT. Patient 5 was 
subjected to a dynamic scan for 120 min with the gamma camera in the AP position, at 1 
min per frame during the first hour and 2 min per frame during the second hour. At 4, 6 and 
20 h p.i., a static scan in the AP position was made for 10, 30 and 30 min, respectively. In 
patients 6-8 a dynamic scan was made for 60 min, 1 min per frame, followed by SPECT/CT 
and single-frame, 30-min static images at 2, 4 and 6 hours p.i. Additionally, in patients 3, 4, 
6, 7 and 8, a transurethral catheter was inserted in order to drain the bladder and reduce 
local radioactivity. 
Images were reconstructed using iterative reconstruction (Flash 3D, 8 iterations, 16 
subsets, Gaussian 9.0 filter). In addition to anatomical localization, CT was also used to 
obtain an attenuation map. Dynamic and static images were displayed in coronal planes, 
and SPECT images were displayed in transaxial, coronal and sagittal planes. The tumor to 
normal tissue ratios were determined by placing a region of interest (ROI) over the area 
showing the most activity in tumor and an identically sized ROI over the gluteal muscles. 
Image analysis and subjective assessment were performed by a nuclear physician (JP) 
blinded to patient data and 1 non-blinded researcher (HA) .  
 
5.2.6  Monitoring of Vital Parameters and Side-effects 
Because this was a first-in-man study, the heart rate, oxygen saturation and blood 
pressure were monitored in all patients during the first hour p.i. at regular intervals (0, 5, 10, 
15, 20, 25, 30, 45 and 60 min) and were compared with baseline measurements before 
injection of 99mTc-HABN. Side-effects, if reported by the patient within 24 h p.i., were 
documented. 
 
5.2.7  Analysis of radioactivity in blood  
Blood samples (2 ml/time point) were collected from six patients via a venous canula 
in the right forearm at 0, 2, 5, 10, 30, 60, 120, 240, 360 and 1200 min (the last time point 
was not analyszed for patients 7 and 8) p.i. of 99mTc-HABN. No blood sampling of patients 
2 and 6 was performed due to technical failure.  
Blood serum samples were acquired by centrifuging the blood sample at 3000 rpm for 
5 min. For each sample, the radioactivity of both full blood and blood serum (250 μl), as 
well as the original 99mTc-HABN saline solution (10 μl in triplicate) was determined in a 
γ-counter. The radioactivity accumulation of 99mTc-HABN in full blood and serum was 
calculated as follows: counts of the 250-μl sample *4 / total injected counts (percentage of 
the injected dose/ml, mean ± SD, n=6). 
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5.2.8  Metabolic Stability of 99mTc-HABN 
The in vivo metabolic stability of 99mTc-HABN was determined by analyzing blood 
serum samples collected at 0 (baseline) 2, 5, 10, 30, 60 and 120 min p.i. of 99mTc-HABN 
from patients 1, 3, 4 and 5. Blood serum samples were acquired as described above. The 
protein of blood serum samples was removed by centrifuging at 3000 rpm for 5 min after 
mixing with a 10-fold volume of ACN. The supernatant was passed through a Sep-Pak 
C18 Light cartridge and washed with water (5 ml) and EtOH (2 mL).  The radioactivity of 
the eluents was determined in a γ-counter. The percentage of metabolites was calculated as 
follows: (aqueous eluent radioactivity / (aqueous eluent radioactivity + ethanol eluent 
radioactivity)) * 100% (mean ± SD, n=4). 
 
5.2.9  Immunohistochemical staining of GRPR 
In patients scheduled for RP, prostatectomy specimens were used for 
immunohistochemical staining of GRPR. In patients who did not undergo RP, prostate 
biopsy specimens were used. Formalin-fixed, paraffin-embedded blocks of prostate cancer 
tissue were cut into 3-μm thick sections and mounted on APES 
(3-aminopropyltriethoxysilane)-coated slides. A human prostate cancer PC-3 xenograft 
tumor was used as the positive control. As the negative control, the primary antibody was 
omitted during immunohistochemical analysis on the positive control tissue. Tris buffered 
saline (TBS) was used for washing and dilution of antibodies. After deparaffinization, 
antigen retrieval was performed by microwave heating (400 W) for 20 min in a 0.1 M 
Tris/HCl buffer at pH 9.0. Endogenous peroxidase was blocked by incubation with 0.3% 
hydrogen peroxide in TBS for 20 min. To decrease non-specific background staining, slides 
were incubated with normal goat serum diluted at 1:10 in TBS for 30 min at room 
temperature. Tissue section slides were incubated with primary anti-human-GRPR rabbit 
polyclonal antibody ab39963 iluted at 1:250 in 1% bovine serum albumin (BSA)/TBS 
overnight at 4 °C. A secondary step with goat anti-rabbit antibody P0448 diluted at 1:100 in 
1% BSA/TBS with 1% AB serum was applied for 60 min at room temperature. Slides were 
immersed for 10 min in a solution of 0.05% 3,3′-diaminobenzidine and 0.03% hydrogen 
peroxide in TBS for visualization of the signal as brown staining. After washing with 
demineralized water, slides were counterstained with hematoxylin and dehydrated. Finally, 
a coverslip was applied using Eukitt mounting medium.  
 
5.2.10  Assessment of GRPR Staining 
An experienced pathologist (SR) blinded to the clinical data scored the staining 
intensity (0 = no staining, 1+ = weak staining, 2+ = moderate staining, 3+ = strong staining) 
of tumor areas for all specimens. Specimens, in which one or more tumor areas with 
different staining intensities were present, were scored for the most prevalent intensity. 
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5.3  Results 
5.3.1  Synthesis and Quality Control of 99mTc-HABN 
99mTc-HABN was prepared (n=8) with a radiochemical yield of 43 ± 4%, a specific 
activity of 87.2 ± 9.4 TBq/mmol and a radiochemical purity of 97.3 ± 0.9%. The bubble 
point test of the sterilization filter was performed before the injection of 99mTc-HABN. The 
sterility, endotoxins and residual solvents tests were performed after the release of the tracer. 
The final productswas sterile and apyrogenic (<0.25 EU/ml), and resideual solvents were 
found to be < 50 mg/L and 100 g/L for ACN and EtOH, respectively. Release and 
post-release specifications are summarized in table 1. 
Table 1: release and post-release specifications 99mTc-HABN. 




Appearance Clear, colorless Yes Every synthesis 
pH 5-8 Yes Every synthesis 
Radiochemical purity (%) >95% Yes Every synthesis 
Specific activity (MBq/mg) >5000 Yes Every synthesis 
Bubble point test sterilization filter <20% Yes Every synthesis 
Sterility Sterile No Every synthesis 
Endotoxins (EU/ml) <0.25 No Every synthesis 
EtOH concentration (g/l) <100 No Every synthesis 
ACN concentration (mg/l) <50 No Every synthesis 
5.3.2  Patient characteristics 
Details of included patients and results of histology can be found in table 2. 
Although initially selected for EBRT, patients 7 and 8 proved to have lymph node 
metastases and were subsequently selected for hormonal therapy. 
 
Table 2: patient characteristics. 
Pt.nr Age PSA PrV Therapy T-stage TumorV Gl PLND 
1 59 5,9 35 RP pT2ca 5%a 7a np 
2 55 16 21 RP pT2ca >50%a 6a np 
3 69 12 47 RP pT2ca <50%a 7a pN0 
4 73 7,8 56 EBRT cT1cb Left/5/5/75%, 
Right/5/1/5%c 
7c pN0 
5 55 15,5 23 RP pT3aa >50%, capsular 
penetration lefta 
8a np 
6 73 69.8 38 EBRT cT2cb Left/5/2/15%, 
Right/5/4/45%c 
9c pN0 
7 71 221.5 55 HT cT3b Left/4/4/65%, 
Right/4/4/10%c 
7c pN1 




Biopsy results are not displayed when histology of a radical prostatectomy is available. In 
EBRT or hormonal therapy patients, only prostate biopsy histology is available. PSA in 
ng/ml, PrV = prostate volume in ml, RP = radical prostatectomy, EBRT = external beam 
radiotherapy, HT = hormonal therapy, T-stage = tumor stage, a = based on histology of 
radical prostatectomy specimens, b = based on digital rectal examination and histology of 
prostate biopsies, c = based on histology of prostate biopsies, TumorV = % tumor volume 
(tumorvolume based on prostate biopsies are presented as: side/biopsy cores taken on that 
side/number of positive cores on that side/%tumorvolume), Gl = Gleason sum score, PLND 
= pelvic lymph node dissection, np = not performed, pN0 = no pelvic lymph node 
metastases, pN1 = pelvic lymph node metastases. 
 
5.3.3  Image Analysis 
Thorough analysis of the dynamic, static and SPECT images with or without CT by one 
dedicated nuclear medicine physician (JP) blinded to patient data and non-blinded one 
researcher (HA), revealed no uptake of radioactivity in the prostate or pelvic lymph nodes 
(histologically proven lymph node metastases in patients 7 and 8). Rapid distribution via 
blood was observed, and excration via urine was observed within 5-7 min. T transurethral 
catheter reduced radioactivity in the pelvis, improving visualization of tissue in the 
immediate vicinity of the bladder. The procedure did not lead to detection of a hot-spot in 
the prostate. Furthermore, no other hot-spots outside the bladder or prostate were observed 
in the pelvis. No ROIs were drawn because the tumor was not visualized.  
 
5.3.4  Monitoring of Vital Parameters and Side-effects 
In the first hour after 99mTc-HABN injection, vital parameters (heart-rate, oxygen 
saturation and blood-pressure) were measured at regular intervals and were compared with 
baseline measurements. No clinically significant changes in heart rate (>15% change), 
oxygen saturation (>5% change) and blood pressure (>15% change) were recorded. None 
of the patients suffered from adverse or subjective side effects.  
 
5.3.5  Analysis of Radioactivity in Blood  
Figure 1 shows the full blood and serum radioactivity curves after 99mTc-HABN 
injections in patients during the 1200-min study period (n=6, except at the 1200-min time 
point were n=4). A steady decline of the radioactivity was observed in blood and serum 





Figure 1: full blood and serum activity curves during the 1200 min study. Values are 
expressed as percentage of the injected dose per ml (%ID/m, mean ± SD, n=6, 1200 min 
time-point n=4). 
 
5.3.6  Metabolic Stability of 99mTc-HABN 
Figure 2 shows the in vivo degradation of 99mTc-HABN. There are low metabolic 
stability and rapid degradation of 99mTc-HABN, with 22%, 44% and 53% of the 
radioactivity degraded within 2, 5 and 10 min p.i., respectively. After 30 minutes less than 
20% of 99mTc-HABN was still intact. 
 
5.3.7  Assessment of immunohistochemical GRPR staining 
Immunohistochemistry on paraffin slides of prostate cancer specimens (four whole 
prostate sections, four prostate needle biopsy specimens) demonstrated low-to-moderate 
staining of prostate cancer for GRPR in 8/8 cases (table 3).  
 
5.4  Discussion  
Targeted imaging could improve the lack of accuracy observed in current imaging 
techniques used in different stages of prostate cancer. Recently, we have developed the 
novel BN-based radiopharmaceutical, designated 99mTc-HABN, and evaluated its imaging 
potential in a xenograft mouse model of human prostate cancer(20). The aim of thestudy 
presented here was to perform a first-in-man clinical pilot study to evaluate the feasibility 
of 99mTc-HABN SPECT/CT for detection of prostate cancer in patients. We were able to 
synthesize a radiopharmaceutical with high yield, specific activity and purity, in the 
absence of any signs of adverse or subjective side effects after patientadministration. 
However, 99mTc-HABN scintigraphy and SPECT/CT did not detect prostate cancer in 
patients with proven disease.  
Although immediate distribution via the vascular system and rapid excretion via the 
renal route were deduced from the dynamic images, no uptake in the prostate was observed 
at any time point in any patient. Although bladder drainage using a transurethral catheter 
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proved to be helpful in reducing activity in the bladder with an improved ability to assess 
pelvic organs, it did not aid in detecting hot-spots.  
Because small tumors could be missed with SPECT, patients with larger tumor 
volumes and higher PSA values were selected in the second half of the patient inclusion 
(patients 5–8). The different patient selection sorted no effect. Additionally, there has been 
some discussion concerning the level of GRPR expression according to various Gleason 
sum scores. Although this could not be proven in lymph node and bone metastases of 
prostate cancer(12), Beer et al. demonstrated that a higher Gleason sum score tends to 
express lower levels of GRPR(13). Therefore, a range of Gleason sum scores was selected 
(Gleason 6–9; lower scores are seldom observed, and Gleason 10 is only rarely eligible for 
local therapy), but did not give other results with 99mTc-HABN scintigraphy and SPECT/CT. 
One reason for the failure to visualize the prostate tumors is that, by chance, GRPR 
expression in 8 prostate cancer patients could be absent. However, with 
immunohistochemistry on paraffin slides of the prostate cancerspecimens of these patients, 
we proved the presence of GRPR in all our patients (Table 3). Although 
immunohistochemistry shows the presence and tissue distribution of an antigen, the 
technique cannot demonstrate absolute antigen density and is therefore not a strong 
predictor for uptake of a GRPR-targeting radiopharmaceutical. 
 
Table 3: Staining intensities of the antibodies in prostate cancer specimens 
Patient number Pathology Staining intensity 
1 Radical prostatectomy + 
2 Radical prostatectomy + 
3 Radical prostatectomy + 
4 Prostate needle biopsy + 
5 Radical prostatectomy + 
6 Prostate needle biopsy + 
7 Prostate needle biopsy ++ 
8 Prostate needle biopsy + 
 
The difference between the in vitro stability in human serum samples determined in 
our previous study on 99mTc-HABN (20) and the in vivo metabolic stability determined in 
the present study, is striking. In our previous study, we have demonstrated that 77% 
of 99mTc-HABN is intact after 24 h in human serum in vitro (20). However, the results of 
the current study indicate that metabolites are formed as early as 10 min p.i. and that less 
than 20% of 99mTc-HABN is intact after 30 min. Thus, we must conclude that one of 
themain reasons for the failure to visualize the prostate tumors is the rapid in vivo 
degradation of 99mTc-HABN (Figure 2). Similar results were observed in a study by Linder 
et al., where the metabolism of 177Lu-AMBA in mice and rats in vivo was much more rapid 
than that in vitro (21).  
Rapid and highly selective proteolytic cleavage of bioactive peptides is not unexpected 
because this is the key in the autonomic regulation of the biologic effects of peptides. It is 
unknown which enzymes are responsible for the degradation of BN in vivo. In this respect, 
ecto-enzymes located on the cell surface that shed in blood and are highly expressed in the 
liver and kidneys could be major players in this process (22). Therefore, to more accurately 
determine radiochemical stability, it was suggested by Ocak et al. to use liver and kidney 
homogenates (23). By contrast, in another study by the same author, it was shown that rat 
liver and kidney homogenates were not good predictors for in vivo stability (24).  
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Figure 2: the in vivo metabolic stability of 99mTc-HABN. Results are plotted as the 
percentage of formed metabolites at different time points (mean ± SD, n=4).  
 
In a pre-clinical study in a xenograft tumor model for human prostate cancer in 
athymic mice, we have demonstrated moderate uptake of 99mTc-HABN in tumors (20). 
Moderate uptake in tumors does not pose a real problem provided that the background 
uptake is low to create high tumor-to-background ratios and excellent contrast. 
Performance of a BN-like radiopharmaceutical in a pre-clinical mouse model is not a strong 
predictor for clinical performance in humans because there is a different body 
biodistribution of GRPR in mice compared with humans. Nevertheless, the moderate 
uptake of 99mTc-HABN in tumor cells as previously demonstrated in the preclinical study 
could be another contributing factor leading to failure to visualize the prostate tumors in 
prostate cancer patients in this study.  
Other clinical studies in prostate cancer patients with BN-like radiopharmaceuticals 
have shown fairly good results (19). A study by Scopinaro et al. is particularly interesting 
because high uptake in the prostate was found in all eight prostate cancer patients, and 
pathology confirmed invasion in obturator nodes was found in three of these patients (26). 
Despite the clinical results of other groups and the findings of our pre-clinical studywhere 
the prostate tumorwas clearly visualized in mice with 99mTc-HABN microSPECT, we could 
not detect prostate cancer with99mTc-HABN scintigraphy and SPECT/CT in patients of the 
current clinical study. Two main reasons for the inability to detect prostate cancer with 
scintigraphy and SPECT/CT are most likely the low in vivo stability of 99mTc-HABN 
resulting in low-circulating intact radiopeptide and the absolute tumor uptake 
of 99mTc-HABN being too low because of the relatively low to moderate expression of 
GRPR in primary prostate cancer. When considering the IC50, the in vivo tumor uptake and 
tumor-to-normal-tissue ratios in the pre-clinical study, the affinity and performance 
of 99mTc-HABN are essentially similar compared with other BN analogs reported in the 
literature (19, 25). The pre-clinical data of the BBN-like radiopharmaceuticals that have 
been used for imaging of prostate cancer patients are not available in the international 
literature and, therefore, cannot be compared with our pre-clinical data.  
The findings that the in vitro stability of a BBN-like radiopharmaceutical in human 
serum does not correlate with in vivo stability and that the in vivo performance of a BN-like 
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radiopharmaceutical in a mouse tumor model does not correlate with in vivo performance in 
man are interesting. As demonstrated previously, determination of the stability of a 
radiolabelled peptide in vitro in serum has no predictive value for its in vivo stability in 
rodents (21, 23, 24). The development of new or improved in vitro stability tests or better 
preclinical in vivo tumor models may prove to be a better approach for selecting 
radiolabelled peptides of appropriate stability and affinity for clinical testing. Future studies 
should focus on developing high affinity BN-like radiopharmaceuticals that have been 
proven to be highly stable in a pre-clinical setting. Additionally, instead of using the 
relatively low-resolution SPECT for imaging, the use of radiopeptides suitable for PET 
imaging will aid in improvement of imaging.  
 
5.5  Conclusions 
99mTechnetium-HYNIC(tricine/TPPTS)-Aca-Bombesin(7–14) SPECT/CT for the 
detection of prostate cancer is safe but is hampered by an unexpectedly low in vivo 
metabolic stability in man. The difference between the excellent in vitro stability in human 
serum determined in our previous study on 99mTc-HABN and the low in vivo metabolic 
stability determined in the present study is striking. Furthermore, the current study showed 
that the in vivo performance in a mouse tumor model does not correlate with in vivo 
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Radiolabelled bombesin analogues are promising tracers for the Gastrin-Releasing- 
Peptide-Receptor (GRPR), a receptor highly expressed in human prostate cancer. For 
achieving high accumulation in tumor and high tumor-to-normal tissue contrast, we 
designed a [123I]-labelled bombesin tracer. The [123I]-cubyl-carboxyl-ε-aminocaproic 
acid-bombesin(7-14) ([123I]-CABN) was developed as a potential metabolically stable 
tracer against deiodination with a relatively long radioactive half-life. In this study, we 
evaluated the targeting ability of the tracer in vitro and in tumor bearing athymic mice in 
vivo. 
Methods: [123I]-CABN was synthesized by coupling the synthon [123I]-cubyl- 
carboxyl-tetrafluorophenyl ([123I]-cubyl-TFP) ester with ε-aminocaproic acid–bombesin 
(7-14)(Aca-BN). The internalization and efflux properties of [123I]-CABN were determined 
in a PC-3 human prostate cancer cell line. The biodistribution profiles and the 
imaging characteristics were determined in athymic mice bearing human PC-3 tumor 
xenografts.           
Results and Conclusion: The novel universal labeling [123I]-cubyl moiety was 
successfully conjugated to the Aca-BN peptide. The radiochemical yield of [123I]-CABN 
starting from [123I]-cubyl-TFP ester was 49±18% and the radiochemical purity was higher 
than 95% after purification. [123I]-CABN showed good cell uptake (11.0 ± 0.7% of 
incubation dose at 1 h post incubation) and efflux kinetics (efflux half-life was 88 min), but 
the unfavourable in vivo stability proved to be the limiting factor for tumor targeting as the 
radiotracer was sensitive to peptidase activity. Although [123I]-CABN may not be a proper 
tracer for prostate cancer imaging, the [123I]-cubyl moiety is a promising motif for labeling 
of biomolecules. 
 






















6.1  Introduction 
Bombesin (Pyr-Gln-Arg-Leu-Gly-Asn-Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH2) is a 
14 amino acid peptide first isolated from frog skin and reported in 1970 (1). Neuromedin B 
receptor (BB1), GRPR (BB2) and Bombesin receptor subtype 3 (BRS-3 or BB3) are known 
as mammalian bombesin receptors (2). GRPR not only functions as a glycosylated, 
7-transmembrane G-protein coupled receptor, which, upon binding, rises a complex 
cascade of intracellular reactions (3-5), but is over expressed in several primary human 
tumours and metastases such as breast and prostate cancer (6-9).  
Prostate cancer is the most common cancer in males in western countries (10). 
Because of the poor positive predictive value and low resolution of current prostate cancer 
detection methods, a high sensitive, non-invasive, in vivo method is urgently required.   
Bombesin derivatives have been labelled for SPECT imaging with 99mTc, 177Lu, 67Ga 
and 111In (11-15) and for PET imaging with 64Cu, 68Ga and 18F (16-20), thus bombesin 
analogues with a large range of radioactive half-lives are available (21). In our previous 
study it was shown that 99mTc-HYNIC(Tricine/TPPTS) labeling is a suitable approach for 
bombesin tracer synthesis (12). For 99mTc-HYNIC(tricine/TPPTS)-Aca-Bombesin(7-14), 
the optimal tumor-to-background contrast was reached at 4 hours post tracer injection. As 
an alternative to 99mTc we explored 123I. The half life of 123I is 13.3 hours which is suitable 
for peptide labeling for application in SPECT imaging. If the new radioiodinated bombesin 
would show to be a suitable tracer, other iodine radioisotopes could be applied as well. 124I 
and 131I could supply alternatives for PET imaging and radioimmunotherapy. Therefore, 
[123I] was selected for SPECT imaging in this study. 
To avoid deiodination and subsequent high accumulation in the thyroid gland, we 
introduced the [123I]-cubyl-moiety (figure 2, A), as a stable labeling synthon, to develop a 
stable radiotracer and evaluated the possibility for targeting GRPR in human prostate 
cancer xenograft. 
 
6.2  Materials and Methods 
All chemicals obtained commercially were used without further purification. Aca-BN 
was obtained from Peptide International (Louisville, KY, USA). 125I-Tyr4-BN(1-14) was 
purchased from Perkin-Elmer Life and Analytical Sciences (Waltham, MA, USA).  
 
6.2.1  Methods: 
For radio-HPLC, a HITACHI L-2130 HPLC system (Hitachi High Technologies 
America Inc., Pleasanton, CA, USA) equipped with a Bicron Frisk-tech area monitor was 
used. Analysis and isolation of radiolabelled peptides was performed using a 
reversed-phase Grace Smart RP-C18 column (Lokeren, Belgium) (4.6 mm × 250 mm, 10 
μm). The flow rate was 1 ml/min. The mobile phase was isocratic with 90% solvent A (0.01 
M phosphate buffer, pH 6.0) and 10% solvent B (acetonitrile) at 0-5 min, followed by a 
gradient mobile phase going from 10% solvent B at 5 min to 60% solvent B at 15 min, and 
from 90% solvent B at 22.5 min, back to baseline 10% solvent B at 25 min afterwards.  
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6.2.2  Chemistry 
6.2.2.1  Hydrolysis of 1,4-iodocubylcarboxylicacid-methylester  
1,4-iodocubylcarboxylicacid-methylester(1) (65 mg, 0.225 mmol) (Boron molecular, 
Durham, North Carolina , USA) was suspended in 3 mL THF and 7 mL H2O. The pH of 
the solution was adjusted to 13 and maintained at this value for 5 hours at room temperature 
by the continuous addition of an aqueous KOH solution (2 mol/L). The reaction mixture 
was then acidified to around pH 4 with 2 M HCl, forming a suspension. The acid 
containing suspension was extracted by diethyl ether until there was no suspension formed 
when a new charge of acid was added. The resultant diethyl ether solution was dried over 
anhydrous MgSO4. After removal of MgSO4, the solvent was evaporated and the crystals 
were collected. This solid was further dried at 40oC for 24 hours in the vacuum oven, giving 
around 50 mg (80%) free acid 1,4-iodocubylcarboxylicacid (2). 1H NMR (400 MHz, 
CDCl3, δ): 4.42(3H, m, CHCO), 4.30(3H, m, CHI). 
 
6.2.2.2  Synthesis of 1,4-iodocubylcarboxylicacid-N-hydroxysuccinimide 
(active ester (3)) 
1,4-iodocubylcarboxylicacid (2) (50 mg, 0.182 mmol) was dissolved in 5 mL 
methylene chloride. To this solution dry and finely powdered N-hydroxysuccinimide (NHS, 
21 mg, 0.183 mmol was added. The flask was cooled in an ice-water bath, after which 
dicyclohexyl carbodiimide (DCC, 37.7 mg, 0.183 mmol) was added in a molar ratio of 
1.001 times of free acid. The reaction mixture was stirred vigorously at 0 oC for 1 h and at 
room temperature for 12 hours. After the removal of precipitated dicyclohexyl urea by 
filtration, the crude product was extracted with distilled water. The resultant was dried over 
anhydrous MgSO4. Afterwards, MgSO4 was removed by filtration. The product was 
collected to give 60.8 mg (90%) 1,4-iodocubylcarboxylicacid-N-hydroxysuccinimide active 
ester (3). 1H NMR (400 MHz, CDCl3, δ): 4.58(3H, m, CHCO), 4.36(3H, m, CHI), 2.84(4H, 
s, CH2N). 
 
6.2.2.3  Synthesis of Non-Radiolabelled I-CABN:  
1,4-iodocubylcarboxylicacid-N-hydroxysuccinimide active ester (3) (6 mg) was 
dissolved in 0.5 mL acetonitrile. 0.5 mL (2 mg/mL in 0.1 M borate buffer) of Aca-BN was 
added to the active ester and the reaction mixture was well mixed and kept in room 
temperature for 2 h (figure 1). The reaction mixture was purified with HPLC. The 
collection was formulated by using Waters Sep-Pak Light C18 cartridge. The I-CABN was 
eluted with ethanol and dried under nitrogen flow (0.6 mg). The final product was 
characterized by mass spectrometry, C58H81IN14O11S calculated molecular weight 1305.32, 
observed 1306.1 ([M+H]+).  
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Figure 1. Synthesis of I-CABN. (1)= 1,4-iodocubylcarboxylicacid-methylester, (2)= 
1,4-iodocubylcarboxylicacid, (3)= 1,4-iodocubylcarboxylicacid-N-hydroxysuccinimide 
active ester 
 
6.2.3  Cell Culture 
The GRPR positive PC-3 human prostate cancer cell line (ATCC, Manassas, Virginia, 
USA) was cultured in RPMI 1640 (Lonza, Verviers, France) supplemented with 10% fetal 
calf serum (Thermo Fisher Scientific Inc., Logan, Utah, USA) at 37 °C in a humidified 5% 
CO2 atmosphere.  
 
6.2.4  In Vitro Competitive Binding Assay: 
The in vitro GRPR binding affinities of Aca-BN and non-radiolabelled I-CABN were 
compared via a competitive displacement assay by using 125I-Tyr4-BN(1-14) as the GRPR 
specific radioligand. Experiments were performed with PC-3 human prostate cancer cells 
according to a method previously described (12). The 50% inhibitory concentration (IC50) 
values were calculated by fitting the data with nonlinear regression using GraphPad Prism 
5.0 (GraphPad Software, San Diego, California, USA). Experiments were performed with 
triplicate samples. IC50 values are reported as an average of these samples plus the standard 
deviation (SD). 
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6.2.5  Synthesis of [123I]-cubyl-TFP Ester 
 [123I]-cubyl-TFP ester was prepared by the Department of Nuclear Medicine and PET 
Research, VU University Medical Center, Amsterdam, The Netherlands. Preparation of 
[123I]-cubyl-TFP ester was performed as reported [patent WO2006083983(A2)]. In brief, 
the synthesis was started with Methyl-4-Bromocubylcarboxylate (1.5 mg), Cu(II)triflate 
(0.01 mg) and N,N-dimethylpiperazine. The mixture was added to non-carrier added [123I] 
in 150 µL of acetonitrile (22). This mixture was heated in a closed vial for 40 min at 140 °C 
[123I]methyl-4-iodocubylcaboxylate (83% radiochemical yield) was isolated from the 
precursor by HPLC (Kromasil 100 C18, MeCN/H2O/DIPA 50/50/0.2, 1 ml/min, with a 
retention time of 20 -23 min). To the collected fraction 10 µL of 1 M NaOH was added. 
This mixture was heated for 30 min at 120 °C. Next the mixture was acidified to pH 6 with 
1 M HCl, and 80 mg of EDAC and 60 mg of 2,3,5,6-tetrafluorophenol was added to the 
solution, and was left at room temperature for 45 min. To this solution water was added 
until the solution became a 10% acetonitrile solution, and was passed over a Sep-Pak C18 
plus cartridge and washed with 20 mL water. The final product was eluted with acetonitrile 
in an overall yield of 40-60%. 
 
6.2.6  Synthesis of [123I]-CABN  
The synthesis of [123I]-CABN was performed by coupling Aca-BN with 
[123I]-cubyl-TFP ester. 400 μl of Aca-BN (1 mg/ml, in 0.1 M sodium bicarbonate buffer, pH 
9.5), 100 μl of [123I]-cubyl-TFP ester (~200 MBq, in acetonitrile) were added to a glass vial 
and gently mixed. The mixture was sealed and kept at room temperature for 30 min. The 
tracer was analyzed and purified using radio-HPLC system. Retention time of Aca-BN and 
[123I]-CABN were 16 and 23 min, respectively. The organic solvents in the product were 
removed by trapping the HPLC-collected product (after dilution with water) on a 
preactivated Waters Sep-Pak C18 light cartridge. [123I]-CABN was eluted with 0.4 
ml ethanol and diluted with saline solution.  
 
Figure 2. Synthesis of [123I]-CABN. 
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6.2.7  Partition Coefficient 
To measure the partition coefficient, 0.1 MBq of [123I]-CABN was dissolved in 1 
ml equivalent volume mixture of PBS (25 mM, pH 7.4) and n-octanol. The mixture was 
vortexed for 5 min at room temperature. After centrifugation (5 min 3000 rpm), 100 µl of 
both layers were counted with a γ-counter (Compugamma CS1282, LKB-Wallac, Turku, 
Finland). The experiment was performed in triplicate. The log D value was calculated as 
log(counts of organic phase/counts of water phase) (mean ± SD).  
 
6.2.8  In vitro Stability 
100 µl of [123I]-CABN was diluted with 2 ml saline and kept at room temperature. 
Samples were taken and analyzed using radio-HPLC at 1, 2, 4, 24 h after incubation.  
Another 100 µl of [123I]-CABN was diluted with 2 ml human serum and incubated at 
37 oC for same time period as mentioned earlier.  Serum samples were precipitated with 
acetonitrile/ethanol solution (Vacetonitrile: Vethanol=1: 1) and centrifuged at 3000 rpm for 3 min. 
The supernatants were passed through a 0.22 µm filter and analyzed by radio-HPLC. 
 
6.2.9  In vitro Cell Uptake Assay 
The PC-3 cells were harvested and placed in 6-wells plates (0.5 million cells/well) one 
day before the experiments. The cells were rinsed three times with PBS before use. PC-3 
cells were incubated with 3.7 kBq of [123I]-CABN at 37 °C for 1 hour. For determining the 
binding specificity of [123I]-CABN, 20 µg of unlabelled Aca-BN was co-incubated with 
cells in the blocking group. To remove unbound radioactivity, the cells were washed twice 
with ice-cold PBS and afterwards the cells were lysed by incubation with 1 M NaOH at 
37 °C. The cell associated radioactivity was determined by the γ-counter. Experiments were 
performed in triplicate. The cellular uptake was calibrated against a known aliquot of 
radiotracer and expressed as percentage of total incubated radioactivity (mean ± SD). 
    
6.2.10  Internalization and Efflux Kinetics 
Internalization and efflux kinetics of [123I]-CABN in a PC-3 cell line were evaluated 
following a protocol reported previously (12). The experiments were performed in 
triplicate.  
 
6.2.11  Animal Models 
The animal model for the biodistribution studies, microSPECT/microCT imaging and 
in vivo stability studies was generated by subcutaneous injection of 1×106 PC-3 cells 
(suspended in 0.1 ml of sterile saline) in the shoulder of male athymic nude mice (Harlan, 
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Zeist, The Netherlands). During the injection, animals were anesthetized with a gas 
composed of 3.5% isoflurane in an air and oxygen mixture. The mice were used for animal 
experiments when the tumor volume reached a mean diameter of 0.8 - 1.0 cm (3 - 4 weeks 
after inoculation). All animal experiments were performed in accordance with the 
regulations of Dutch law on animal welfare and the institutional ethics committee for 
animal procedures approved the protocol. 
 
6.2.12  MicroSPECT Imaging and Biodistribution 
The subcutaneous tumor bearing mice were used for microSPECT imaging and 
biodistribution when the tumor volume reached 250-300 mm3 (4-5 weeks after inoculation). 
MicroSPECT scans were performed using a three-head γ-camera (MILabs, 
U-SPECT-II, Utrecht, The Netherlands) equipped with a multi-pinhole high-resolution 
collimator. The MicroSPECT scans were performed with mice under isoflurane anesthesia 
after penile vein injection of ~33 MBq [123I]-CABN. A dynamic microSPECT scan of 60 
min (10 min per frame) was performed immediately after injection. For the 
receptor-blocking experiment, 300 µg of unlabelled Aca-BN was pre-injected 30 min 
before the tracer injection through the same catheter. The mice for dynamic scans were 
sacrificed after the scan. Blood, tumor, major organs and tissue samples were collected, 
weighted and counted by a γ-counter. The percentage of injected dose per gram (%ID/g) 
was determined for each sample. For each mouse, radioactivity of the tissue samples was 
calibrated against a known aliquot of radiotracer. 
 
6.2.13  In Vivo Stability  
The in vivo stability of [123I]-CABN was evaluated in PC-3 prostate cancer bearing 
athymic nude mice. [123I]-CABN (in 0.2 ml saline, ~ 22 MBq) was administered via penile 
vein. The animals were sacrificed at 10 min after tracer injection. Blood samples were 
collected and centrifuged at 3000 rpm for 5 min of Serum samples (250 µl) were extracted 
and well mixed with 750 µl acetonitrile. The mixture was centrifuged at 3000 rpm for 5 min. 
The supernatant of the mixture was filtered through a 0.22 μm Millex-LG filter and 
analyzed by radio-HPLC. The elution of the radio-HPLC was collected with plastic tubes 
(0.5 ml/tube) and measured by a γ-counter. The results were analyzed using GraphPad 
Prism 5.0 (GraphPad Software, San Diego, California, USA). 
 
6.2.14  Statistical Analysis 
Quantitative data are expressed as mean ± SD. Means were compared using Student’s t 
test. P values<0.05 were considered significant. 
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6.3  Results 
6.3.1  Radiochemistry, Partition Coefficient and In Vitro Stability 
The preparation of [123I]-CABN was accomplished by coupling the [123I]-cubyl-TFP 
ester with Aca-BN peptide in moderate condition (pH=9.3, 30 min at room temperature). 
The labeling yield of [123I]-CABN starting from [123I]-cubyl-TFP ester was 49±18% (n=11). 
After HPLC purification, the radiochemical purity was > 95% according to radio-HPLC. 
The specific activity was 326±62 MBq/µmol (n=11) calculated from native Aca-BN. 
[123I]-CABN was completed separated from Aca-BN by using HPLC. The partition 
coefficient was determined with a mixture of n-octanol and phosphate buffer (pH 7.4). The 
log D value of [123I]-CABN was 1.20 ± 0.02. The in vitro stability of [123I]-CABN was 
tested in saline and human serum. Figure 3 shows the in vitro stability of [123I]-CABN. 
After 4 hours of incubation in saline solution, more than 95 % of the radioactivity 
corresponds to the parent compound of [123I]-CABN. When incubated with human serum at 
37 oC for 2 h, 50% of radioactivity maintained the form of parent compound. Only ~10 % 
of [123I] was still in its original form after 4 hours incubation in human serum.   
 
Figure 3. In vitro stability of [123I]-CABN in saline (at room temperature), and human 
serum (at 37 oC). Results are plotted as % of the parent compound at different time points. 
 
6.3.2  In Vitro Competitive Binding Assay 
The GRPR binding affinity of Aca-BN and non-radiolabelled I-CABN was 
investigated by replacing the GRPR-bound of 125I-Tyr4-BN(1-14) in PC-3 cells. Figure 4 
shows the results of the competitive binding assay. The IC50 value of Aca-BN and 
non-radiolabelled I-CABN were 2.5±0.4 and 72.9±1.7 nM, respectively. 
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Figure 4. Displacement curve of 125I-Tyr4-BN(1-14) binding to GRPR in PC-3 cells. 
Log[M]: log of increasing concentration of Aca-BN and non-radiolabelled I-CABN. 
 
6.3.3  In vitro Cell Uptake Assay  
The cellular uptake of [123I]-CABN was evaluated in the PC-3 prostate cancer cell line, 
and the receptor-mediated uptake was determined by co-incubation with excess blocking 
agent at 37 oC. The cellular uptake of [123I]-CABN at 1 hour in the presence and absence of 
excess unlabelled bombesin(1-14) was 11.0 ± 0.7% and 5.6 ± 0.3%, respectively.  
 
6.3.4  Internalization and Efflux Kinetics 
Figure 5 shows the internalization and efflux kinetics of [123I]-CABN. The 
internalization of [123I]-CABN increased rapidly in 15 min after start of the incubation with 
PC-3 cells and reached plateau after 30 min incubation with maximum internalization ratio 
66 ± 4%. After 4 h incubation in medium, 38 ± 2% of the internalized radioactivity 
remained in the PC-3 cells. T1/2 of efflux of [123I]-CABN was 88 min. 
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Figure 5. Internalization (A) and efflux (B) kinetics of [123I]-CABN in PC-3 cells (n=3, 
mean ± SD). 
. 
6.3.5  MicroSPECT Imaging and Biodistribution 
Biodistribution and microSPECT imaging of [123I]-CABN were performed in athymic 
mice bearing PC-3M human prostate cancer xenograft.  The uptake of [123I]-CABN and 
the tumor-to-normal-tissue ratio (T/NT) in organs of interest are shown in table 1. 
The organs with high uptake were liver, kidney and small intestine; the uptake was 
30.9±7.3, 23.6±16.5, and 7.3±2.4%ID/g, respectively. The tumor uptake of [123I]-CABN at 
1 hour post injection was 0.26±0.08 %ID/g and was reduced to 0.18±0.08 %ID/g with 
excess of blocking agent. In pancreas, which is a GRPR rich organ, radioactivity uptake 
was 1.11 ± 0.21%ID/g. Only 32% of the radioactivity accumulation in pancreas was 




Table 1 Biodistribution and tumor-to-non-tumor-tissue ratio (T/NT) of [123I]-cubyl-Aca-BN 
after intravenous injection in PC-3 prostate cancer bearing athymic nude mice.  
 
Organ 
1 h 1 h with blocking agent 
%ID/g T/NT %ID/g 
Blood 0.27 ± 0.07 0.97 0.25 ± 0.12 
Heart 0.19 ± 0.08 1.52 0.20 ± 0.13 
Liver 30.99 ± 7.31 0.01 38.74 ± 14.95 
Spleen 0.47 ± 0.36 1.38 0.59 ± 0.49 
Kidney 7.34 ± 2.43 0.04 9.53 ± 2.37 
Small intestine 23.61 ± 16.54 0.03 22.02 ± 11.48 
Large intestine 1.65 ± 1.47 0.31 0.97 ±0.36 
Stomach 1.00 ± 0.45 * 0.30 0.38 ± 0.21 * 
Bone 0.15 ± 0.18 3.63 0.11 ± 0.09 
Muscle  0.14 ± 0.09 2.48 0.07 ± 0.03 
Pancreas 1.11 ± 0.21 0.23 0.76 ± 0.42 
PC-3 tumor 0.26 ± 0.08 1.00 0.18 ± 0.08 
Uptake values are expressed as %ID/g, mean ± SD (n=3) and as T/NT ratios. 300 μg of 
unlabelled Aca-BN was administered as blocking agent; * = statistically significant 
different (P<0.05). 
 
Figure 6 shows the microSPECT imaging of [123I]-CABN with and without blocking 
agent in athymic mice bearing PC-3 human prostate cancer xenograft. A strong 
radioactivity signal was observed in liver and intestines in all SPECT images. The PC-3 
tumor xenografts, which are present on the shoulder of the nude mice in the CT images, 




Figure 6. MicroSPECT and microCT images of [123I]-cubyl-Aca-Bombesin(7-14) in PC-3 
tumor bearing athymic mice without (A, acquired at 10 min p.i.; B, acquired at 60 min p.i.) 
and with blocking agent (C, acquired at 10 min p.i.; D, acquired at 60 min p.i.;). Arrows are 
pointed at the tumor. 
 
6.3.6  In Vivo Stability 
Since the tumor uptake of [123I]-CABN at 1 h p.i. was low and non-specific, a 
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metabolite study was performed in PC-3 tumor bearing athymic nude mice to investigate 
the in vivo stability of the [123I]-CABN at early time point (10min). Figure 7 shows a 
typical HPLC chromatogram of the blood sample collected at 10 min post injection. The 
retention time of original [123I]-CABN was around 23 min. Two major metabolites were 
found in the blood samples with a retention time of 16 min (25.2 % of sample radioactivity) 
and 19 min (27.3 % of sample radioactivity). Unbound radioiodine which has a retention 
time around 5 min (< 2% of sample radioactivity), was not found in the blood samples.  
 
Figure 7. Radio-HPLC chromatogram of blood samples collected at 10 min post tracer 
injection in PC-3 tumor bearing athymic mice. 
 
6.4  Discussion 
Compared to radiolabelled antibodies, tumor targeting radiopharmaceuticals based on 
peptides show superb in vivo behaviour on immunogenicity, clearance, rapid penetration 
and accumulation in tumor, but underperform on metabolic stability, tumor retention (23). 
In this study, we introduced a [123I]-cubyl-TFP ester for peptide based SPECT tracer 
preparation. The carbon-iodine bond of the [123I]-cubyl-TFP ester has been proven 
metabolically stable in preclinical studies (24). Therefore we chose this labeling moiety to 
apply in radiolabelling of bombesin. The use of iodine as radionuclide has the additional 
advantages that [124I] and [131I] can be used as PET-tracer and radioimmunotherapy 
purposes, respectively. 
We successfully synthesised the [123I]-CABN under mild reaction conditions with 
good coupling yields and high radiochemical purities (>95%) achieved by HPLC 
purification. The GRPR targeting ability of [123I]-CABN was evaluated in vitro by cellular 
uptake experiments with PC-3 prostate cancer cell line. The results of in vitro competitive 
binding assay indicate that the iodocubyl group effects the binding of the bombesin to 
GRPR. Compared to Aca-BN, the binding affinity of non-radiolabelled I-CABN was about 
30 times lower. However, the in vitro cellular uptake of [123I]-CABN was comparable to 
that of 99mTc labelled Aca-BN (data not shown). Compared to other bombesin tracers 
(11-12), a higher logD value of [123I]-CABN was observed due to the hydrophobic character 
of the iodocubyl structure. Because of the lipophilicity of [123I]-CABN, the non-specific 
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adhesion of the tracer to PC-3 cells was almost half of total cellular uptake. The 
internalization and efflux patterns of [123I]-CABN were also evaluated in the PC-3 cell line. 
The internalization and efflux kinetics of [123I]-CABN were similar to those 
of 99mTc-HABN (12). A rapid internalization was observed in 5 min after incubation.. 
Despite the excellent in vivo stability of the iodine-carbon bond has been proven (24), 
the in vivo stability of the entire tracer is still an issue. The in vitro stability results of 
[123I]-CABN in human serum solution indicate that the radiotracer was sensitive towards 
degradation by serum enzymes. The results of in vivo stability experiments in blood showed 
comparable results to the in vitro stability data. The [123I]-CABN was not able to maintain 
its initial structure in athymic mouse blood at 10 min after injection. Furthermore, the 
HPLC analysis of blood samples indicated that the major radioactive metabolites (Rt=17 
and 19 min) were not in the form of [123I]- (Rt=5 min). The metabolism will likely occur at 
the amide bond between the cubyl moiety and the ε-aminocaproic acid, since 99mTc-HABN 
and [123I]-CABN share the same Aca-BN motif and 99mTc-HABN showed good in vitro 
stability in human serum solution. To prevent the hydrolysis of the amide bond by 
proteolytic enzymes in blood, introduction of the concept of click chemistry in tracer 
development would be a good choice to provide stable covalent links between the 
[123I]-cubyl moiety and biomolecules. The triazole group formed in the click reaction 
resembles an amide bond regarding physiological behaviour.   
Low radioactivity residence in blood and extremely high radioactivity accumulation in 
liver, small intestine and kidney at 1 hour after tracer injection indicate that the 
[123I]-CABN and its metabolites were cleared rapidly from blood and predominately 
through the hepatobiliary route and partly via the renal route. [123I]-CABN showed low 
accumulation in both tumor and pancreas, which are GRPR expressing tissues. In the 
blocking study, uptake of [123I]-CABN in pancreas and tumor did not show significant 
difference compared to the control group which indicates the poor specificity of the tracer 
to GRPR.  From the SPECT images of [123I]-CABN acquired in 1 hour dynamic scans it 
was concluded that the human prostate cancer xenograft was not visible mainly due to the 
poor in vivo stability and low tumor accumulation mentioned above. No radioactivity 
accumulation was detected in thyroid from SPECT imaging proving the good stability of 
iodine-carbon bond in vivo.  Although [123I]-CABN is not suitable for prostate cancer 
imaging, the [123I]-cubyl structure showed to be a stable radioiodine labeling synthon which 
can be widely applied in radiopharmaceutical development.    
 
6.5  Conclusion 
We synthesised a [123I]-labelled bombesin tracer and evaluated in vitro and in prostate 
cancer bearing nude mice. Despite the fact that [123I]-CABN showed its GRPR targeting 
ability in the prostate cancer cell line, it is not a suitable tracer for prostate cancer SPECT 
imaging due to the low in vivo stability.   
Although [123I]-CABN is unsuitable for prostate cancer imaging, the [123I]-cubyl 
structure showed to be a stable radioiodine labeling synthon which can be widely applied in 
radiopharmaceutical development.    
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Chapter 7  
Synthesis and evaluation of 18F labelled stabilized 
bombesin analogues for GRPR imaging 
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To enhance the resistance against proteolytic enzymes and to improve the gastrin 
releasing peptide receptor (GRPR) targeting ability of radiolabelled bombesin, we 
developed a series of lanthionine-stabilized full-length bombesin analogues. The best 
two candidates with the highest in vitro affinity were labelled with 18F for positron 
emission tomography (PET) imaging of GRPR-expressing prostate cancer. The binding 
affinity, lipophilicity, stability and in vivo behaviour of two 18F-labelled bombesins 
varied due to the position of intra-molecular cross-linkages and the N-terminal amino 
acid 1-6 sequence at the N terminal. Both tracers showed GRPR targeting potential in a 
PC-3 tumor bearing mouse model. The tumor uptake of 18F-4-Fluorobenzoyl-Bombesin 
C5 (18F-C5) and 18F-4-Fluorobenzoyl-Bombesin C6 (18F-C6) were 0.7 ± 0.1 and 3.5 ± 
0.9 %ID/g at 1 h post injection. For 18F-C5 and 18F-C6, PC-3 tumors were clearly 
visualized on microPET images with best contrast at 3 h post injection. 
 
Keywords: stabilized bombesin peptide, GRPR, prostate cancer, PC-3, N-succinimidyl 






























7.1  Introduction 
Bombesin is a 14-amino acid peptide binding with high affinity to the receptor pockets 
of the GRPR with its [7-14] amino acids motif at the C-terminal (1-2). The GRPR is 
over-expressed in a variety of human malignancies including primary and metastasized 
prostate cancer while being absent or sparse present in normal or hyperplastic prostate (3-7). 
Hence, radiolabelled bombesin analogues combined with high resolution PET or single 
photon emission computed tomography (SPECT), exhibit potential as a diagnostic and 
immunotherapeutic tool in prostate cancer imaging.  
Compared to truncated Bombesin(7-14), full-length bombesin has a larger size and 
shows relatively slower pharmacokinetics. However, full-length bombesin offers more 
modification and / or labeling possibilities within the first N-terminal 6 amino acids by 
substituting amino acids and / or attaching bifunctional groups. Lys3-Bombesin is one of the 
best studied full-length bombesins (8). Its third amino acid at the N-terminus is replaced by 
a lysine. Bombesin has been labelled with 99mTc, 111In, 64Cu, and 18F by coupling with 
bifunctional reagents to the amino acid side-chain of lysine (9-14). Although most of the 
radiolabelled Lys3-Bombesin analogues show high binding affinity to GRPR in vitro, the 
stability of the peptide, the tumor uptake and in vivo the kinetics of radiolabelled 
Lys3-Bombesin still needs to be improved.  
To overcome the rapid degradation of full-length bombesin analogues, internal 
thioether cross-links were introduced within either the N-terminal 6 amino acids (C5, C6 
and C7, table 1) or within the C-terminal amino acids [7-14] of the peptide (G and H, table 
1). In this study, two of the five stabilized full-length bombesin analogues were selected 
according to the binding affinity to GRPR and labelled with 18F. The properties of the two 
selected lanthionine-stabilized peptides were assessed in vitro and in vivo. The GRPR 
targeting ability and imaging potential of 18F-labelled stabilized bombesin analogues were 
investigated in mice xenografted with human prostate cancer cells.  
 
7.2  Experimental section 
7.2.1 Materials 
All chemicals were obtained from commercial suppliers Sigma-Aldrich, Fluka, and 
Merck and used without further purification. Solid phase extraction cartridges were 
obtained from Waters Chromatography Division, Millipore Corporation, USA.  
Reversed phase high-performance liquid chromatography (RP-HPLC) was performed 
on a HITACHI L-2130 HPLC system (Hitachi High Technologies America Inc., Pleasanton, 
CA, USA) equipped with a Bicron Frisk-Tech area monitor. Isolation and quality control of 
purified radiolabelled peptides were performed using a reversed phase Grace Smart RP-C18 
column (Lokeren, Belgium) (4.6 mm × 250 mm, 5 μm). The flow was set at 1 mL/min 
using a gradient system starting from 90% solvent A (0.01 M phosphate buffer, pH = 6.0) 
and 10% solvent B (acetonitrile) (5 min), followed by a gradient mobile phase going from 




7.2.2  Synthesis of stabilized Bombesin analogues 
Peptides stabilized by a methyllanthionine in the C-terminal half were produced 
stereospecifically by Lactococcus lactis containing lanthionine introducing enzymes (15-16) 
followed by pGlu formation and amidation as performed previously (17). Since the 
N-terminal half of bombesin is too hydrophilic, no success was obtained with the 
stereospecific introduction of thioether bridges in this region. Therefore, lanthionines in the 
N-terminal half were introduced by base-assisted sulfur extrusion (15). In brief: the linear 
peptides bombesin-5 and bombesin-6 with respectively the sequences: 
pEQKdCGNCWAVGHLM-NH2 and pEdCKLGCQWAVGHLM-NH2 (pE stands for 
pyroglutamate and dC stands for D-cysteine) were obtained from JPT Peptide Technologies 
(Berlin, Germany). For introduction of the lanthionine bridge, both bombesin variants were 
dissolved in water to a concentration of 2 mg/mL. Ammonia was added till an final 
concentration of 0.3 % and mixtures were incubated at 37 oC overnight. The ammonia was 
removed and the peptide was dried by using a speedvac concentrator (Thermo Fisher 
Scientific Inc., Logan, UT, USA). Reaction mixtures were purified by HPLC. The final 
products, mixtures of lanthionine-stabilized bombesin analogues, were characterized by 
mass spectrometry (Table 1). Formation of a lanthionine by desulphurization of a 
disulfide-bridged peptide causes a loss in mass of 34 Dalton. Mass spectra were recorded 
with a Voyager DE Pro Maldi-TOF mass spectrometer. 
 
7.2.3  Cell culture 
The GRPR-positive human prostate cancer cell line PC-3 (ATCC, Manassas, VA, USA) 
was cultured in RPMI 1640 (Lonza, Verviers, France) supplemented with 10% fetal calf 
serum (Thermo Fisher Scientific Inc., Logan, UT, USA) at 37 oC in a humidified 5% CO2 
atmosphere. 
 
7.2.4  In vitro competitive binding assay 
In vitro competitive binding assay was performed by replacing the binding of GRPR 
specific targeting tracer 125I-Tyr4-Bombesin to the PC-3 tumor cells with C5, 
C6, 19F-C5, 19F-C6, C7, G and H as reported previously (18).  The 50% inhibitory 
concentration (IC50) value were calculated by fitting the data with nonlinear regression 
using GraphPad Prism 5.0 (GraphPad Software, San Diego, CA, USA) and expressed as an 
average plus the standard deviation. Experiments were performed with triplicate samples. 
 
7.2.5  Synthesis of 19F-C5 and 19F-C6 
The lanthionine-stabilized bombesin peptides C5 or C6 (1 mg) was dissolved with 
0.1 mL 50% acetonitrile and added to a glass vial. Five equivalents 
of 19F-Succimidyl-fluorobenzoic acid (SFB) (1 mg/mL, in acetonitrile) were slowly 
added to C5 or C6 and well mixed. The mixture was kept at room temperature for 2 
hours and purified with HPLC. The acetonitrile in the final product was removed by 
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using Waters Sep-Pak Light C18 cartridge (55-105µm). The 19F-C5 and 19F-C6 were 
eluted with ethanol and dried.  The molecular weights of 19F-C5 and 19F-C6 were 
measured by mass spectrometry. For 19F-C5, C75H102FN21O18S2 calculated molecular 
weight 1644.85, observed 1646.1 ([M+H]+). For 19F-C6, C75H107FN20O17S2 calculated 
1643.90, observed 1645.49 ([M+H]+). 
 
7.2.6  Synthesis of 18F-SFB 
18F-SFB was prepared according the methods described previously by Wester et 
al.(19). Aqueous 18F-fluoride was produced by irradiation of 18O-water with a Scanditronix 
MC-17 cyclotron via the 18O(p,n)18F nuclear reaction. The 18F-fluoride solution was passed 
through a SepPak Light Accell plus QMA anion exchange cartridge (Waters, USA) to 
recover the 18O-enriched water.  
18F-fluoride was eluted from the QMA anion exchange cartridge with 1 mL of K2CO3 
(1 mg/mL) and collected in a vial with 5 mg Kryptofix222. To this solution, 1 mL 
acetonitrile was added and the solvents were evaporated at 130 oC. The radioactive residue, 
(18F-KF/Kryptofix complex) was carefully dried 3 times by addition and evaporation of 
anhydrous acetonitrile (0.5 mL at 130 °C). After addition of 10 mg of ethyl 
4-[trimethylammonium]benzoate in DMF (0.250 mL), the mixture was heated at 90 °C for 
12 min. Then, 1 M of HCl (0.5 mL) was added. The reaction mixture was heated at 100 °C 
for 5 min. After cooling the reaction mixture was passed through a Waters Sep-Pak Light 
C18 cartridge for solid phase extraction. After washing the cartridge with water, 
purified 18F-fluorobenzoic acid was eluted from the cartridge with 2 mL of acetonitrile into 
a vial containing 10 mg of Kryptofix222 and 5 mg of K2CO3. 
The eluate was dried under an argon stream at 130 °C. Complete drying was ensured 
by addition and evaporation of anhydrous acetonitrile (3-fold, 0.5 mL). 
Then, the solution of O-(N-succinimidyl)-1,1,3,3-tetramethyluronium tetrafluoroborate 
(TSTU, 20 mg) in anhydrous acetonitrile (0.5 mL) was added, and the mixture was heated 
at 90 °C for 5 min. The mixture was cooled down and diluted with 0.03 M of HCl. 
18F-SFB was diluted with 15 mL of water before being passed through Oasis Cartridge 
HLB (30 mg, 1 mL) for solid phase extraction. The cartridge was washed with 5 mL of 
water and eluted with ethanol (0.5mL) to obtain the final pure 18F-SFB solution. The 
purified 18F-SFB was analyzed by HPLC.  
To reduce the radiation burden to the operator, the labeling procedure has been fully 
automated using a Zymark robotic system. 
 
7.2.7  Coupling 18F-SFB with C5 or C6 
18F-C5 and 18F-C6 were synthesized by coupling 18F-SFB (300 MBq, in 0.1 mL 
acetonitrile) with stabilized peptide C5 and C6 (10 mg/mL, in 0.1 mL 50% acetonitrile) in 
0.3 mL phosphate buffer (0.1 M, pH 8.3-8.6) at 50 oC for 30 minutes. The radiolabelled 
peptides were isolated and analyzed by using HPLC. Retention time of 18F-SFB, 18F-C5 
and 18F-C6 was 20.1, 18.4 and 19.6 min, respectively. To eliminate the acetonitrile, 
purified 18F-C5 and 18F-C6 were diluted with 10 mL of water and loaded on a Waters 
Sep-Pak Light C18 cartridge. Final products were eluted with 0.4 mL ethanol and diluted 
with saline solution for cell experiments and animal experiments. 
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7.2.8  Partition Coefficient 
18F-C5 or 18F-C6 (37 kBq) was dissolved in a mixture of 0.5 mL n-octanol and 0.5 mL 
25 mM PBS (pH 7.4) and well mixed for 5 min at room temperature. Afterwards, the 
mixture was centrifuged at 3000 rpm for 5 minutes. 100 μL samples were obtained from 
n-octanol and aqueous layers and counted in a γ-counter (Compugamma CS1282, 
LKB-Wallac, Turku, Finland). The log D value is reported as an average of three different 
measurements (mean ± SD). 
 
7.2.9  In Vitro Stability 
The in vitro stability of 18F-C5 and 18F-C6 in saline solution and human serum solution 
was evaluated following the protocol as reported previously (18). In brief, 18F labelled C5 
or C6 was incubated in saline solution (at room temperature) and human serum solution (at 
37 oC), samples were collected after 1, 2, 3 or 4 h incubation. For solution stability in saline, 
samples were analyzed by HPLC. For stability in human serum solution, 250 μL of the 
sample was precipitated with 750 μL of ethanol/acetonitrile solution (Vethanol: Vacetonitrile=1: 
1), the supernatants of the mixture after centrifugation were filtered by 0.22 μm filter and 
analyzed by HPLC.  
 
7.2.10  In Vitro Cell Uptake and Internalization Kinetics 
One day prior to the assay, PC-3 cells at confluence were placed in 6-well plates (0.5 
×106 cells/well). The cells were washed with PBS and incubated with 18F-C5 or 18F-C6 
(0.04 MBq/well) at 37 °C for 0, 15, 30, 45, 60, 90, 120 and 240 minutes in triplicate to 
allow for cellular uptake. 20 μg of unlabelled bombesin was co-incubated with 
radiolabelled C5 or C6 in a blocking group. To remove unbound radioactivity, the cells 
were washed twice afterwards with ice-cold PBS. The cells were incubated with 1 mL of an 
acid glycine buffer (50 mM glycine−HCl/100 mM NaCl, pH 2.8) for 3 minutes twice and 
washed with ice-cold PBS. The glycine acid solutions and PBS solution were collected, and 
the radioactivity was measured in gamma counter as membrane receptor bound 
radioactivity. The cells were lysed by incubating with 1 M NaOH at 37 °C and the resulting 
lysate in each well was aspirated to determine the internalized radioactivity in a gamma 
counter. Total cellular uptake of 18F-C5 or 18F-C6 was calculated as the sum of the 
internalized and membrane receptor bound radioactivity and expressed as mean ± SD (n = 
3).  
 
7.2.11  Efflux Kinetics 
About 24 h before the experiments, 1 million PC-3 cells were placed in 6 well plates 
and kept in a 37 °C incubator. The cells were washed with PBS and then incubated 
with 18F-C5 or 18F-C6 (0.04 MBq/well) for 1 h at 37 °C to allow for maximal internalization. 
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To remove unbound radioactivity, the cells were washed twice afterwards with ice-cold 
PBS and were then incubated in the prewarmed culture medium at 37 °C for 0, 15, 30, 45, 
60, 90, 120, and 240 min in triplicate to allow for externalization. To remove cell-surface 
bound radiotracer, the cells were washed twice for 3 min with an acid glycine buffer (50 
mM glycine−HCl/100 mM NaCl, pH 2.8). Then, the cells were lysed by incubation with 1 
M NaOH at 37 °C, and the resulting lysate in each well was aspirated to determine the 
remaining radioactivity in a gamma counter. Results are expressed as the percentage of 
maximum intracellular radioactivity (remaining activity at specific time-point / activity at 
time-point 0) (mean±SD). 
 
7.2.12  Animal Model 
The xenograft tumor model for human prostate cancer in athymic mice was generated 
by subcutaneous injection of 1×106 PC-3 cells (suspended in 0.1 mL of sterile saline) in the 
flank of male athymic mice (Harlan, Zeist, The Netherlands). During the injection, animals 
were anesthetized with gas (3.5 % isoflurane in an air/oxygen mixture). The mice were 
used for biodistribution experiments and microPET/CT imaging when the tumor volume 
reached a mean diameter of 0.8 - 1.0 cm (3 - 4 weeks after inoculation). All animal 
experiments were performed in accordance with the regulations of Dutch law on animal 
welfare and the institutional ethics committee for animal procedures approved the protocol. 
 
7.2.13  MicroPET/CT imaging and Biodistribution 
The PC-3 prostate cancer bearing athymic mice were used for animal experiments 
when the tumor volume reached 250-300 mm3 (4-5 weeks after inoculation). 
MicroPET scans were performed by using a Focus 200 rodent scanner (CTI Siemens, 
Munich, Germany). PC-3 tumor bearing athymic nude mice were injected in the penis vein 
with ~ 8 MBq of 18F-C5 or 18F-C6 and imaged for 1h at 0, 2 and 3 h post injection. All mice 
were sacrificed before the acquisition of the 2 and 3 h images. MicroCT scans were 
performed after each microPET scans. For the receptor-blocking imaging studies, 300 µg of 
unlabelled ε-aminocaproic acid-bombesin(7-14)(Aca-BN(7-14)) was pre-injected 30 min 
before the tracer injection.  Animals of the blocking group were scanned at 2 h after tracer 
injection as described above. PET/CT image confusion was accomplished with Inveon 
Research Workplace Software (Siemens Inveon Software, Erlangen, Germany). 
Biodistribution studies of 18F-C5 and 18F-C6 were also performed in PC-3 tumor 
bearing athymic nude mice. Approximately 600 kBq of 18F-C5 or 120 kBq of 18F-C6 was 
administered by penis vein injection. The injection dose of 18F-C5 was set 5-fold as high as 
that of 18F-C5 according to the specific activity of both tracers. Animals were sacrificed at 1 
h post injection. Blood, tumor, heart, liver, spleen, lung, kidney, stomach, bone, muscle and 
intestine samples were collected, weighed and measured by using a γ-counter. The 
percentage of injected dose per gram (%ID/g) was determined for each sample. For each 
mouse, radioactivity of the tissue samples was calibrated against a known aliquot of 
radiotracer. To investigate the specificity of 18F-C5 and 18F-C6, a receptor-blocking study 
was performed with 300 µg of unlabelled Aca-BN(7-14) pre-injected 30 min before tracer 
injection. Biodistribution of the blocking group was determined as well and reported as 
mean± SD (n=4).  
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7.2.14  Statistical Analysis 
Quantitative data are expressed as mean ± SD. Means were compared using the 
Student t test. P values <0.05 were considered significant. 
 
7.3  Results 
7.3.1  Synthesis of Stabilized Bombesin Analogues, 19F-SFB 
conjugated reference compound and In Vitro Competitive Receptor Binding 
Assay 
 
The lanthionine-stabilized peptides C5, C6, C7, G and H (Table 1) were 
synthesized as described in the materials and methods and confirmed by HPLC and 
mass spectrometry (Table 1). The binding affinity of bombesin analogues to the GRPR 
was measured by replacing the binding of the well-known GRPR-specific 
ligand 125I-Tyr4-Bombesin to PC-3 prostate cancer cells. The IC50 values of stabilized 
bombesin analogues are presented in Table 2. The binding affinities of C5, C6 and C7 
to GRPR were in the nanomolar range. For G and H, which contain the internal 
crosslink in the amino acid 7-14 region half of the peptide, the IC50 values of them 
were higher than 10000 nM. Based on the binding affinity of stabilized bombesin 
analogues, C5 and C6 were selected for developing their 18F labelled PET derivatives. 
Reference compounds were synthesized by coupling bombesin C5, C6 and 19F-SFB 
under basic conditions. The final products were confirmed by mass spectrometry, the 
conversions were higher than 95%. The binding affinity of 19F-C5 and 19F-C6 was 
determined by competitive receptor binding assay as well. When coupled to 19F-SFB, 
the IC50 value of C5 and C6 increased from 248±6 and 26±1 nM to 1299±249 and 
35±14 nM, respectively (table 3). Coupling of the fluorobenzoyl group had a minor 
effect on the binding affinity for both bombesin analogues. 
Table 1. (Methyl) lanthionine–stabilized bombesin analogs. 
Variant Sequence Mono-siotopic mass Reference 





1569.9 1568.8 (110) 
H pEQKLGNQWA[AbucGHA]cM-NH2 1565.7 1564.7 (110) 
C5 pEQK[AcGNA]cWAVGHLM-NH2 1522.7 1521.7 (114) 
C6 pE[AcKLGA]cQWAVGHLM-NH2 1521.7 1520.7 (114) 
C7 pE[AcKLGNA]cWAVGHLM-NH2 1507.7 1506.7 (114) 
* pE is pyroglutamate; Abu is aminobutyric acid. 
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Table 2. IC50 values of stabilized Bombesin analogues, mean±SD (n=3). 
 Crosslink within 
N-terminal amino acids 1-6 
Crosslink in 
the C-terminal half 
Stabilized Bombesin analogues C5 C6 C7 G H 
IC50 (nM) 248±6 26±1 719 ±12 >10000 >10000 
 
Table 3. IC50 values of 19F-C5 and 19F-C6, mean±SD (n=3). 
Bombesin analogues 19F-C5 19F-C6 
IC50 (nM) 1299±249 35±14 
 
7.3.2  Radiochemistry, Partition Coefficient and In Vitro Stability 
Radiolabelled 18F-SFB was synthesized in three steps based on the procedure 
described by Wester et al.(19). The synthesis of 18F-SFB was optimized by our group. First, 
4-18F-fluorobenzoic acid was purified by using a C18 cartridge and eluted in a vial with 5 
mg of potassium carbonate and 15 mg of Kryptofix 222 and secondly dried afterwards to 
avoid the deleterious effect of moisture during conversion of 4-18F-fluorobenzoic acid into 
the corresponding activated ester. The automated system produced 18F-SFB in 90-100 min 
with a good radiochemical yield (34–38%). The radiochemical purity after SPE ranged 
from 93% to 96%, as determined by HPLC.  
 18F-C5 and 18F-C6 were synthesized by coupling 18F-SFB with C5 and C6 under 
slightly basic conditions (pH 8.3-8.6) at 50 oC for 30 min. The radiochemical yield 
of 18F-C5 and 18F-C6 was ~10 % and ~30% from 18F-SFB. Radiochemical purity of both 
tracers was high (>95 %) after HPLC purification. Since the labelled 18F-C5 and 18F-C6 
have similar retention times as their unlabelled peptide precursor, the HPLC separation of 
peptide precursor from the final product was not complete. The apparent specific activity 
of 18F-C5 and 18F-C6 was estimated to be 1437±329 and 218±135 MBq/μmol respectively, 
based on the HPLC analysis of purified product. The overall synthesis time for 18F-C5 
and 18F-C6 was approximately 160 min. 
The partition coefficient of 18F-C5 and 18F-C6 was determined in a 1: 1 mixture 
solution of n-octanol and PBS solution. Log D value of 18F-C5 and 18F-C6 was -0.5± 0.1 
and 0.8± 0.1, respectively. 
In vitro stability of 18F-C5 and 18F-C6 was evaluated in saline and human serum 
solution (Figure 1).  Results were expressed as percentage of initial 18F-labelled C5 and 
C6 at different time points. For both tracers, more than 90 % of the radioactivity remained 
in its initial form after 4 h incubation in saline. In human serum, 86% of 18F dissociated 




Figure 1. In vitro stability of 18F-C5 and 18F-C6 in saline and human serum solution. The 
radiochemical purity of 18F-C5 and 18F-C6 in the solutions was analyzed by HPLC. 
 
7.3.3  Cell Uptake, Internalization and Efflux Kinetics. 
The cellular uptake and internalization kinetics of 18F-C5 and 18F-C6 were 
evaluated in a PC-3 prostate cancer cell line at 37 oC up to 3 h.  After removing the 
unbound tracer, radioactivity which accumulated on membrane was released by 
incubating with ice cold glycine-acid solution and collected.  PC-3 cells were 
harvested and the radioactivity counted was a measure of the internalization of the 
tracer. Results are shown in Figure 2. For 18F-C6, the internalization occurred within 15 
min after start of incubation with a steady increase and reached the internalization 
plateau after 2 h incubation. The total cellular uptake of 18F-C6 followed the same 
trend as the internalization with 6.7±0.3 % of initial applied radioactivity at 2 h.  
Internalization of 18F-C5 was observed within 15 min after incubation and reached 
the highest value at 15 min. The highest cellular uptake of 18F-C5 was about 5 times 
lower than that of 18F-C6. Co-incubated with an excess of unlabelled bombesin, the 
cellular uptake ratio of both tracers dropped to < 0.1 % at all experimental time points 
(not shown in figure 2), indicating high specificity of 18F-C5 and 18F-C6.  
The efflux kinetics of 18F-C5 and 18F-C6 were also compared in the PC-3 prostate 
cancer cell line (Figure 3). Both tracers showed similar efflux characteristics. 
For 18F-C5 and 18F-C6, 36±5 % and 33±2 % of internalized radioactivity remained in 





Figure 2. Cellular uptake of 18F-C5 and 18F-C6 in the PC-3 prostate cancer cell line. 
 
Figure 3. Efflux kinetics of 18F-C5 and 18F-C6 in the PC-3 prostate cancer cell line. 
 
7.3.4  Biodistribution Experiments. 
Biodistribution of 18F-C5 and 18F-C6 at 1 h post injection was determined in PC-3 
prostate tumor-bearing athymic nude mice and specificity of both tracers was also 
evaluated by co-injecting excess of unlabelled bombesin peptide. Uptake of 18F-C5 
and 18F-C6 in relevant organs is shown in Figure 4.  The tumor uptake of 18F-C5 
and 18F-C6 at 1 h was 0.7 ± 0.1 and 3.5±0.9 %ID/g, respectively.  Low recovery of 
radiolabelled peptide from the blood might indicate rapid clearance of 18F-C5 
and 18F-C6.  
In a blocking study, where the radiolabelled analogs were co-injected with excess 
of unlabelled bombesin, tumor uptake of 18F-C6 decreased from 3.5±0.9 %ID/g to 2.1 
±0.6 %ID/g. For 18F-C5, the tumor uptake was slightly reduced from 0.7± 0.1 %ID/g to 
0.6± 0.1 %ID/g by excess of blocking agent. No effect of blocking agent was found in 
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the presence of 18F-C5 and 18F-C6 in non-GRPR expressing organs, such as kidney, 
liver and heart.  
 
Figure 4. Biodistribution of 18F-C5 and 18F-C6 in PC-3 prostate tumor-bearing athymic 
nude mice at 1 h post injection. “*” = Significant difference. 
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7.3.5  MicroPET/CT imaging. 
 
The microPET and CT coronal images of 18F-C5 and 18F-C6 in prostate tumor 
bearing athymic nude mice are shown in Figure 5 and Figure 6.  High abdominal 
background was observed for both tracers in the 3 h experimental period. PC-3 tumor 
xenografts were visible from PET images of both tracers. With excess blocking agent, 
the radioactivity signal in PC-3 tumors was reduced compared to the images of the 
animals in the control group. The injection dose corrected region of interesting (ROI) 
values of PC-3 tumor from micro-PET images are shown in figure 7. For both tracers, 
the ROI values of PC-3 tumor rapidly decreased during 3 hours experimental period, 
and slightly reduction was observed when co-injected with excess of blocking agent, 
which is correlated to the results of blocking study.  
 
7.4  Discussion 
Despite rapid development of radiolabelled bombesin analogues for prostate cancer 
diagnosis and therapy in the last decade (18), the clinical transfer of bombesin 
radiopharmaceuticals is still limited due to unfavorable in vivo kinetics of bombesin tracers. 
The lack of stability of radiolabelled bombesins is seriously hampering successful 
clinical application. A variety of bifunctional chelators and linkers has been reported to 
improve the in vivo stability (20-24). By applying the substitution of amino acids in 
positions 6 and 13 with the non-nature amino acids D-Phe and Leu-NHEt, a series of 
Bombesin like peptides were developed for SPECT imaging by Nock et al. (25-26). In this 
study, the stabilized bombesin analogues C5, C6 and C7 were generated by chemically 
introducing a thioether linkage by the desulphurization method described by Galande et al. 
(27). The stabilized bombesin analogues H and G were produced biologically by a modified 
L. lactis strain which procedure has been described by Kluskens et al. (15). For the 
bombesin analogues H and G, it was determined that the binding affinity was dramatically 
decreased by the modification of the binding motif. For analogues C5, C6 and C7, binding 
affinity to GRPR varied due to the different positions of the thioether cross-links and 
concomitant structural difference in the N-terminal [1-6] half of bombesin.  With the 
acceptable remaining binding affinity for the GRPR receptor, C5 and C6 were selected 
for 18F labeling through the side chain of lysine and we subsequently compared these 
analogs in vitro and in vivo. Compared to 18F-C5, the cellular uptake of 18F-C6 was 3 times 
higher which was caused by a higher binding affinity for GRPR. As agonists, both 
tracers 18F-C5 and 18F-C6 were mostly internalized into PC-3 cells via GRPR in the 
internalization experiments.  
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 Figure 5. MicroPET/CT scan of 18F-C5 and 18F-C6  in PC-3 prostate tumor-bearing 
athymic nude mice at 10 min, 60 min , 2 h and 3 h post injection. Arrows point at PC-3 
tumors. 
 
Figure6.  MicroPET/CT scan of 18F-C5 and 18F-C6 in PC-3 prostate tumor-bearing 
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athymic nude mice at 10 min , 60 min  post injection with or without  blocking agent. A, 
C, E and G are same images correspond to Figure 5A, 5B, 5E and 5F, respectively. Arrows 
point at PC-3 tumors. 
 
Figure 7. Injection dose corrected region of interesting values of PC-3 tumor from 
micro-PET images of 18F-C5 and 18F-C6 (mean± SD).   
 
18F labeling becomes increasingly attractive for tracer development.  Furthermore, 
the application of PET is growing. Due to the optimal radionuclear characteristics of 18F 
and the physical half-life of 110 min which fit the in vivo biological half-life of 
peptides, 18F was selected for PET tracer development in this study. Lys3-Bombesin, 
truncated bombesin and Arginine-Glycine-Aspartic acid-Bombesin(RGD-BN) heterodimers 
were coupled with 18F-SFB, and proved to be potential probes for GRPR-expressing cancer 
targeting by Chen et al. (14, 28-30).  The in vitro binding assay of 19F-C5 and 19F-C6, 
demonstrated that the conjugation of SFB motif has negative effect on the binding affinity 
of bombesin as reported (14). The reduction of binding affinity to GRPR was more serious 
for C5 than C6 which may be due to the distance between the lysine and bombesin(7-14) 
sequence which was smaller for C5 than that of C6.  
A similar effect of the distance between SFB and the bombesin motif on the labeling 
yield has been reported by the group of Chen (30).  
Although better stability may lead to longer blood circulation for 18F-C5, 3-fold lower 
tumor uptake was observed compared to 18F-C6. This likely is the result of the lower 
binding affinity to the GRPR which reduces the tumor uptake. 
In blocking studies, no significant reduction was observed in biodistribution of both 
tracers in most organs at 1 h post injection.  The absence of specificity of both tracers is 
presumably due to the relatively low specific radioactivity (1437±329 MBq/μmol 
for 18F-C5 and 218±135 MBq/μmol for 18F-C6), compared to other 18F-bombesin analogues 
(which varied from 62 to 250 GBq/μmol)(14, 28, 30). The low specific radioactivity 
furthermore leads to reduced uptake of radioactivity in the tumor. The self-inhibition of 
receptor-specific uptake in PC-3 tumor in the control group was also observed in in vivo 
studies of 18F-FB-Aca-BBN(7–14) (14). 
Due to the low tumor-to-nontumor ratios of both tracers 18F-C5 and 18F-C6 at 1 h post 
injection, PC-3 tumor could not be detected with PET. A clear tumor-to-background 
contrast was observed for 18F-C5 and 18F-C6 in PC-3 tumor at 2 and 3 h post injection. This 
is mainly due to the faster wash out of the tracer from the normal organs than from the 
tumor. In the PET images of tumor-bearing mice with18F-C6, a strong signal was shown in 
kidney and liver. This indicated that it was subject to both hepatobiliary and renal clearance 
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routes. For 18F-C5, due to the hydrophilicity of the tracer, high kidney uptake was found in 
PET images during the 3 h experimental period. 
 
7.5  Conclusion 
To overcome stability issues of radiolabelled peptides for receptor-mediated cancer 
imaging, we synthesized a series of lanthionine-stabilized full-length bombesin-like 
peptides and two promising candidates were successfully labelled with 18F. Both tracers 
showed GRPR targeting moderate potential in vitro and in a vivo mouse model.  
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Introduction: Multimerization of peptides can improve the binding characteristics of 
the tracer by increasing local ligand concentration and decreasing dissociation kinetics. In 
this study, a new bombesin homodimer was developed based on a ε-aminocaproic acid- 
bombesin(7-14) (Aca-bombesin(7-14)) fragment which has been studied for targeting the 
gastrin-releasing-peptide-receptor (GRPR) in prostate cancer.  
Methods: The bombesin homodimer was conjugated to 
6-Hydrazinopyridine-3-carboxylic acid (HYNIC) and labelled with 99mTc for SPECT 
imaging. The in vitro binding affinity to GRPR, cell uptake, internalization and efflux 
kinetics of the radiolabelled bombesin dimer were investigated in the GRPR-expressing 
human prostate cancer cell line PC-3. Biodistribution and the GRPR targeting potential 
were evaluated in PC-3 tumor-bearing athymic nude mice.  
Results: When compared to the bombesin monomer, the binding affinity of the 
bombesin dimer is about 10 times lower. However the 99mTc labelled bombesin dimer 
showed a three times higher cellular uptake at 4 hours after incubation, but similar 
internalization and efflux characters in vitro. Tumor uptake and in vivo pharmacokinetics in 
PC-3 tumor bearing mice were comparable. The tumor was visible on the dynamic images 
in the first hour and could be clearly distinguished from non-targeted tissues on the static 
images after 4 hours.  
Conclusion:  The GRPR targeting ability of the 99mTc labelled bombesin dimer was 
proven in vitro and in vivo. This bombesin homodimer provides a good starting point for 
further studies on enhancing the tumor targeting activity of bombesin multimers. 
  
Keywords: GRPR, bombesin homodimer, radiolabelled, imaging, prostate cancer, 





















8.1  Introduction 
Prostate cancer is one of the most common cancers in men in the USA and in Europe 
(1-2). In the course of the disease bone metastases will develop in the majority of cases 
with advanced prostate cancer. This number will reach 90% in patients with castrate 
resistant prostate cancer treated with chemotherapy (3).  
At present there is an unmet need to measure response to treatment of prostate cancer 
metastases in the skeleton. With a specific radiotracer and specific target in the tumor, 
positron emission tomography (PET) and single photon emission computed tomography 
(SPECT) would be powerful diagnostic tools in detection of prostate cancer.  
The Gastrin-Releasing-Peptide Receptor (GRPR) is a subtype of the bombesin 
receptor family. Mammalian GRPR is preferentially expressed in non-neuroendocrine 
tissues of the breast and pancreas and in neuroendocrine cells of the brain, gastrointestinal 
tract, and lung (4-8). It has also been shown that GRPR is overexpressed in a large variety 
of human tumors, including prostate, breast, renal and (non) small cell lung cancer. Due to 
the enhanced expression of GRPR in prostate cancer, GRPR is considered as a potential 
target for the diagnosis, staging or treatment of prostate cancer.   
Bombesin is a 14 amino acid peptide which was first isolated from the skin of frogs in 
the 1970 (9). Bombesin and its mammalian counterpart share 7 identical amino acid 
residues at the C-terminal, which was identified as the binding domain of the bombesin 
receptor (10).  
Radiolabelled bombesin analogs have proven their GRPR binding ability in several 
cancer cell lines and in various tumor models (11-14). Previously, an ε-aminocaproic acid 
(Aca) modified bombesin analogue was labelled with 18F and the compound was evaluated 
in a prostate cancer animal model (11). Although 18F-FB-Aca-Bombesin(7–14) showed its 
ability to target GRPR in an animal  model, due to the lipophilic character of the tracer 
detection of the orthotopic prostate cancer was hampered by high abdominal background 
levels.  
Recently, we developed HYNIC conjugated Aca-BN(7–14) and labelled it with 99mTc 
for SPECT imaging of prostate cancer in an animal model (15). Compared 
to 18F-FB-Aca-Bombesin(7–14), 99mTc-HYNIC(Tricine/TPPTS)-Aca-BN(7–14) 
(99mTc-HABN) showed reduced abdominal background  and improved 
tumor-to-normal-tissue (T/NT) contrast (tumor-to-muscle ratio from lower than 5 increased 
to 13.9 ± 5.9 at 1 hour post injection) on SPECT images .   
While most bombesin-like peptides are monomers, we applied the dimerization 
technology and synthesized a new dimeric bombesin with 2 identical Aca-Bombesin(7–14) 
units. Multivalent interactions are frequently found in nature where they increase the 
affinity of weak ligand–receptor interactions such as in the DNA-DNA duplex formation by 
multiple weak interactions between individual complementary nucleotides, or the typical 
Y-shaped antibody composed of two heavy chains and two light chains which are joined by 
disulfide linkages (16-19). Multivalent structures have become a strategy for the 
development of drugs and diagnostic agents. It has been shown by several research groups 
that multivalent compounds are able to enhance the interaction between the ligand and 
corresponding receptor (20-25). One of the most prominent examples are multivalent 
Arginine-Glycine-Aspartic acid (RGD) analogues. Several isotopes (99mTc, 111In, 18F, 68Ga, 
etc) and chelators (HYNIC, DOTA, DTPA, etc) have been applied for the preparation of 
dimeric and tetrameric RGD tracers (21-25). The binding affinity is significantly increased 
at higher orders of binding valency, a principle usually referred to as avidity. The aim of 
this study is to investigate the GRPR targeting characteristics of the bombesin 
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homodimer as a potential imaging agent for prostate cancer. 
 
8.2  Materials and Methods 
8.2.1 Chemicals:  
Tricine (N-(Tri(hydroxymethyl)methyl)glycine) was purchased from Sigma/Aldrich 
(St. Louis, Missouri, USA). Trisodium triphenylphosphine-3,3',3'' -trisulfonate (TPPTS) 
was purchased from Alfa Aesar (Karlsruhe, Germany). Both were used without further 
purification. The peptide Glu[Aca-BN(7-14)]2 was provided by Peptides International 
(Louisville, KY, USA). Na99mTcO4 was eluted from the 99Mo/99mTc generator MTcG-4 (IAE 
Radioisotope Centre POLATOM, Świerk, Poland). 125I-Tyr4-BN was obtained from 
Perkin-Elmer Life and Analytical Sciences (Waltham, Massachusetts, USA). 
 
8.2.2  Equipment:   
Semi-preparative reversed-phase high-performance liquid chromatography (RP-HPLC) 
was performed on a HITACHI L-2130 HPLC system (Hitachi High Technologies America 
Inc., Pleasanton, California, USA) equipped with a Bicron Frisk-Tech area monitor. 
Isolation and quality control of 99mTc-HYNIC(Tricine/TPPTS)-Glu[Aca-BN(7-14)]2 
(99mTc-HABN2) were performed using a Phenomenex reversed-phase Luna C18 column (10 
mm × 250 mm, 5 μm) (Torrance, California, USA). The flow was set at 2.5 mL/min using a 
gradient system starting from 90% solvent A (0.01 M phosphate buffer, pH=6.0) and 10% 
solvent B (acetonitrile) (5 minutes) and ramped to 45% solvent A and 55% solvent B at 35 
minutes (HPLC Method 1).  
HPLC Method 2 used a LabAlliance semi-preparative HPLC system equipped with a 
UV-Vis detector (λ = 254 nm) and Zorbax C18 semi-prep column (9.4 mm x 250 mm, 100 
Å pore size).  The flow rate was 2.5 mL/min.  The mobile phase was isocratic with 60% 
solvent A (0.1% acetic acid in water) and 40% solvent B (0.1% acetic acid in acetonitrile) at 
0 – 5 min, followed by a gradient mobile phase going from 60% solvent A and 40% solvent 
B at 5 min to 20% solvent A and 80% solvent B at 30 min.   
HPLC Method 3 used a LabAlliance semi-preparative HPLC system equipped with a 
UV-Vis detector (λ = 254 nm) and Zorbax C18 semi-preparative column (9.4 mm x 250 
mm, 100 Å pore size).  The flow rate was 2.5 mL/min.  The gradient mobile phase goes 
from 90% solvent A (0.1% acetic acid in water) and 10% solvent B (0.1% acetic acid in 
acetonitrile) at 0 min to 75% solvent A at 5 min, followed by a gradient mobile phase going 
from 75% solvent A to 65% solvent A  at 40 min.   
 
8.2.3 Synthesis of HYNIC-Glu[Aca-BN(7-14)]2 
Sodium succinimidyl 6-(2-(2-sulfonatobenzaldehyde)hydrazono)nicotinate (HYNIC 
-NHS) was prepared according to literature method (26).   
HYNIC-NHS (21.8 mg, 50 μmol) and Glu[Aca-BN(7-14)]2 (5.8 mg, 2.6 μmol) were 
dissolved in 1.5 mL of DMF.  The pH was adjusted to 8.5 – 9.0 with DIPEA.  The 
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mixture was stirred for 7 days at room temperature to make sure that the reaction was 
complete as indicated by the disappearance of the peptide peak. The product was purified 
by HPLC (Method 1).  The peak of interest at ~28 min was collected.  The collected 
fractions were combined, and lyophilized to obtain 1.7 mg product, which was re-purified 
by HPLC (Method 2).  Fraction at ~32.5 min was collected.  Lyophilization of the 
collected fractions gave the final product 0.8 mg (13%) with the purity > 95% by HPLC. 
ESI-MS: C114H161N33O27S3, calculated 2521.9, observed 2522 ([M+H]+).  
 
8.2.4  Radiochemistry 
100 μL of the HYNIC-Glu[Aca-BN(7-14)]2 solution (1 mg/mL in H2O), 100 μL of 
tricine solution (50 mg/mL in 25 mM succinate buffer, pH 5.0), 100 μL of TPPTS solution 
(50 mg/mL in 25 mM succinate buffer, pH 5.0), 5 μL of SnCl2 solution (3.0 mg/mL in 0.1 
N HCl) and 100 μL of Na99mTcO4 (370 MBq) in saline were added to a 1.5 mL Eppendorf 
cup. The Eppendorf cup containing the reaction mixture was sealed and heated at 95 °C for 
20 min. After cooling to room temperature, the mixture was purified by HPLC (Method 1). 
The product was then passed through a Waters Sep-Pak C18 light cartridge. 99mTc-HABN2 
was eluted with ethanol (0.4 mL) and diluted with saline solution for in vitro and in vivo 
experiments. A sample of the resulting solution was analyzed by the same HPLC system 
(method 1). 
 
8.2.5  Partition Coefficient 
The partition coefficient was determined using the method described previously(15). 
The tracer was dissolved in a mixture of 0.5 mL n-octanol and 0.5 mL 25 mM phosphate 
buffer (pH 7.4) and well mixed for 5 min at room temperature. Then the mixture 
was centrifuged at 3000 rpm for 5 minutes. 100 μL samples were obtained from n-octanol 
and aqueous layers. All samples were counted in a γ-counter (Compugamma CS1282, 
LKB-Wallac, Turku, Finland). The log D value is reported as an average of three different 
measurements. 
 
8.2.6  In Vitro Stability 
The tracer was dissolved in 1 mL saline or L-Cysteine solution (1 mg/mL), incubated 
at room temperature and analyzed by HPLC (Method 1) at 1, 2, 4, 6, and 24 hours post 
incubation. 
Human serum from healthy donors was incubated at 37 °C with 99mTc-HABN2 for 
different time periods (1, 2, 4, 6, 24 h). After incubation, a sample of 250 μL was 
precipitated with 750 μL acetonitrile/ethanol (Vacetonitrile/Vethanol =1:1) and then centrifuged 
(3 minutes at 3000 rpm), the supernatants were passed through a Millex-LG filter 
(Millipore, Co. Cork, Carrigtwohill, Ireland) and afterwards analyzed by HPLC (Method 1). 
Results were plotted as radiochemical purity (RCP) at different time-points.   
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8.2.7  Cell Culture 
The GRPR-positive human prostate cancer cell line PC-3 (ATCC, Manassas, Virginia, 
USA) was cultured in RPMI 1640 (Lonza, Verviers, France) supplemented with 10% fetal 
calf serum (Thermo Fisher Scientific Inc., Logan, Utah, USA) at 37 °C in a humidified 5% 
CO2 atmosphere.  
 
8.2.8  In Vitro Competitive Receptor Binding Assay 
The in vitro GRPR binding affinities of Glu[Aca-BN(7-14)]2 and HYNIC-Glu[Aca 
-BN(7-14)]2 were assessed via a competitive displacement assay with 125I-Tyr4-BN(1-14) as 
the GRPR specific radioligand. Experiments were performed with PC-3 human prostate 
cancer cells according to a method previously described (15). The 50% inhibitory 
concentration (IC50) values were calculated by fitting the data with nonlinear regression 
using GraphPad Prism 5.0 (GraphPad Software, San Diego, California, USA). Experiments 
were performed with triplicate samples. IC50 values are reported as an average of these 
samples plus the standard deviation (SD). 
 
8.2.9  Cellular uptake studies 
One day prior to the assay, PC-3 cells at confluence were placed in 6-well plates (0.5 
million cells/well). The cells were washed twice with PBS solution before using for the 
experiments. 99mTc-HABN or 99mTc-HABN2 (0.0037 MBq/well) was incubated with cells at 
37 °C for 0, 15, 30, 45, 60, 90, 120 or 240 minutes in triplicate to allow for cellular uptake. 
20 μg of unlabelled Glu[Aca-BN(7-14)]2 was co-incubated with 99mTc-HABN 
or 99mTc-HABN2 in blocking groups. To remove unbound radioactivity, the cells were 
washed twice with ice-cold PBS and the cells were lysed by incubation with 1 M NaOH at 
37 °C. The resulting lysate in each well was aspirated to determine the uptake of activity 
with a γ-counter. Results are expressed as percentage of incubated radioactivity 
(mean±SD). 
 
8.2.10  Internalization and efflux Studies 
For the internalization study, 1 million PC-3 cells were placed in 6-well plates before 
the experiments and kept at 37 °C overnight. The cells were washed with PBS and then 
incubated with 99mTc-HABN2 (0.0037 MBq/well) for 2 hours at 4 °C. To remove unbound 
radioactivity, the cells were washed twice with ice-cold PBS and incubated with the 
pre-warmed culture medium at 37 °C for 0, 5, 15, 30, 45, 60, 90 and 120 minutes in 
triplicate to allow for internalization.  
To remove cell-surface bound radiotracer, the cells were washed twice for 3 minutes 
with acid (50 mM glycine−HCl/100 mM NaCl, pH 2.8). The acid solution was collected 
and measured with a γ-counter. The results were collected as the surface-bound activity. 
Subsequently, the cells were lysed by incubation with 1 M NaOH at 37 °C and the resulting 
lysate in each well was measured to determine the internalized radioactivity with γ-counter. 
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Results are expressed as the percentage of total radioactivity (internalized activity / 
(surface-bound activity + internalized activity)), (mean±SD). 
For the efflux study, 1 million PC-3 cells were placed in 6-well plates 1 day before the 
experiments and kept at 37 °C. The cells were washed with PBS and then incubated 
with 99mTc-HABN2 (3.7 KBq/well) for 1 hour at 37 °C to allow for maximum 
internalization. To remove unbound radioactivity, the cells were washed twice afterwards 
with ice-cold PBS and were then incubated in the pre-warmed culture medium at 37 °C for 
0, 15, 30, 45, 60, 90, 120, and 240 minutes in triplicate to allow for externalization. To 
remove cell-surface bound radiotracer, the cells were washed twice for 3 minutes with acid 
(50 mM glycine−HCl/100 mM NaCl, pH 2.8). Then, the cells were lysed by incubation 
with 1 N NaOH at 37 °C, and the resulting lysate in each well was aspirated to determine 
the remaining radioactivity in a γ-counter. Results are expressed as the percentage of 
maximum intracellular radioactivity (remaining activity at specific time-point / activity at 
time-point 0) (mean±SD). 
 
8.2.11  Animal Model 
In the PC-3 tumor model, 2 × 106 PC-3 cells (suspended in 0.1 mL sterile saline) were 
subcutaneous injected into the left front flank of male athymic mice (Harlan, Zeist, The 
Netherlands). During the injection, animals were anesthetized with a gas composed of ~3.5% 
isoflurane in an air/oxygen mixture. The mice were used for biodistribution experiments 
and microSPECT and CT imaging when the tumor volume reached a mean diameter of 
0.8-1.0 cm (typically 3-4 weeks after tumor inoculation).  
All animal experiments were performed in accordance with the regulations of Dutch 
law on animal welfare and the institutional ethics committee for animal procedures 
approved the protocol. 
 
8.2.12  MicroSPECT imaging and Biodistribution 
The subcutaneous tumor bearing mice were separated into 4 groups (4 animals per 
group) and used for imaging and biodistribution when the tumor volume reached 250-300 
mm3 (4-5 weeks after inoculation). 
MicroSPECT scans were performed on a three-head γ-camera (MILabs, U-SPECT-II, 
Utrecht, The Netherlands) equipped with a multi-pinhole high-resolution collimator. For the 
microSPECT scans ~30MBq 99mTc-HABN2 were administered by penis vein injection 
under isoflurane anesthesia. 60 min of dynamic microSPECT data was acquired 
immediately after injection. Mice (group 1) that were used for dynamic scanning were 
sacrificed directly after the scan with an overdose of isoflurane anesthesia. CT scan and 
biodistribution were performed afterwards. Blood, tumor, major organs and tissue samples 
were collected, weighted and counted by γ-counter. The percentage of injected dose per 
gram (%ID/g) was determined for each sample. For each mouse, radioactivity of the tissue 
samples was calibrated against a known aliquot of radiotracer. 
For static imaging, mice were sacrificed at 4 (group 2) and 24 h (group 3) after 
injection. Afterwards, 60-min microSPECT and microCT images were acquired. 
Biodistribution was performed as described above. 
For the receptor-blocking experiment 300 µg of unlabelled Aca-BN(7-14) was 
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pre-injected 30 min before the tracer injection.  The animals of the blocking group (group 
4) were sacrificed and 60-min static microSPECT & CT images were acquired at 4 hours 
after tracer injection. Biodistribution was performed after the CT scan. 
Images were reconstructed by using U-SPECT-Rec v 1.34i3 (MILabs, Utrecht, the 
Netherlands) with a pixel-based ordered-subsets expectation maximum (POSEM) algorithm. 
Final images were 1 mm slices, made with Amide 0.9.1 (open source software). 
 
8.2.13  Statistical Analysis 
Quantitative data are expressed as mean ± SD. Means were compared using the 
Student t test. P values <0.05 were considered as significant. 
 
8.3  Results 
8.3.1  Synthesis, Radiolabelling, Partition Coefficient and In Vitro Stability 
99mTc-HABN2 (figure 1) was prepared at 95 °C with moderate labeling yield (>80%). 
After purification the radiochemical purity was higher than 95%. The specific activity was 
~17.4 ± 9.7 GBq/µmol (n=7). 99mTc-HABN2 was well separated from precursor using 
HPLC system. The retention time (HPLC Method 1) of 99mTc-HABN2 and 
HYNIC-Glu[Aca-BN(7-14)]2 was around 28 and 24 min, respectively. 
 
Figure 1 99mTc-HYNIC(Tricine/TPPTS)-Glu[Aca-BN(7-14)]2 
   
The partition coefficient was determined in a mixture of n-octanol and phosphate 
buffer (pH=7.4). The log D value of 99mTc-HABN2 was -1.54 ± 0.16. The in vitro stability 
of 99mTc-HABN2 was evaluated in saline, human serum and in the presence of excess 
L-Cysteine (1.0 mg/mL, pH 7.4) (figure 2). 99mTc-HABN2 was stable in the presence of 
excess L-Cysteine and human serum for at least 4 hours (RCP> 95 %). The RCP 
of 99mTc-HABN2 in serum slowly decreased to ~84% after 24 hours. 
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Figure 2 In vitro stability of 99mTc-HABN2 in saline (at room temperature), human serum 
(at 37 oC ) and L-Cysteine (at room temperature). Results are plotted as the radiochemical 
purity at different time points 
 
8.3.2  In vitro Competitive Receptor Binding Assay 
Using 125I-Tyr4-BN(1-14) as GRPR specific radioligand, the binding affinities of 
Glu[Aca-BN(7-14)]2 and HYNIC-Glu[Aca-BN(7-14)]2 for GRPR were compared via an in 
vitro competitive binding assay. Results are plotted as sigmoid curves for the displacement 
of 125I-Tyr4-BN(1-14) as a function of increasing concentrations of Glu[Aca-BN(7-14)]2, 
and HYNIC-Glu[Aca-BN(7-14)]2 (figure 3). The IC50 values were found to be 31.4 ± 0.4 
nM and 63.4 ± 11.7 nM for Glu[Aca-BN(7-14)]2 and HYNIC-Glu[Aca-BN(7-14)]2, 
respectively. 
 
Figure 3 Inhibition of 125I-[Tyr4]-BN(1-14) binding to GRPR on PC-3 cells by 
Glu[Aca-BN(7-14)]2 and HYNIC-Glu[Aca-BN(7-14)]2. Log [M] = log of increasing 
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concentration (mol/L) of Glu[Aca-BN(7-14)]2 and HYNIC-Glu[Aca-BN(7-14)]2  
8.3.3  Cellular uptake studies 
The in vitro uptake of 99mTc labelled bombesin monomer and dimer in PC-3 cells are 
shown in Figure 4. Compared to 99mTc-HABN, 99mTc-HABN2 has slower cellular uptake 
within 30 min of incubation, but keeps accumulating in PC-3 cells over the 4 hours 
experiment period. The highest cellular uptake for 99mTc-HABN and 99mTc-HABN2 is 10.9 
± 0.7 % (1 hour post incubation) and 32.5 ± 1.8 % (4 hours post incubation) of added 
radioactivity, respectively. Co-incubation with excess unlabelled bombesin significantly 
reduced the cellular uptake of both tracers (<1% of added activity was belonging to 
non-specific uptake).  
 
Figure 4 Cellular uptake assay of 99mTc-HABN and 99mTc-HABN2 in PC-3 cells. The 
cellular uptake results were expressed as percentage added dose (n=3, mean ± SD) 
 
8.3.4  Internalization and Efflux Studies 
The internalization study depicted in figure 5 A showed rapid internalization 
of 99mTc-HABN2 into PC-3 cells within 5 minutes incubation. The portion of intracellular 
activity reached a plateau at 15 min post incubation and 80% of cell bound activity 
internalized into the cells.  
The results of the efflux study is shown in figure 5 B. For 99mTc-HABN2, steady efflux 
was observed within 2 hours incubation. About 60% of the intracellular radioactivity was 
maintained in the cells at the end of the 4 hours experiment period. The efflux half life 
of 99mTc-HABN2 was 84 min. 
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Figure 5. Internalization (A) and efflux (B) kinetics of 99mTc-HABN2 in PC-3 cell line (n=3, 
mean ± SD) 
 
8.3.5  Biodistribution Experiments 
Biodistribution of 99mTc-HABN2 was evaluated in athymic nude mice bearing 
subcutaneous PC-3 tumors after performing the microSPECT and CT scans. The results are 
shown in Figure 6. Tumor uptake of 99mTc-HABN2 was 1.58 ± 0.18 %ID/g at 60 min after 
injection, with a steady decrease to 0.47 ± 0.13 %ID/g at 24 h after injection. The highest 
radioactivity uptake (15.1±6.4 %ID/g) in kidney was observed at 4 h post injection. The 
tracer has low blood uptake and was cleared from blood rapidly. The uptake 
of 99mTc-HABN2 in non-targeting organs (except kidney and pancreas) such as liver, bone, 
intestines was lower than 3 %ID/g and washed out rapidly. Due to the slower washout from 
tumor compared to normal-tissue, the T/NT ratio increased during the 24 h experiment 
period.The tumor-to-muscle ratio increased from 3.7 ± 1.1 at 1h after injection to 24.1 ± 
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21.5 at 24 h after injection.  
For determining the specificity of 99mTc-HABN2 binding to GRPR, an excess of 
unlabelled Aca-BN(7-14) (300 µg/mouse) was injected before the tracer injection. At 4 
hours post injection, the radioactivity accumulation was substantially reduced in tumour 
(from 0.8 ± 0.3 %ID/g to 0.4 ± 0.1 %ID/g) and pancreas (from 9.6 ± 7.6 %ID/g to 3.1 ± 
0.2 %ID/g).  
8.3.6  MicroSPECT Imaging 
Typical microSPECT images of PC-3 tumor bearing mice at different time points after 
tracer injection are shown in figure 7. The tumors were clearly visible from static 
miroSPECT images acquired at 4 hours after injection of 99mTc-HABN2 (B). Prominent 
uptake of 99mTc-HABN2 was also observed in the kidneys and pancreas at all images during 
the 4 h experiment period (A, B). With excess blocking agent (Aca-BN(7-14), 300 
µg/mouse), significant reduction of tumor uptake was observed from the images of the 
blocking group(C), but kidney and bladder (urine) uptake remained high.  
 
Figure 7. Dynamic coronal microSPECT images of 99mTc-HABN2 on PC-3 tumor bearing 
athymic mice during first hour after injection without blocking agent (A) (10 min/frame). 
Static coronal, sagittal and axial images of 99mTc-HABN2 on PC-3 tumor bearing mice 
without (B) and with blocking agent (C) at 4 h after injection. Arrows pointed at the tumor. 
 
8.4  Discussion 
Dimerization was applied to evaluate a new dimeric bombesin with 2 identical 
Aca-Bombesin(7–14) units for its GRPR targeting characteristics as a potential imaging 
agent for prostate cancer. A side by side comparison of the in vitro and in vivo behavior of 
monomer and dimer is listed in table 1.  
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In a comparative binding assay, bombesin dimer replaced 50% binding 
of 125I-tyr4-BN(1-14) from the GRP receptors in relatively higher nanomolar concentration 
(31.4 ± 0.4 nM) than the corresponding monomer (15). HYNIC conjugation showed similar 
slightly negative effect on binding affinity of HYNIC-Glu[Aca-BN(7-14)]2. The additional 
Aca-BN(7-14) motif and the linker may not be sufficiently flexible to fit in the binding 
pocket of the GRP receptor as compared to the monomer. The linker may be too short 
thereby causing steric hindrance upon binding of the molecule to the receptor. However the 
IC50 of HYNIC-Glu[Aca-BN(7-14)]2 is still in an acceptable range. Thus, we decided to 
label bombesin homodimer with 99mTc for in vitro and in vivo characterizations. 
Although development of PET facilities and radiotracers for PET imaging is blooming 
nowadays, developing new tracers for SPECT imaging is still important because of the 
availability of SPECT in most areas all over the world. Due to the favorable radioisotope 
characters and widespread clinical use, we chose to use the γ-emitting isotope 99mTc. As we 
reported in previous study (15), the HYNIC/tricine/TPPTS complex was used to serve as 
chelator for our new tracer because of its high labeling efficiency (rapid and high yield 
radiolabelling), high solution stability and relatively easy use (12, 15, 28). It was also 
chosen because of its hydrophilic character leading to the preferred excretion route via the 
renal-urinary system. Although urinary activity can limit the clinical use in the pelvic and 
retroperitoneal areas, this limitation will not be relevant for evaluation of metastases in the 
skeleton. 
 
Table 1 Comparison of the in vitro and in vivo behavior of bombesin monomer (15) and 
dimer. 
 99mTc-HABN 99mTc-HABN2 
IC50 (nM) a 12.81±1.34 63.40 ± 11.70 
In vitro stability (in human serum) Stable in 6 h Stable in 6 h 
Log D value _-1.60 ±0.06 -1.54 ± 0.16 
Highest  cellular uptake (% of 
incubation dose) 
10.9 ± 0.7 b 32.5 ± 1.8 c 
Half-life of efflux (Min) 37 84 
Tumor uptake (%ID/g) 1.51±0.38 1.58 ± 0.18 
Kidney uptake (%ID/g) 6.39±0.83 10.07±1.76 
Pancreas uptake (%ID/g) 8.92±1.74 11.26±4.11 
Tumor-to-muscle ratio 13.92 3.70 
Uptake values (in %ID/g) and T/NT ratios are determined in several organs and PC-3 
tumour at 1h p.i. unless stated otherwise; a=IC50 determined with HYNIC conjugations 
(HYNIC-Aca-BN(7-14) or HYNIC-Glu[Aca-BN(7-14)]2); b= cellular uptake value 
determined at 1 h post incubation; c= cellular uptake value determined at 4 h post 
incubation. 
144 
         
99mTc-HABN2 was prepared with high purity. Due to the same 99mTc labeling core, 
monomer and dimer shared similar character in labeling, hydrophilicity and solution 
stability in saline, cysteine and human serum.  However, we noticed that several days of 
incubation is necessary to complete the conjugation of the HYNIC chelator to the bombesin 
homodimer due to the position of active glutamic acid. The slightly lower rate 
of 99mTc-HYNIC(Tricine/TPPTS)-Glu[Aca-BN(7-14)]2 complex construction may be 
caused for the same reason.  
The in vitro cellular uptake, internalization and efflux kinetics were evaluated using 
the GRPR-expressing human prostate cancer cell line PC-3. Although the binding affinity 
of bombesin homodimer was 10 times lower than monomer, the specific accumulation 
of 99mTc-HABN2 showed almost a linear increasing during 4 h experiment period with 
highest cellular uptake of 32.5 ± 1.8 % added activity (3-fold as high as that 
of 99mTc-HABN), whereas that of 99mTc-HABN reached an uptake plateau in 30 min, which 
may due to the higher bombesin “local concentration” of the homodimer in the vicinity of 
the receptor.  In the in vitro competitive receptor binding assay, PC-3 cells were incubated 
with the bombesin ligands for 1 h to allow for the replacement of the GRPR-bound 
of 125I-tyr4-BN(1-14). Cellular uptake of 99mTc-HABN2 gradually increased over time and 
became higher than 99mTc-HABN only after 1 h post incubation. This finding indicated 
that 99mTc-HABN2 may be more suitable for cancer imaging at later time points (for 
example 4 h, 24 h p.i.).  Therefore, we decided to evaluate the biodistribition and SPECT 
imaging characters of radiolabelled homodimer in a human prostate cancer xenograft 
bearing mouse animal model till 24 h post injection. 
For 99mTc-HABN and 99mTc-HABN2, tumors are visualized in the first time frame of 
microSPECT image at 10 min post injection, it reflected the rapid receptor binding and 
internalization via GRPR. The slightly higher tumor uptake of 99mTc-HABN2 
(0.78±0.26 %ID/g) compared to 99mTc-HABN (0.67±0.26 %ID/g) at 4h post injection could 
be attributed to the combination of higher cellular uptake, slower efflux and molecular size 
effect. Instead of steady decreases over time, the uptake of 99mTc-HABN2 remains constant 
high (11.2±4.9 %ID/g at 24 h post injection) in pancreas which may be because of same 
reasons. 
 Not only in the GRPR expressing tissues but also in the non-GRPR tissues, 
the 99mTc-HABN2 showed a longer retention compared to 99mTc-HABN. The apparent 
increase in molecular size resulted in an increased circulation time and slower clearance of 
the bombesin dimer. The accumulation in blood for 99mTc-HABN2 was 4 times higher as 
that for 99mTc-HABN at 1h post injection. Although T/NT ratios were constantly increasing 
due to the slower excretion of 99mTc-HABN2 in tumor than in non-target tissues (Figure 6), 
it was well feasible to visualize the tumor with the SPECT images till 4 hours post injection. 
The contrast of tumor in SPECT images is expected to be better at 24 h post injection, but 
due to the short half life of 99mTc, it was not possible to perform the SPECT scan at 24h post 
injection.   
Because of the doubled positive charge from 2 Aca-BN(7-14) motifs, the radioactivity 
accumulation of 99mTc-HABN2 in kidney remains at high level within 24 hours, with 
highest accumulation of 15.1±6.4 %ID/g at 4 h post injection and decreased to 
4.7±0.9%ID/g at 24 h. The high radioactivity accumulation in kidney and urine observed 
from SPECT imaging and/or biodistribution results indicate that the 99mTc-HABN2 was 
excreted through renal-urine pathway which is consist with other 99mTc-HYNIC-peptides.  
 The agonist property of 99mTc-HABN2 was confirmed by its rapid internalization. 
Although it’s still unclear which of agonist and antagonist is more suitable for the imaging 
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of GRPR-expressing cancer, a few radiolabelled bombesin antagonists, such as 
Demobesin-1 (29), have already showed their superior to agonists in tumor accumulation, 
retention of radioactivity and in vivo pharmacokinetics. Compare to those 
antagonists, 99mTc-HABN2 exhibited comparable tumor accumulation, but less favorable 
pharmacokinetics. Further studies which focus on improving the binding affinity and 
pharmacokinetics of bombesin homodimer are undergoing.    
 
Figure 6. (A) Biodistribution of 99mTc-HABN2 at 1, 4, 24 hours postinjection in athymic 
nude mice bearing subcutaneous PC-3 tumor (mean ± SD %ID/g), (B)T/NT ratio 
of 99mTc-HABN2 at 1, 4, 24 hours postinjection (mean ± SD), (C) Biodistribution 
of 99mTc-HABN2 at 4 hours postinjection with and without blocking agent (mean ± 
SD %ID/g), (D) Uptake of 99mTc-HABN2 in kidney and pancreas at 4 hours postinjection 
with and without blocking agent (mean ± %ID/g); *= statistically significant difference 
(p<0.05). 
  
Recently, series of radiolabelled Arginine-Glycine-Aspartic acid-bombesin 
(RGD-BBN) heterodimers for the GRPR targeting were reported (14, 30-33). Those 
heterodimers aim for targeting two types of receptors simultaneously, to enhance tumor 
contrast when either or both receptor types are expressed. In the RGD-BBN heterodimer 
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molecular containing one bombesin motif and one RGD motif, the RGD motif is 
responsible for targeting integrin αvβ3-receptors which are upregulated on activated tumor 
endothelial cells and also highly expressed on some tumor cells such as glioblastoma, 
breast and prostate tumors, malignant melanomas, and ovarian carcinomas (34). Compared 
to the bombesin monomer or RGD monomer, the heterodimer shows a synergistic effect for 
in vivo PC-3 tumor targeting in an animal model (33). However using heterodimers the 
target specificity of the SPECT or PET image is lost, but general detection of tumor lesions 
may be improved. The RGD-BBN heterodimer labelled with radiometals (68Ga and 64Cu) 
showed higher background than 18F-labelled tracer but slower washout and higher tumor 
uptake in nude mice bearing breast tumors (14). It’s worth to explore the potency of 
different radioisotopes and chelators on the binding properties and pharmacokinetics of 
bombesin homodimers.  
 Within 99mTc-HABN2, two identical bombesin ligands were conjugated with glutamic acid. 
Based on the results described in this paper it is not possible for the two bombesin moieties 
to bind to GRPR simultaneously. It would be interesting to investigate the effects of linkers 
with differences in length, lipophilicity and flexibility, on the in vitro and in vivo behavior 
of the tracer. 
8.5  Conclusion 
 We successfully developed a 99mTc labelled homodimeric bombesin tracer which 
showed binding with acceptable affinity and specificity to the GRP receptor-positive PC-3 
prostate cancer cells in vitro and in vivo. Moreover we have shown its ability of tumor 
imaging. Further studies on modification of homodimeric bombesin are required. The 
current dimer is a useful lead compound for this purpose. 
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Chapter 9  






















9.1  Conclusion 
Prostate cancer is one of the most common forms of cancer in western countries. A 
Transrectal ultrasound guided biopsy is the gold standard for histological prostate cancer 
diagnosis. Unfortunately this procedure can lead to over-estimation or under-estimation of 
disease due to sampling error. Therefore, a noninvasive specific imaging tool is urgently 
needed. Positron emission tomography (PET) and single photon computed tomography 
(SPECT) with high sensitivity, specificity and resolution may fit the requirements of 
prostate cancer diagnosis. 
Gastrin releasing peptide receptor (GRPR) is a G-protein receptor. Due to the high 
expression in several human cancer cell lines (breast cancer, colon cancer, prostate cancer) 
and absence in most normal organs, GRPR could be used as a potential target for cancer 
detection. Radiolabelled bombesin analogues could be potential probes for nuclear imaging 
of cancer by targeting GRPR.  
Although developments of PET facilities and radiotracers for PET imaging are 
blooming nowadays, developing new tracers for SPECT imaging is still important because 
of the availability of SPECT in most areas all over the world. 99mTc is the most commonly 
used radionuclide for nuclear imaging with SPECT due to its excellent nuclear properties 
(t1/2 =6 h and single photon emission at 140 keV), rich and diverse coordination chemistry, 
easy availability at low cost, and high specific activity. In chapter 3, we reported the 
synthesis and preclinical evaluation of 99mTc(HYNIC-ABN)(tricine)(TPPTS),which is a 
combination of  a truncated bombesin(7-16) peptide as biomolecules, a β-Alanine spacer, 
and ternary ligand system (HYNIC, tricine, and TPPTS). Rapid excretion 
of 99mTc(HYNIC-ABN)(tricine)(TPPTS) via the renal route with low radioactivity 
accumulation in the blood, liver, muscle and gastrointestinal was observed in HT-29 colon 
cancer bearing mice at 1 h post injection. The highest absolute tumor uptake 
of 99mTc(HYNIC-ABN)(tricine)(TPPTS) was 1.59 ± 0.23 %ID/g at 30 min p.i. Colon 
cancer xenografts were clearly visible with high contrast from static planar images of the 
tumor-bearing mice. 99mTc(HYNIC-ABN)(tricine)(TPPTS) is a promising tracer with 
favorable phamacokinetis for imaging colon cancer although the absolute tumor uptake was 
not the highest in reported bombesins.  
 We designed and developed our second bombesin tracer 99mTc-HABN (Chapter 4) 
based on experience from 99mTc(HYNIC-ABN)(tricine)(TPPTS). To further reduce the 
steric hindrance effect of 99mTc-HYNIC(tricine)(TPPTS) labeling core to the GRPR binding 
affinity of bombesin, a longer å-aminocaproic acid (Aca) linker was introduced instead of 
β-Alanine. 99mTc-HABN was evaluated in PC-3 prostate cancer bearing mice which is the 
most common animal model for the evaluation of GRPR targeting ability. Lower IC50 value 
(higher GRPR binding affinity), higher absolute tumor uptake, longer tumor retention, 
lower accumulation in liver and kidney, higher tumor-to-muscle, tumor-to-blood and 
tumor-to-liver ratios, but also a higher accumulation in gastrointestinal region was observed 
compared to 99mTc(HYNIC-ABN)(tricine)(TPPTS).  Indeed, the Aca linker improved the 
in vivo kinetics of 99mTc-labelled bombesin. Therefore, 99mTc-HABN was selected for a 
clinical study of human primary prostate cancer imaging. The pharmaceutical translation 
work of 99mTc-HABN was summarized in Chapter 5.  We successfully prepared 
the 99mTc-HABN with high specific activity and purity, in the absence of any signs of 
adverse or subjective side effect after administration to patients. Unfortunately 
the 99mTc-HABN SPECT/CT was not able to detect prostate cancer in patients with proven 
disease. We hypothesize that the low accumulation of 99mTc-HABN on prostate cancer was 
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mainly due to the rapid degradation and moderate binding to GRPR.  
An attempt to increase the shelf time and retention of radioactivity signal in tumor was 
conducted by introducing a radioiodine labelled cubane moiety (Chapter 6). We 
successfully prepared the [123I]-CABN under mild conditions with moderate yield and high 
purity after purification. The internalization and efflux profile of [123I]-CABN were similar 
with 99mTc-HABN. The in vitro stability of [123I]-CABN in saline solution was high, 
unfortunately, the metabolic stability of [123I]-CABN in vivo was poor. No de-iodination 
was observed in SPECT imaging studies, the rapid degradation of [123I]-CABN was 
possibly due to the breakdown of amide bond between cubyl moiety and the 
ε-aminocaproic acid. Therefore, it was not possible to visualize a prostate cancer xenograft 
with [123I]-CABN SPECT imaging since not enough radioactivity could accumulate in the 
tumor.  
Further studies were carried out to develop bombesin analogues which could have 
better stability against proteolytic enzymes (Chapter 7). A series of lanthionine-stablized 
bombesins were synthesized and two of them (C5 and C6) were selected according to the 
binding affinity to GRPR. Both 18F-C5 and 18F-C6 showed GRPR targeting potential, PC-3 
tumors can be clearly observed from PET images at 2 h post injection. However, further 
improvement may be needed on radiochemical yield, specific activity, in vivo kinetics 
before it could be translated into a clinical trial.  
In Chapter 8, we described the development of a novel bombesin homodimer. 
Although a higher IC50 value of bombesin homodimer than the monomer was observed, 
the 99mTc-HABN2 exhibited comparable tumor uptake. The in vitro cellular uptake kinetics 
proved that the higher local concentration of bombesin moiety improved the GRPR 
targeting ability. However, the double positive charge and the molecular weight effect led to 
less optimal in vivo pharmacokinetic properties such as high radioactivity accumulation and 
long retention in kidney, and intestines. Further studies on optimizing the in vivo kinetics of 
bombesin homodimer by using other chelators, labeling methods, linkers based 
on 99mTc-HABN2 are warranted.  
 
9.2  Future Perspectives: 
This thesis has solely focused on imaging of the GRPR, but several other receptors 
which are specifically expressed in prostate cancer, such as Prostate specific membrane 
antigen (PSMA) could also be considered as target for imaging prostate cancer. Already 
several lead structures both based on antibodies and small molecules have recently been 
published. The combination of information of the receptor status of GRPR with other 
molecular targets will be of great additional value. 
Imaging of GRPR still needs further improvement. Improving absolute tumor uptake 
is still the key factor when developing new bombesin tracers for imaging prostate cancer. 
Multimerization is a promising strategy for improving binding affinity and kinetics of 
radiolabelled bombesin peptide. By incorporating multiple targeting moieties local receptor 
ligand concentrations can be enhanced resulting in higher overall binding affinities. The 
binding affinity of the bombesin dimer as investigated in this thesis was not increased as we 
expected but decreased possibly due to the lack of flexibility of the bombesin(7-14) moiety 
and the glutamine linker. Therefore studies on the linker (e.g. length and flexibility) and 
bifunctional chelator are necessary for improving the performance of the bombesin dimer.       
Another way to improve binding characteristics of bombesin tracers is to improve their 
metabolic stability by introducing non-natural amino acids to replace certain amino acids 
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sequences of bombesin peptide without detrimental effect on the biological activity of the 
peptide. Several examples have already been published and showed their stabilizing effect.   
Although most promising bombesin tracers are agonists, which may internalize and be 
captured in tumor cells, bombesin antagonists may offer better in vivo pharmacokinetic 
properties as cancer imaging probes. Bombesin antagonists could also be used for prostate 
cancer imaging due to fast clearance from normal organs and long retention in tumor cells.  
All these issues could be combined to develop the bombesine tracer with optimal 
affinity, pharmacokinetics and metabolic stability. In combination with new versatile 
radiolabelling techniques such as click chemistry a tool can be provided to study GRPR in 






























































Chapter 10  

















Prostaatkanker is een van de meest voorkomende vormen van kanker in de westerse 
wereld.  
De diagnose prostaatkanker is definitief wanneer histologisch bewijs verkregen is. 
Meestal gebeurt dit door middel van transrectale echogeleide biopten. Deze procedure heeft 
echter ‘sampling error’ als nadeel. Hierdoor kan overschatting en onderschatting van 
prostaatkanker ontstaan. Dit is een van de belangrijkste redenen waarom een niet-invasieve 
beeldvormende techniek voor het diagnosticeren van prostaatkanker wenselijk is.  
Positron emissie tomografie (PET) en single photon computed tomography (SPECT) 
hebben een hoge gevoeligheid, specificiteit en resolutie en kunnen bijdragen aan het 
verbeteren van de diagnostiek van prostaatkanker.  
Gastrine-releasing peptide receptor (GRPR) is een G-eiwit gekoppelde receptor. 
GRPR kan worden gebruikt als een potentieel doelwit voor kankerdetectie, vanwege de 
hoge expressie in verschillende vormen van kanker (borstkanker, darmkanker en 
prostaatkanker) en de afwezigheid in gezond weefsel. Radioactief gelabelde bombesine 
analogen hebben potentie binnen de nucleaire beeldvorming van kanker doordat zij zich 
richten op GRPR. 
De ontwikkeling van PET faciliteiten en radiotracers neemt een grote vlucht. 
Daarnaast is de ontwikkeling van nieuwe tracers voor SPECT nog steeds belangrijk, 
vanwege de grote beschikbaarheid van SPECT wereldwijd. 99mTc is de meest gebruikte 
radionuclide voor nucleaire beeldvorming met SPECT vanwege de uitstekende nucleaire 
eigenschappen (de halfwaardetijd bedraagt 6 uur en ‘single photon emissie’ vindt plaats bij 
140 keV), rijke en gevarieerde coördinatie chemie, eenvoudige beschikbaarheid tegen lage 
kosten en de hoge specifieke activiteit. In hoofdstuk 3 wordt de synthese en preklinische 
evaluatie van 99mTc(HYNIC-ABN)(tricine)(TPPTS) beschreven. 99mTc(HYNIC-ABN) 
(tricine)(TPPTS) bestaat uit een verkorte vorm van bombesine (7-16), een β-alanine spacer 
en een tertiair ligand systeem (respectievelijk HYNIC, tricine en TPPTS) .  
In vivo onderzoek met HT-29 coloncarcinoom geincubeerde muizen liet een snelle 
uitscheiding van 99mTc(HYNIC-ABN)(tricine)(TPPTS) via de nieren zien. Daarnaast werd er 
1 uur na injectie een lage accumulatie van radioactiviteit waargenomen in het bloed,  in de 
lever, in de spieren en in het gastro-intestinale systeem. De hoogste absolute opname 
van 99mTc(HYNIC-ABN)(tricine)(TPPTS) in tumorweefsel bedroeg 30 minuten na injectie 
1,59 ± 0,23 %ID/g. Coloncarcinoom xenotransplaat was duidelijk zichtbaar met een hoog 
contrast in de tumordragende muizen. 99mTc(HYNIC-ABN)(tricine)(TPPTS) is een 
veelbelovende tracer met gunstige phamacokinetische eigenschappen voor de beeldvorming 
van coloncarcinoom. Echter, de absolute tumoropname in dit onderzoek was niet zo hoog als 
de tumoropname van andere reeds beschreven bombesine tracers. 
Op basis van de ervaringen die opgedaan zijn door de productie en het gebruik 
van 99mTc(HYNIC-ABN)(tricine)(TPPTS) werd een tweede bombesine tracer, 
genaamd 99mTc–HABN, ontwikkeld (hoofdstuk 4). Om de sterische hindering 
van 99mTc-HYNIC (tricine)(TPPTS) te beperken werd een langere spacer dan β-alanine 
geïntroduceerd, namelijk aminocapronzuur (Aca). Hierdoor kan de bindingsaffiniteit van 
bombesine voor GRPR verhoogd worden. 99mTc-HABN werd geëvalueerd in muizen die 
geincubeerd waren met de humane PC-3 prostaatkankercellijn. PC-3 is het meest gebruikte 
diermodel voor de evaluatie van GRPR als aangrijpingspunt voor beeldvorming. In 
vergelijking met 99mTc(HYNIC-ABN)(tricine)(TPPTS), leidde 99mTc-HABN tot een lagere 
IC50 waarde (een hoger GRPR bindingsaffiniteit) , een hogere absolute tumoropname , 
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toegenomen  retentie van de tracer in tumorweefsel , een lagere accumulatie in de lever en 
nieren , een hogere tumor/spier- , tumor/bloed- en tumor/lever ratio , maar ook een hogere 
accumulatie in het gastro-intestinale systeem.De Aca spacer leidde zoals verwacht tot 
verbetering van de in vivo kinetiek van met 99mTc gelabeld bombesine. 99mTc-HABN werd 
vanwege bovengenoemde resultaten geselecteerd voor klinisch onderzoek naar de 
beeldvorming van prostaatkanker bij patiënten.  
In hoofdstuk 5 wordt de overgang van de preklinische toepassing naar de klinische 
toepassing van 99mTc-HABN beschreven. 99mTc-HABN werd succesvol geproduceerd met 
hoge specifieke activiteit en zuiverheid. Er werden geen bijwerkingen gezien. Echter 
prostaatkanker kon niet aangetoond worden door middel van 99mTc-HABN SPECT/CT bij 
patiënten met histologisch bewezen ziekte. De hypothese is dat de lage accumulatie 
veroorzaakt wordt door de snelle degradatie van de tracer en de matige binding aan GRPR.  
Een radioactief gelabeld synthetische koolstof werd in de de tracer gebracht met 
als doel om de bewaartijd en de retentie van het radioactieve signaal te vergroten 
(hoofdstuk 6). [123I]-CABN werd succesvol geproduceerd met een goede opbrengst en een 
hoge zuiverheid. De mate van internalisatie en externalisatie van [123I]-CABN was 
vergelijkbaar met 99mTc-HABN. De in vivo stabiliteit van [123I]-CABN was hoog in een 
fysiologische zoutoplossing. Helaas was de metabole stabiliteit van [123I]-CABN in vivo 
slecht. Er was geen sprake van deionidisatie tijdens SPECT scans. De slechte metabole 
stabiliteit van [123I]-CABN wordt mogelijk veroorzaakt door de afbraak van de amide 
binding tussen de koolstof groep en het ε–aminocapronzuur. Als gevolg van de lage 
accumulatie van de tracer kon prostaatkanker niet afgebeeld worden door middel van 
[123I]-CABN SPECT.  
Aanvullende studies werden uitgevoerd om bombesine tracers te ontwikkelen die 
minder gevoelig zijn voor proteolytische enzymen en daardoor een hogere stabiliteit hebben 
(hoofdstuk 7). Een serie lanthionine-gestabiliseerde bombesine tracers werd ontwikkeld. Op 
basis van de hoge bindingsaffiniteit voor GRPR werden C5 en C6 geselecteerd. 
Zowel 18F-C5 als 18F-C6 was in staat om 2 uur na injectie de humane PC-3 
prostaatkankercellijn in vivo af te beelden door middel van PET. Echter verdere verbetering 
van de radiochemische opbrengst, de specifieke activiteit en de in vivo kinetiek is nodig 
voordat deze tracers in een klinische studie geëvalueerd kunnen worden. In hoofdstuk 8 
wordt de ontwikkeling van een nieuwe bombesine homodimeer beschreven. De bombesine 
homodimeer vertoonde een hogere IC50 waarde dan de bombesine monomeer. Desondanks 
was de tumoropname identiek. In vitro cellulaire opnamekinetiek toonde aan dat de hogere 
concentratie van bombesine de affiniteit voor GRPR verbeterde. Echter, de tweevoudige 
positieve lading en het moleculair gewicht, leidden tot minder gunstige in vivo 
farmacokinetische eigenschappen, zoals toegenomen radioactieve accumulatie en 
langdurige retentie in de nieren en de darmen. Nader onderzoek naar het optimaliseren van 
de in vivo kinetiek van de bombesine homodimeren, door het gebruik van andere chelators , 
radioactieve labbeling en linkers op basis van 99mTc - HABN2, zijn nodig.  
 
10.2 Toekomstperspectieven : 
Dit proefschrift is uitsluitend gericht op beeldvorming van GRPR. Er zijn echter 
verschillende andere receptoren die specifiek bij prostaatkanker tot expressie komen , zoals 
prostate-pecific membrane antigen (PSMA),  Deze receptoren kunnen ook beschouwd 
worden als een doelwit voor de beeldvorming van prostaatkanker. Er zijn reeds 
verschiedene tracers, zowel gebaseerd op antilichamen als ‘small molecules’, in de 
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literatuur beschreven. Informatie over de expressie van GRPR en andere moleculaire 
doelwitten is van grote toegevoegde waarde in de ontwikkeling van tracers.  
De beeldvorming van GRPR moet verder verbeterd worden. Vergroting van de 
absolute tumoropname is noodzakelijk in de ontwikkeling van bombesine tracers voor de 
beeldvorming van prostaatkanker. Multimerisatie is een veelbelovende techniek voor het 
verbeteren van de bindingsaffiniteit en kinetiek van radioactief gelabelde bombesine 
tracers.  
De bindingsaffiniteit van de in dit onderzoek onderzochte bombesine dimeer, was 
tegen de verwachting in niet toegenomen. Er was zelfs sprake van een afname van de 
bindingsaffiniteit, hetgeen mogelijk veroorzaakt werd door het gebrek aan flexibiliteit van 
bombesin(7-14) en van de glutamine spacer. Nader onderzoek naar de spacer (lengte en 
flexibiliteit) en de bifunctionele chelator zijn noodzakelijk om de prestaties van de 
bombesine dimeer te verbeteren. 
Een andere manier om de bindingseigenschappen van bombesine tracers te verbeteren is 
om hun metabolische stabiliteit te verhogen. Dit kan gedaan worden door bepaalde 
aminozuurcomplexen in het bombesine eiwit te vervangen door niet-natuurlijke aminozuren 
zonder dat er nadelige effecten op de biologische activiteit van het eiwit ontstaat. 
Verschillende voorbeelden zijn reeds gepubliceerd en toonden hun stabiliserende werking. 
Ondanks dat de meest veelbelovende bombesine tracers agonisten zijn (waardoor influx en 
retentie van de tracer in de cel), vertonen bombesine antagonisten mogelijk betere 
farmacokinetische eigenschappen. Bombesine antagonisten kunnen ook gebruikt worden 
voor de beeldvorming van prostaatkanker vanwege de snelle klaring uit gezond weefsel en 
langdurige retentie in tumorcellen. 
Bovengenoemde zaken kunnen worden gecombineerd om een bombesine tracer te 
ontwikkelen met een hoge affiniteit, gunstige farmacokinetiek en hoge metabolische 
stabiliteit. Nieuwe veelzijdige radiolabelling technieken zoals click chemie kunnen 
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